US20180057594A1 - Pseudotyped oncolytic viral delivery of therapeutic polypeptides - Google Patents

Pseudotyped oncolytic viral delivery of therapeutic polypeptides Download PDF

Info

Publication number
US20180057594A1
US20180057594A1 US15/720,696 US201715720696A US2018057594A1 US 20180057594 A1 US20180057594 A1 US 20180057594A1 US 201715720696 A US201715720696 A US 201715720696A US 2018057594 A1 US2018057594 A1 US 2018057594A1
Authority
US
United States
Prior art keywords
virus
nucleic acid
mir
acid sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/720,696
Other languages
English (en)
Inventor
Luke Evnin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mpm Capital
Oncorus Inc
Original Assignee
Oncorus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US15/720,696 priority Critical patent/US20180057594A1/en
Assigned to MPM CAPITAL reassignment MPM CAPITAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EVNIN, LUKE
Assigned to ONCORUS, INC. reassignment ONCORUS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MPM CAPITAL
Application filed by Oncorus Inc filed Critical Oncorus Inc
Assigned to ONCORUS, INC. reassignment ONCORUS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MPM CAPITAL
Assigned to MPM CAPITAL reassignment MPM CAPITAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EVNIN, LUKE
Publication of US20180057594A1 publication Critical patent/US20180057594A1/en
Priority to US16/170,764 priority patent/US10604574B2/en
Assigned to ONCORUS, INC. reassignment ONCORUS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MPM CAPITAL
Assigned to MPM CAPITAL reassignment MPM CAPITAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EVNIN, LUKE
Priority to US16/775,164 priority patent/US11078280B2/en
Assigned to ONCORUS, INC. reassignment ONCORUS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FINER, MITCHELL H.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • bispecific antibodies to direct cytotoxic T cells to tumor cells, and chimeric antigen receptors (CARs) to engineer antigen specificity onto an immune effector cell are being demonstrated to provide a therapeutic benefit.
  • oncolytic virus technologies are useful additions to the current standard of care of solid tumors, expected to have a safety profile and the ability to infect, replicate in, and lyse tumor cells.
  • the antitumor efficacy of the bispecific antibodies, CARs and oncolytic virus are suboptimal, demonstrating the continued need for further advances of oncology, antibodies, and oncolytic virus therapy.
  • the present invention provides a pseudotyped oncolytic virus comprising a recombinant nucleic acid comprising (i) a first nucleic acid sequence encoding an engager polypeptide, wherein the engager polypeptide comprises an activation domain specific for an antigen expressed on an effector cell and an antigen recognition domain specific for a cell-surface antigen expressed on a target cell.
  • the antigen recognition domain specifically binds to a tumor antigen.
  • tumor antigen is selected from Table 2.
  • the present invention provides a pseudotyped oncolytic virus comprising a recombinant nucleic acid comprising (i) a first nucleic acid sequence encoding an engager polypeptide, wherein the engager polypeptide comprises an activation domain specific for an antigen expressed on an effector cell and a therapeutic molecule domain that binds to an inhibitory antigen expressed on a cell surface.
  • the therapeutic molecule domain specifically binds to PD1, PDL1, or CD47.
  • the recombinant nucleic acid further comprises a second nucleic acid sequence encoding a therapeutic polypeptide.
  • the therapeutic polypeptide is an immune modulator polypeptide.
  • the immune modulator polypeptide is selected from a cytokine, a costimulatory molecule, an immune checkpoint polypeptide, an anti-angiogenesis factor, a matrix metalloprotease (MMP), or a nucleic acid.
  • a cytokine a costimulatory molecule
  • an immune checkpoint polypeptide an immune checkpoint polypeptide
  • an anti-angiogenesis factor a matrix metalloprotease (MMP)
  • MMP matrix metalloprotease
  • the immune checkpoint polypeptide comprises (i) an inhibitor of PD-1, PDL-1, CTLA-4, LAG3, TIM3, neuropilin, or CCR4; (ii) an agonist of GITR, OX-40, or CD28; or (iii) a combination of (i) and (ii).
  • the immune checkpoint polypeptide comprises an MMP, wherein the MMP is MMP9.
  • the immune checkpoint polypeptide comprises a cytokine, wherein the cytokine is selected from IL-15, IL-12, and CXCL10.
  • the effector cell engaged by the engager molecules herein is a T cell, an NKT cell, an NK cell, or a macrophage.
  • the activation domain of the effector molecule specifically binds to CD3, CD4, CD5, CD8, CD16, CD28, CD40, CD134, CD137, or NKG2D.
  • the recombinant nucleic acid provides herein are multicistronic sequences.
  • the multicistronic sequence is a bicistronic sequence or a tricistronic sequence.
  • the multicistronic sequence comprises a picomavirus-2a-like sequence, and wherein the first and second nucleic acid sequences are expressed from a single promoter sequence present in the recombinant nucleic acid.
  • the present invention provides a pseudotyped oncolytic virus comprising a recombinant nucleic acid sequence comprising (i) a first nucleic acid sequence encoding an engager polypeptide, wherein the engager polypeptide comprises an activation domain specific for an antigen expressed on an effector cell and an antigen recognition domain specific for a tumor cell antigen expressed on a target cell, wherein the antigen expressed on the effector cell is CD3, and wherein the tumor cell antigen is CD19.
  • the recombinant nucleic acid sequence encodes a polypeptide sequence that is at least 90% identical to SEQ ID NO: 44.
  • the recombinant nucleic acid sequence comprises SEQ ID NO. 43.
  • the recombinant nucleic acid sequence further comprises (ii) a second nucleic acid sequence encoding a therapeutic molecule, wherein the therapeutic molecule is IL-12. In such embodiments, the recombinant nucleic acid sequence encodes a polypeptide sequence that is at least 90% identical to SEQ ID NO: 54. In some embodiments, the recombinant nucleic acid sequence further comprises (ii) a second nucleic acid sequence encoding a therapeutic molecule, wherein the therapeutic molecule is IL-15. In such embodiments, the recombinant nucleic acid sequence encodes a polypeptide sequence that is at least 90% identical to SEQ ID NO: 53.
  • the recombinant nucleic acid sequence further comprises (ii) a second nucleic acid sequence encoding a therapeutic molecule, wherein the therapeutic molecule is CXCL10.
  • the recombinant nucleic acid sequence encodes a polypeptide sequence that is at least 90% identical to SEQ ID NO: 55.
  • the recombinant nucleic acid sequence further comprises (ii) a second nucleic acid sequence encoding a therapeutic molecule, wherein the therapeutic molecule is MMP9.
  • the present invention provides a pseudotyped oncolytic virus comprising a recombinant nucleic acid sequence comprising (i) a first nucleic acid sequence encoding an engager polypeptide, wherein the engager polypeptide comprises an activation domain specific for an antigen expressed on an effector cell and an therapeutic molecule domain specific for an inhibitory antigen, wherein the antigen expressed on the effector cell is CD3, and wherein the inhibitory antigen is PDL1.
  • the recombinant nucleic acid sequence comprises a nucleic acid sequence encoding a polypeptide sequence that is at least 90% identical to SEQ ID NO: 50.
  • the recombinant nucleic acid sequence comprises SEQ ID NO: 49.
  • the recombinant nucleic acid sequence further comprises (ii) a second nucleic acid sequence encoding a therapeutic molecule, wherein the therapeutic molecule is IL-12. In some embodiments, the recombinant nucleic acid sequence encodes a polypeptide sequence that is at least 90% identical to SEQ ID NO: 63. In some embodiments, the recombinant nucleic acid sequence further comprises (ii) a second nucleic acid sequence encoding a therapeutic molecule, wherein the therapeutic molecule is IL-15. In some embodiments, the recombinant nucleic acid sequence encodes a polypeptide sequence that is at least 90% identical to SEQ ID NO: 62.
  • the recombinant nucleic acid sequence further comprises (ii) a second nucleic acid sequence encoding a therapeutic molecule, wherein the therapeutic molecule is CXCL10. In some embodiments, the recombinant nucleic acid sequence encodes a polypeptide sequence that is at least 90% identical to SEQ ID NO: 64. In some embodiments, the recombinant nucleic acid sequence further comprises (ii) a second nucleic acid sequence encoding a therapeutic molecule, wherein the therapeutic molecule is MMP9. In some embodiments, the engager molecule further comprises a third binding domain. In some embodiments, the third binding domain comprises an immunoglobulin Fc domain. In some embodiments, the recombinant nucleic acid sequence encodes a polypeptide sequence that is at least 90% identical to SEQ ID NO: 52. In some embodiments, the recombinant nucleic acid sequence comprises SEQ ID NO: 51.
  • the present invention provides a pseudotyped oncolytic virus comprising a recombinant nucleic acid sequence comprising (i) a first nucleic acid sequence encoding an engager polypeptide, wherein the engager polypeptide comprises an activation domain specific for an antigen expressed on an effector cell and an therapeutic molecule domain specific for an inhibitory antigen, wherein the antigen expressed on the effector cell is CD3, and wherein the inhibitory antigen is SIRP1 ⁇ .
  • the recombinant nucleic acid sequence comprises a nucleic acid sequence encoding a polypeptide sequence that is at least 90% identical to SEQ ID NO: 46 or 48.
  • the recombinant nucleic acid sequence comprises SEQ ID NO: 45 or 47. In some embodiments, the recombinant nucleic acid sequence further comprises (ii) a second nucleic acid sequence encoding a therapeutic molecule, wherein the therapeutic molecule is IL-12. In some embodiments, the recombinant nucleic acid sequence encodes a polypeptide sequence that is at least 90% identical to SEQ ID NO: 58 or 59. In some embodiments, the recombinant nucleic acid sequence further comprises (ii) a second nucleic acid sequence encoding a therapeutic molecule, wherein the therapeutic molecule is IL-15.
  • the recombinant nucleic acid sequence encodes a polypeptide sequence that is at least 90% identical to SEQ ID NO: 56 or 57. In some embodiments, the recombinant nucleic acid sequence further comprises (ii) a second nucleic acid sequence encoding a therapeutic molecule, wherein the therapeutic molecule is CXCL10. In some embodiments, the recombinant nucleic acid sequence encodes a polypeptide sequence that is at least 90% identical to SEQ ID NO: 60 or 61. In some embodiments, the recombinant nucleic acid sequence further comprises (ii) a second nucleic acid sequence encoding a therapeutic molecule, wherein the therapeutic molecule is MMP9.
  • the recombinant nucleic acid sequence encodes a polypeptide sequence that is at least 90% identical to SEQ ID NO: 65 or 66. In some embodiments, the recombinant nucleic acid sequence further comprises (ii) a second nucleic acid sequence encoding a therapeutic molecule, wherein the therapeutic molecule is an anti-PDL1 scFv linked to an IgG1 Fc domain. In some embodiments, the recombinant nucleic acid sequence encodes a polypeptide sequence that is at least 90% identical to SEQ ID NO: 68 or 70. In some embodiments, the recombinant nucleic acid sequence comprises SEQ ID NO: 67 or 69.
  • the pseudotyped oncolytic viruses of the present invention are selected from adenovirus, herpes simplex virus 1 (HSV1), myxoma virus, reovirus, poliovirus, vesicular stomatitis virus (VSV), measles virus (MV), lassa virus (LASV), or Newcastle disease virus (NDV).
  • the pseudotyped oncolytic virus comprises a reduced neurotropism activity and/or neurotoxicity activity in a human subject as compared to a reference virus.
  • the reference virus is i) a non-pseudotyped oncolytic virus, or ii) a vaccinia virus.
  • the pseudotyped oncolytic virus is an attenuated oncolytic virus. In some embodiments, the virus is not a vaccinia virus.
  • the pseudotyped oncolytic viruses of the present invention comprise a single recombinant nucleic acid. In some embodiments, the pseudotyped oncolytic viruses comprise a plurality of recombinant nucleic acids. In some embodiments, the oncolytic virus selectively infects a target cell. In some embodiments, the target cell is a tumor cell and wherein the oncolytic virus is capable of selectively replicating within the tumor cell.
  • the engager polypeptide is a bipartite polypeptide and is comprised of an antibody, an antibody domain, a human immunoglobulin heavy chain variable domain, a dual-variable-domain antibody (DVD-Ig), a Tandab, a diabody, a flexibody, a dock-and-lock antibody, a Scorpion polypeptide, a single chain variable fragment (scFv), a BiTE, a DuoBody, an Fc-engineered IgG, an Fcab, a Mab2, or DART polypeptide.
  • the present invention provides a pharmaceutical composition comprising any of the pseudotyped oncolytic viruses described herein.
  • the pseudotyped oncolytic virus induces an immune response.
  • immune response is selectively cytotoxic to a target cell.
  • the target cell is a solid tumor cell or a hematologic cancer cell.
  • the target cell expresses one or more tumor antigens.
  • the one or more tumor antigens are selected from Table 2.
  • the present invention provides a method of treating a cancer in a subject in need thereof, comprising administering a therapeutically effective amount of an oncolytic virus described herein or a pharmaceutical composition described herein.
  • the method further comprises administering one or more additional therapies to the subject in need thereof.
  • the one or more additional therapies comprise surgery, radiation, chemotherapy, immunotherapy, hormone therapy, or a combination thereof.
  • the present invention provides a method of treating one or more tumors in a subject in need thereof comprising administering a therapeutically effective amount of an oncolytic virus described herein or a pharmaceutical composition described herein to a patient, wherein the one or more tumors express a tumor antigen.
  • the present invention provides a method of selecting a patient for treatment comprising (a) determining the expression of a tumor antigen on one or more tumor cells derived from the patient; and (b) administering an oncolytic virus described herein or a pharmaceutical composition described herein if the tumor cells obtained from the patient express the one or more tumor antigens.
  • the one or more tumor antigens are selected from Table 2.
  • the present invention provides a method of delivering an engager polypeptide and a therapeutic polypeptide to a tumor site comprising administering to a patient in need thereof an oncolytic virus described herein or a pharmaceutical composition described herein.
  • FIG. 1 illustrates an amino acid sequence of a CD19-CD3 bipartite polypeptide comprising a first single chain variable fragment (scFv) directed against CD19 linked to a second scFv directed against CD3.
  • scFv single chain variable fragment
  • FIG. 2 illustrates an amino acid sequence of a CD19-CD3-IL15 construct encoded by a bicistronic gene.
  • the first gene encodes a bipartite polypeptide comprising a first scFv directed against CD19 linked to a second scFv directed against CD3.
  • a second gene encoding IL-15 is linked to the bipartite gene sequence by a T2A self-cleaving polypeptide linker.
  • FIG. 3 illustrates an amino acid sequence of a CD19-CD3-IL12 construct encoded by a multicistronic gene.
  • the first gene encodes a bipartite polypeptide comprising a first scFv directed against CD19 linked to a second scFv directed against CD3.
  • a second gene encoding the p35 subunit of IL-12 is linked to the bipartite gene sequence by a T2A self-cleaving polypeptide linker and a third gene encoding the p40 subunit of IL-12 is linked by a T2A self-cleaving polypeptide linker.
  • FIG. 4 illustrates an amino acid sequence of a CD19-CD3-CXCL10 construct encoded by a bicistronic gene.
  • the first gene encodes a bipartite polypeptide comprising a first scFv directed against CD19 linked to a second scFv directed against CD3.
  • a second gene encoding CXCL10 is linked to the bipartite gene sequence by a T2A self-cleaving polypeptide linker.
  • FIG. 5 illustrates an amino acid sequence of a SIRP1 ⁇ -CD3 bipartite polypeptide comprising a first protein comprising the first 120 amino acids of SIRP1 ⁇ linked by a single amino acid linker to an scFv directed against CD3.
  • FIG. 6 illustrates an amino acid sequence of a SIRP1 ⁇ -CD3-LL bipartite polypeptide comprising a first protein comprising the first 120 amino acids of SIRP1 ⁇ linked by a G4S motif linker to an scFv directed against CD3.
  • FIG. 7 illustrates an amino acid sequence of a SIRP1 ⁇ -CD3-IL15 construct encoded by a bicistronic gene.
  • the first gene encodes a bipartite polypeptide comprising the first 120 amino acids of SIRP1 ⁇ linked by a single amino acid linker to an scFv directed against CD3.
  • a second gene encoding IL-15 is linked to the bipartite gene sequence by a T2A self-cleaving polypeptide linker.
  • FIG. 8 illustrates an amino acid sequence of a SIRP1 ⁇ -CD3-IL5-LL construct encoded by a bicistronic gene.
  • the first gene encodes a bipartite polypeptide comprising the first 120 amino acids of SIRP1 ⁇ linked by a G4S motif linker to an scFv directed against CD3.
  • a second gene encoding IL-15 is linked to the bipartite gene sequence by a T2A self-cleaving polypeptide linker.
  • FIG. 9 illustrates an amino acid sequence of a SIRP1 ⁇ -CD3-IL12 construct encoded by a multicistronic gene.
  • the first gene encodes a bipartite polypeptide comprising the first 120 amino acids of SIRP1 ⁇ linked by a single amino acid linker to an scFv directed against CD3.
  • a second gene encoding the p35 subunit of IL-12 is linked to the bipartite gene sequence by a T2A self-cleaving polypeptide linker and a third gene encoding the p40 subunit of IL-12 is linked by a T2A self-cleaving polypeptide linker.
  • FIG. 10 illustrates an amino acid sequence of a SIRP1 ⁇ -CD3-IL2-LL construct encoded by a multicistronic gene.
  • the first gene encodes a bipartite polypeptide comprising the first 120 amino acids of SIRP1 ⁇ linked by a G4S motif linker to an scFv directed against CD3.
  • a second gene encoding the p35 subunit of IL-12 is linked to the bipartite gene sequence by a T2A self-cleaving polypeptide linker and a third gene encoding the p40 subunit of IL-12 is linked by a T2A self-cleaving polypeptide linker.
  • FIG. 11 illustrates an amino acid sequence of a SIRP1 ⁇ -CD3-CXCL10 construct encoded by a bicistronic gene.
  • the first gene encodes a bipartite polypeptide comprising the first 120 amino acids of SIRP1 ⁇ linked by a single amino acid linker to an scFv directed against CD3.
  • a second gene encoding CXCL10 is linked to the bipartite gene sequence by a T2A self-cleaving polypeptide linker.
  • FIG. 12 illustrates an amino acid sequence of a SIRP1 ⁇ -CD3-CXCL10-LL construct encoded by a bicistronic gene.
  • the first gene encodes a bipartite polypeptide comprising the first 120 amino acids of SIRP1 ⁇ linked by a G4S motif linker to an scFv directed against CD3.
  • a second gene encoding CXCL10 is linked to the bipartite gene sequence by a T2A self-cleaving polypeptide linker.
  • FIG. 13 illustrates an amino acid sequence of a PDL1-CD3 bipartite polypeptide comprising a first scFv directed against PDL1 linked to a second scFv directed against CD3.
  • FIG. 14 illustrates an amino acid sequence of a PDL1-CD3-IL15 construct encoded by a bicistronic gene.
  • the first gene encodes a bipartite polypeptide comprising a first scFv directed against PDL1 linked to a second scFv directed against CD3.
  • a second gene encoding IL-15 is linked to the bipartite gene sequence by a T2A self-cleaving polypeptide linker.
  • FIG. 15 illustrates an amino acid sequence of a PDL1-CD3-IL12 construct encoded by a multicistronic gene.
  • the first gene encodes a bipartite polypeptide comprising a first scFv directed against PDL1 linked to a second scFv directed against CD3.
  • a second gene encoding the p35 subunit of IL-12 is linked to the bipartite gene sequence by a T2A self-cleaving polypeptide linker and a third gene encoding the p40 subunit of IL-12 is linked by a T2A self-cleaving polypeptide linker.
  • FIG. 16 illustrates an amino acid sequence of a PDL1-CD3-CXCL10 construct encoded by a bicistronic gene.
  • the first gene encodes a bipartite polypeptide comprising a first scFv directed against PDL1 linked to a second scFv directed against CD3.
  • a second gene encoding CXCL10 is linked to the bipartite gene sequence by a T2A self-cleaving polypeptide linker.
  • FIG. 17 illustrates an amino acid sequence of a PDL1-CD3-Fc tripartite polypeptide comprising a first scFv directed against CD3, linked by a G4S motif linker to a second scFv directed against PDL1, which is in turn linked to the CH2-CH3 domain of human IgG1 by an IgG1 hinge.
  • FIG. 18A - FIG. 18B illustrate an amino acid sequence of a SIRP1 ⁇ -CD3-MMP9-SL construct encoded by a bicistronic gene ( FIG. 18A ) and an amino acid sequence of a SIRP1 ⁇ -CD3-MMP9-LL construct encoded by a bicistronic gene ( FIG. 18B ).
  • FIG. 19A-19C illustrate the binding of CD19-CD3 BiTE constructs ( FIG. 19A ), SIRP1 ⁇ -CD3 BiTE constructs ( FIG. 19B ), and PDL1-CD3-Fc tripartite T cell engagers ( FIG. 19C ) CD3 + T cells.
  • FIG. 20 illustrates the quantification of the T cell engager construct binding shown in FIG. 19 .
  • FIG. 21A - FIG. 21C illustrate the CD3-specific binding of CD19-CD3 BiTE constructs ( FIG. 21A ), SIRP1 ⁇ -CD3 BiTE constructs ( FIG. 21B ), and PDL1-CD3-Fc tripartite T cell engagers ( FIG. 21C ) through the use of an anti-CD3 antibody, OKT3.
  • FIG. 22 illustrates the specificity of the CD47-binding SIRP1 ⁇ arm of a SIRP1 ⁇ -CD3 BiTE construct.
  • FIG. 23A - FIG. 23B illustrate the binding of CD19-CD3 and SIRP1 ⁇ -CD3 BiTE constructs ( FIG. 23A ) to Raji cells (CD19 + CD47 + ). % binding is quantified in FIG. 23B .
  • FIG. 24A - FIG. 24B illustrate the binding of CD19-CD3 and SIRP1 ⁇ -CD3 BiTE constructs ( FIG. 24A ) to U2OS cells (CD19 ⁇ CD47 + ). % binding is quantified in FIG. 24B .
  • FIG. 25A - FIG. 25B illustrate the binding of CD19-CD3 and SIRP1 ⁇ -CD3 BiTE constructs ( FIG. 25A ) to GBM30-luc cells (CD19 ⁇ CD47 + ). % binding is quantified in FIG. 25B .
  • FIG. 26A - FIG. 26B illustrate the binding of CD19-CD3 and SIRP1 ⁇ -CD3 BiTE constructs ( FIG. 26A ) to U251 cells (CD19 ⁇ CD47 + ). % binding is quantified in FIG. 26B .
  • FIG. 27A - FIG. 27C illustrate the binding of PDL1-Fc-CD3 tripartite T cell engagers to U251 cells.
  • the binding of the PDL1-Fc-CD3 constructs ( FIG. 27B ) is compared to the binding of an anti-PDL antibody ( FIG. 27A ). Binding was not mediated by Fc ⁇ Rs, as U251 cells do not express Fc ⁇ RI, Fc ⁇ RII, or Fc ⁇ RIII ( FIG. 27C ).
  • FIG. 28 illustrates CD19-CD3 BiTE, SIRP1 ⁇ -CD3 BiTE, and PDL1-CD3-Fc tripartite T cell engager-mediated T cell-dependent cytotoxicity (TDCC) of Raji cells.
  • TDCC T cell-dependent cytotoxicity
  • FIG. 29 illustrates CD19-CD3 BiTE and PDL1-CD3-Fc tripartite T cell engager-mediated TDCC of THP1 cells.
  • FIG. 30 illustrates CD19-CD3 BiTE and PDL1-CD3-Fc tripartite T cell engager-mediated TDCC of U251 cells.
  • FIG. 31 illustrates SIRP1 ⁇ -CD3 BiTE-mediated TDCC of 293F cells compared to an osteopontin-fusion control construct.
  • FIG. 32 illustrates expression of SIRP1 ⁇ -CD3 BiTE constructs from oncolytic-HSV vectors. Expression of SIRP1 ⁇ -CD3 BiTE constructs with short linkers (Lanes 1-4 and ONCR085 in lanes 5-6, shown in FIG. 5 ) and SIRP1 ⁇ -CD3 BiTE constructs with long linkers (ONCR087 in lanes 7-8, shown in FIG. 6 ) are shown.
  • FIG. 33 illustrates expression of PDL1-CD3-Fc BiTE constructs from oncolytic-HSV vectors.
  • Purified PDL1-CD3-Fc BiTE protein is shown in lanes 1-4.
  • Concentrated viral supernatants are shown in lanes 5-6.
  • FIG. 34A - FIG. 34B illustrate TDCC of U251 cells by virally produced SIRP1 ⁇ -CD3, SIRP1 ⁇ -CD3-LL, and PDL1-CD3-Fc BiTE constructs. Photographs of U251 cell cultures after incubation with the indicated BiTE constructs and CD8+ T cells are shown in FIG. 34A . Activity of virally produced BiTE constructs, measured by % of cell killing and quantified by flow cytometry, is shown in FIG. 34B .
  • FIG. 35 illustrates that Amicon ultrafiltration effectively removes virus from samples, as determined by Western blotting with polyclonal anti-HSV antibody, and indicated that BiTE-killing is due to the BiTE and not viral infection.
  • FIG. 36 illustrates a cartoon representation of the production of a pseudotyped oncolytic virus and a recombinant oncolytic virus and infection of a target cell by the respective pseudotyped oncolytic virus and the recombinant oncolytic virus.
  • FIG. 37 illustrates an amino acid sequence of a SIRP1 ⁇ -CD3-PDL1-Fc (SL) construct encoded by a bicistronic gene wherein the first gene encodes an anti-PDL1 scFv linked to an IgG1 Fc domain and the second gene encodes a bipartite polypeptide comprising the first 120 amino acids of SIRP1 ⁇ linked by a single amino acid linker to an scFv directed against CD3.
  • SL SIRP1 ⁇ -CD3-PDL1-Fc
  • FIG. 38 illustrates an amino acid sequence of a SIRP1 ⁇ -CD3-PDL1-Fc (LL) construct encoded by a bicistronic gene wherein the first gene encodes an anti-PDL1 scFv linked to an IgG1 Fc domain and the second gene encodes a bipartite polypeptide comprising the first 120 amino acids of SIRP1 ⁇ linked by a G4S motif linker to an scFv directed against CD3.
  • LL SIRP1 ⁇ -CD3-PDL1-Fc
  • FIG. 39 illustrates a schematic of a SIRP1 ⁇ -CD3-PDL1-Fc expression plasmid.
  • Two plasmid constructs, one for SIRP1 ⁇ -CD3-PDL1-Fc (SL) and one for SIRP1 ⁇ -CD3-PDL1-Fc (LL) were generated.
  • FIG. 40A - FIG. 40B illustrate purification of the SIRP1 ⁇ -CD3 BiTE (SL), SIRP1 ⁇ -CD3 BiTE (LL), and the anti-PDL1-Fc compounds from supernatants of transfected 293 T cells.
  • FIG. 40A shows purification of anti-PDL1-Fc compounds assessed by Coomassie.
  • FIG. 40B illustrates purification of SIRP1 ⁇ -CD3 BiTE compounds as assessed by Western Blot using an anti-His detection antibody.
  • FIG. 41A - FIG. 41C show results of a PD1/PDL1 blockade assay.
  • a schematic of the assay is shown in FIG. 41A - FIG. 41B .
  • the results of the PD1/PDL1 blockade assay using the anti-PDL1-Fc compound produced from 293 cells transfected are shown in FIG. 41C
  • the present disclosure provides novel engineered oncolytic viruses, in particular pseudotyped oncolytic viruses that produce multipartite polypeptides and/or other therapeutic polypeptides for the treatment of cancer including solid tumors (e.g., advanced solid tumors) and hematologic malignancies.
  • the oncolytic virus is engineered by pseudotyping or other recombinant technology in order to modulate the tropism of the virus to result in a viral infection specific for tumor cells and/or surrounding tumor stroma and/or for other beneficial purposes as provided herein.
  • the multipartite and/or therapeutic polypeptides produced by the oncolytic viruses described herein mediate or enhance the anti-tumor effects of the oncolytic viruses, such as by effector-cell mediated lysis of target cells (e.g., tumor cells).
  • target cells e.g., tumor cells
  • the oncolytic viruses described herein may have multiple (e.g. dual) modes of action, including effector cell-mediated cytolysis of target cells as a result of the expression of multipartite polypeptides, and viral-mediated destruction of target cells.
  • the present disclosure further provides therapeutic compositions comprising the engineered oncolytic viruses and methods of use in the treatment of solid tumors and hematologic malignancies.
  • the present invention provides pseudotyped oncolytic viruses, compositions thereof, and methods of use for the treatment of cancer.
  • the pseudotyped oncolytic viruses provided herein comprise recombinant nucleic acids that encode engager polypeptides and/or other therapeutic molecules (e.g., therapeutic polypeptides).
  • the engager polypeptides function as effector cell engagers and generally comprise a first domain directed against an activation molecule expressed on an effector cell (e.g., an activation domain or an engager domain) and a second domain directed against a target cell antigen (e.g., an antigen recognition domain) or other cell-surface molecule (e.g., a therapeutic molecule domain).
  • bipartite, tripartite or multipartite polypeptides e.g., comprising one or multiple engager domains, one or multiple antigen recognition domains, or one or multiple therapeutic molecule domains, and optionally one or multiple other functional domains.
  • Also provided are methods of treating cancer comprising the step of delivering to human subject in need thereof a therapeutically effective amount of the oncolytic viruses or pharmaceutical compositions thereof provided herein.
  • Such methods optionally include the step of delivering to the human subject an additional cancer therapy, such as surgery, radiation, chemotherapy, immunotherapy, hormone therapy, or a combination thereof.
  • the terms “about” and “approximately” are used as equivalents. Any numerals used in this application with or without about/approximately are meant to cover any normal fluctuations appreciated by one of ordinary skill in the relevant art.
  • the term “approximately” or “about” refers to a range of values that fall within 30%, 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
  • subject or “subjects” or “individuals” include, but are not limited to, mammals such as humans or non-human mammals, including domesticated, agricultural or wild, animals, as well as birds, and aquatic animals.
  • subjects are livestock such as cattle, sheep, goats, cows, swine, and the like; poultry such as chickens, ducks, geese, turkeys, and the like; and domesticated animals such as dogs and cats.
  • subjects are rodents (e.g., mice, rats, hamsters), rabbits, primates, or swine such as inbred pigs and the like.
  • the subject is a human.
  • “Patients” are subjects suffering from or at risk of developing a disease, disorder, or condition or otherwise in need of the compositions and methods provided herein. None of the terms require or are limited to situations characterized by the supervision (e.g. constant or intermittent) of a health care worker (e.g. a doctor, a registered nurse, a nurse practitioner, a physician's assistant, an orderly or a hospice worker).
  • a health care worker e.g. a doctor, a registered nurse, a nurse practitioner, a physician's assistant, an orderly or a hospice worker.
  • treating refers to any indicia of success in the treatment or amelioration of a disease or condition, particularly cancer. Treating or treatment may be performed in vitro and/or in vivo, and may comprise delivering an oncolytic virus, or composition thereof, described herein to a patient or subject in need thereof. In some embodiments, treating includes, for example, reducing, delaying or alleviating the severity of one or more symptoms of the disease or condition, and/or reducing the frequency with which symptoms of a disease, defect, disorder, or adverse condition are experienced by a subject or patient.
  • “treat or prevent” is used herein to refer to a method that results in some level of treatment or amelioration of the disease or condition, and contemplates a range of results directed to that end, including but not restricted to prevention of the condition entirely.
  • preventing refers to the prevention of a disease or condition, e.g., tumor formation, in a patient or subject and may also be referred to as “prophylactic treatment.” Prevention of disease development can refer to complete prevention of the symptoms of disease, a delay in disease onset, or a lessening of the severity of the symptoms in a subsequently developed disease. As a non-limiting illustrative example, if an individual at risk of developing a tumor or other form of cancer is treated with the methods of the present invention and does not later develop the tumor or other form of cancer, then the disease has been prevented, at least over a period of time, in that individual.
  • therapeutically effective amount and “therapeutically effective dose” are used interchangeably herein and refer to the amount of an oncolytic virus or composition thereof that is sufficient to provide a beneficial effect or to otherwise reduce a detrimental non-beneficial event (e.g. an amount or dose sufficient to treat a disease).
  • the exact amount or dose of an oncolytic virus comprised within a therapeutically effective amount or therapeutically effective dose will depend on variety of factors including: the purpose of the treatment; the weight, sex, age, and general health of the subject or patient; the route of administration; the timing of administrations; and the nature of the disease to be treated.
  • the therapeutically effective amount for a given subject or patient is ascertainable by one skilled in the art using known techniques (see, e.g. Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); and Pickar, Dosage Calculations (1999)).
  • “Pseudotype” refers to a virus particle, wherein a portion of the virus particle (e.g., the envelope or capsid) comprises heterologous proteins, such as viral proteins derived from a heterologous virus or non-viral proteins.
  • Non-viral proteins may include antibodies and antigen-binding fragments thereof.
  • a pseudotyped virus is capable of i) altered tropism relative to non-pseudotyped virus, and/or ii) reduction or elimination of a non-beneficial effect.
  • a pseudotyped virus demonstrates reduced toxicity or reduced infection of non-tumor cells or non-tumor tissue as compared to a non-pseudotyped virus.
  • targeting moiety refers herein to a heterologous protein linked to a virus particle that is capable of binding to a protein on the cell surface of a selected cell type in order to direct interaction between the virus particle and the selected cell type.
  • the targeting moiety may be covalently or non-covalently linked and is generally linked to an envelope protein, e.g., E1, E2, or E3.
  • Representative targeting moieties include antibodies, antigen binding fragments thereof, and receptor ligands.
  • a viral “envelope” protein, or “Env” protein refers to any polypeptide sequence that resides on the surface lipid bilayer of a virion and whose function is to mediate the adsorption to and the penetration of host cells susceptible to infection.
  • vector is used herein to refer to a nucleic acid molecule capable transferring or transporting another nucleic acid molecule.
  • the transferred nucleic acid is generally linked to, e.g., inserted into, the vector nucleic acid molecule.
  • a vector may include sequences that direct autonomous replication in a cell, or may include sequences sufficient to allow integration into host cell DNA.
  • the vector is a virus (i.e., a viral vector or oncolytic viral vector) and the transferred nucleic acid sequence is a recombinant nucleic acid sequence encoding an engager molecule and/or a therapeutic molecule.
  • a viral vector may sometimes be referred to as a “recombinant virus” or a “virus.”
  • the terms “oncolytic virus” and “oncolytic vector” are used interchangeably herein.
  • Nucleic acid genome refers to the nucleic acid component of a virus particle, which encodes the genome of the virus particle including any proteins required for replication and/or integration of the genome.
  • a viral genome acts as a viral vector and may comprise a heterologous gene operably linked to a promoter.
  • the promoter may be either native or heterologous to the gene and may be viral or non-viral in origin.
  • the viral genomes described herein may be based on any virus, may be an RNA or DNA genome, and may be either single stranded or double stranded.
  • the nucleic acid genome is from the family Rhabdoviridae.
  • Retroviral vectors refer to viral vectors based on viruses of the Retroviridae family. In their wild-type (WT) form, retroviral vectors typically contain a nucleic acid genome. Provided herein are pseudotyped retroviral vectors that also comprise a heterologous gene, such as a recombinant nucleic acid sequence described herein.
  • WT wild-type
  • pseudotyped retroviral vectors that also comprise a heterologous gene, such as a recombinant nucleic acid sequence described herein.
  • antibody fragment or derivative thereof includes polypeptide sequences containing at least one CDR and capable of specifically binding to a target antigen.
  • the term further relates to single chain antibodies, or fragments thereof, synthetic antibodies, antibody fragments, such as a Camel Ig, Ig NAR, Fab fragments, Fab′ fragments, F(ab)′2 fragments, F(ab)′3 fragments, Fv, single chain Fv antibody (“scFv”), bis-scFv, (scFv)2, minibody, diabody, triabody, tetrabody, disulfide stabilized Fv protein (“dsFv”), and single-domain antibody (sdAb, nanobody), etc., or a chemically modified derivative of any of these.
  • scFv single chain Fv antibody
  • dsFv disulfide stabilized Fv protein
  • sdAb single-domain antibody
  • antibodies or their corresponding immunoglobulin chain(s) are further modified by using, for example, amino acid deletion(s), insertion(s), substitution(s), addition(s), and/or recombination(s) and/or any other modification(s) (e.g. posttranslational and chemical modifications, such as glycosylation and phosphorylation), either alone or in combination.
  • modification(s) e.g. posttranslational and chemical modifications, such as glycosylation and phosphorylation
  • single-chain refers to the covalent linkage of two or more polypeptide sequences, preferably in the form of a co-linear amino acid sequence encoded by a single nucleic acid molecule.
  • binding to and “interacting with” are used interchangeably herein and refer to the interaction of at least two “antigen-interaction-sites” with each other.
  • An “antigen-interaction-site” refers to a motif of a polypeptide (e.g., an antibody or antigen binding fragment thereof) capable of specific interaction with an antigen or a group of antigens.
  • the binding/interaction is also understood to define a “specific interaction” or “specific binding.”
  • specific binding refers to an antigen-interaction-site that is capable of specifically interacting with and/or binding to at least two amino acids of a target molecule as defined herein.
  • the term relates to the ability of the antigen-interaction-site to discriminate between the specific regions (e.g. epitopes) of the target molecules defined herein such that it does not, or essentially does not, cross-react with polypeptides of similar structures.
  • the epitopes are linear.
  • the epitopes are conformational epitopes, a structural epitope, or a discontinuous epitope consisting of two regions of the human target molecules or parts thereof.
  • a conformational epitope is defined by two or more discrete amino acid sequences separated in the primary sequence which come together on the surface of the folded protein.
  • Specificity and/or cross-reactivity of a panel of antigen bindings construct under investigation can be tested, for example, by assessing binding of the panel of the constructs to the polypeptide of interest as well as to a number of more or less (structurally and/or functionally) closely related polypeptides under conventional conditions (see, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1988 and Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1999).
  • the specific interaction of the antigen-interaction-site with a specific antigen results in the initiation of a signal, e.g. due to the induction of a change of the conformation of the antigen, oligomerization of the antigen, etc.
  • specific binding encompasses a “key-lock-principle.” Therefore in some embodiments, specific motifs in the amino acid sequence of the antigen-interaction-site interact with specific motifs in the antigen and bind to each other as a result of their primary, secondary or tertiary structure, or as the result of secondary modifications of said structure. In some embodiments, the specific interaction of the antigen-interaction-site with its specific antigen results in a simple binding of the site to the antigen.
  • Oncolytic viruses are able to infect, replicate in, and lyse tumor cells, and are further capable of spreading to other tumor cells in successive rounds of replication. While past oncolytic virus therapy has shown promise in preclinical models and clinical studies, anti-tumor efficacy of these oncolytic virus, such as vaccinia, has been suboptimal. For example, these viruses demonstrated limited viral spread throughout the tumor and/or limited activation of anti-tumor T cell responses within the tumor. Therefore, the present disclosure provides an oncolytic virus that 1) facilitates tumor infiltration and activation of effector cells (e.g., T cells), and 2) effectively lyses tumor cells that are not infected the virus (also known as by-stander killing).
  • effector cells e.g., T cells
  • viral vectors which have advantages including one or more of the following properties:
  • VSV vesicular stomatitis viruses
  • the VSV genome includes five genes, l, m, n, p and g, which encode the proteins L, M, N, P and G and are essential for the reproduction of the virus.
  • N is a nucleoprotein which packages the VSV genomic RNA.
  • the VSV genome is replicated as RNA-protein complex and L and P together form a polymerase complex which replicates the VSV genome and transcribes the VSV mRNA.
  • M is a matrix protein which provides structural support between the lipid envelope and nucleocapsid and is important for particle sprouting at the cell membrane.
  • G is the envelope protein which is incorporated in the viral envelope and is essential for the infectivity and tropism of the virus.
  • the present invention provides oncolytic viruses that are capable of being pseudotyped or otherwise engineered.
  • “Pseudotyped viruses” refer to viruses in which one or more of the viral coat proteins (e.g., envelope proteins) have been replaced or modified.
  • a pseudotyped virus is capable of infecting a cell or tissue type that the corresponding non-pseudotyped virus is not capable of infecting.
  • a pseudotyped virus is capable of perferentially infecting a cell or tissue type compared to a non-pseudotyped virus.
  • viruses have natural host cell populations that they infect most efficiently.
  • retroviruses have limited natural host cell ranges
  • adenoviruses and adeno-associated viruses are able to efficiently infect a relatively broader range of host cells, although some cell types are refractory to infection by these viruses.
  • the proteins on the surface of a virus e.g., envelope proteins or capsid proteins
  • the oncolytic viruses described herein comprise a single types of protein on the surface of the virus.
  • retroviruses and adeno-associated viruses have a single protein coating their membrane.
  • the oncolytic viruses described herein comprise more than one type of protein on the surface of the virus.
  • adenoviruses are coated with both an envelope protein and fibers that extend away from the surface of the virus.
  • the proteins on the surface of the virus can bind to cell-surface molecules such as heparin sulfate, thereby localizing the virus to the surface of the potential host cell.
  • the proteins on the surface of the virus can also mediate interactions between the virus and specific protein receptors expressed on a host cell that induce structural changes in the viral protein in order to mediate viral entry.
  • interactions between the proteins on the surface of the virus and cell receptors can facilitate viral internalization into endosomes, wherein acidification of the endosomal lumen induces refolding of the viral coat.
  • viral entry into potential host cells requires a favorable interaction between at least one molecule on the surface of the virus and at least one molecule on the surface of the cell.
  • the oncolytic viruses described herein comprise a viral coat (e.g., a viral envelop or viral capsid), wherein the proteins present on the surface of the viral coat (e.g., viral envelop proteins or viral capsid proteins) modulate recognition of a potential target cell for viral entry.
  • a viral coat e.g., a viral envelop or viral capsid
  • the proteins present on the surface of the viral coat e.g., viral envelop proteins or viral capsid proteins
  • this process of determining a potential target cell for entry by a virus is referred to as host tropism.
  • the host tropism is cellular tropism, wherein viral recognition of a receptor occurs at a cellular level, or tissue tropism, wherein viral recognition of cellular receptors occurs at a tissue level.
  • the viral coat of a virus recognizes receptors present on a single type of cell.
  • the viral coat of a virus recognizes receptors present on multiple cell types (e.g., 2, 3, 4, 5, 6 or more different cell types). In some instances, the viral coat of a virus recognizes cellular receptors present on a single type of tissue. In other instances, the viral coat of a virus recognizes cellular receptors present on multiple tissue types (e.g., 2, 3, 4, 5, 6 or more different tissue types).
  • the oncolytic viruses described herein comprise a viral coat that has been modified to incorporate surface proteins from a different virus in order to facilitate viral entry to a particular cell or tissue type.
  • Such oncolytic viruses are referred to herein as pseudotyped oncolytic viruses.
  • a pseudotyped oncolytic viruses comprises a viral coat wherein the viral coat of a first virus is exchanged with a viral coat of second, wherein the viral coat of the second virus is allows the pseudotyped oncolytic virus to infect a particular cell or tissue type.
  • the viral coat comprises a viral envelope.
  • the viral envelope comprises a phospholipid bilayer and proteins such as proteins obtained from a host membrane.
  • the viral envelope further comprises glycoproteins for recognition and attachment to a receptor expressed by a host cell.
  • the viral coat comprises a capsid.
  • the capsid is assembled from oligomeric protein subunits termed protomers.
  • the capsid is assembled from one type of protomer or protein, or is assembled from two, three, four, or more types of protomers or proteins.
  • the chimeric proteins are comprised of parts of a viral protein necessary for incorporation into the virion, as well proteins or nucleic acids designed to interact with specific host cell proteins, such as a targeting moiety.
  • the pseudotyped oncolytic viruses described herein are pseudotyped in order to limit or control the viral tropism (i.e., to reduce the number of cell or tissue types that the pseudotyped oncolytic virus is capable of infecting).
  • Most strategies adopted to limit tropism have used chimeric viral coat proteins (e.g., envelope proteins) linked antibody fragments. These viruses show great promise for the development of oncolytic therapies.
  • the pseudotyped oncolytic viruses described herein are pseudotyped in order to expand the viral tropism (i.e., to increase the number of cell or tissue types that the pseudotyped oncolytic virus is capable of infecting).
  • viruses e.g., enveloped viruses
  • pseudotypes a process that commonly occurs during viral assembly in cells infected with two or more viruses.
  • HIV-1 human immunodeficiency virus type 1
  • HIV1 infects cells that express CCR4 with an appropriate co-receptor.
  • HIV1 forms pseudotypes by the incorporation of heterologous glycoproteins (GPs) through phenotypic mixing, such that the virus can infect cells that do not express the CD4 receptor and/or an appropriate co-receptor, thereby expanding the tropism of the virus.
  • GPs heterologous glycoproteins
  • VSV G-proteins VSV-G
  • lentivirus pseudotypes include pseudotypes bearing lyssavirus-derived GPs, pseudotyped lentiviruses bearing lymphocytic choriomeningitis virus GPs, lentivirus pseudotypes bearing alphavirus GPs (e.g., lentiviral vectors pseudotyped with the RRV and SFV GPs, lentiviral vectors pseudotyped with Sindbis virus GPs), pseudotypes bearing filovirus GPs, and lentiviral vector pseudotypes containing the baculovirus GP64.
  • pseudotypes bearing lyssavirus-derived GPs pseudotyped lentiviruses bearing lymphocytic choriomeningitis virus GPs
  • lentivirus pseudotypes bearing alphavirus GPs e.g., lentiviral vectors pseudotyped with the RRV and SFV GPs, lentiviral vectors pseudotyped with Sindbis virus GPs
  • the engineered (e.g., pseudotyped) viruses are capable of binding to a tumor and/or tumor cell, typically by binding to a protein, lipid, or carbohydrate expressed on a tumor cell.
  • the engineered viruses described herein may comprise a targeting moiety that directs the virus to a particular host cell.
  • any cell surface biological material known in the art or yet to be identified that is differentially expressed or otherwise present on a particular cell or tissue type e.g., a tumor or tumor cell, or tumor associated stroma or stromal cell
  • the cell surface material is a protein.
  • the targeting moiety binds cell surface antigens indicative of a disease, such as a cancer (e.g., breast, lung, ovarian, prostate, colon, lymphoma, leukemia, melanoma, and others); an autoimmune disease (e.g., a cancer (e.g., breast, lung, ovarian, prostate, colon, lymphoma, leukemia, melanoma, and others); an autoimmune disease (e.g.
  • a cancer e.g., breast, lung, ovarian, prostate, colon, lymphoma, leukemia, melanoma, and others
  • an autoimmune disease e.g.
  • myasthenia gravis multiple sclerosis, systemic lupus erythymatosis, rheumatoid arthritis, diabetes mellitus, and others
  • an infectious disease including infection by HIV, HCV, HBV, CMV, and HPV
  • a genetic disease including sickle cell anemia, cystic fibrosis, Tay-Sachs, J3-thalassemia, neurofibromatosis, polycystic kidney disease, hemophilia, etc.
  • the targeting moiety targets a cell surface antigen specific to a particular cell or tissue type, e.g., cell-surface antigens present in neural, lung, kidney, muscle, vascular, thyroid, ocular, breast, ovarian, testis, or prostate tissue.
  • a cell surface antigen specific to a particular cell or tissue type e.g., cell-surface antigens present in neural, lung, kidney, muscle, vascular, thyroid, ocular, breast, ovarian, testis, or prostate tissue.
  • antigens and cell surface molecules for targeting include, e.g. P-glycoprotein, Her2/Neu, erythropoietin (EPO), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGF-R), cadherin, carcinoembryonic antigen (CEA), CD4, CD8, CD19, CD20, CD33, CD34, CD45, CD117 (c-kit), CD133, HLA-A, HLA-B, HLA-C, chemokine receptor 5 (CCR5), stem cell marker ABCG2 transporter, ovarian cancer antigen CA125, immunoglobulins, integrins, prostate specific antigen (PSA), prostate stem cell antigen (PSCA), dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN), thyroglobulin, granulocyte-macrophage colony stimulating factor (GM-CSF), myogenic differentiation promoting factor-1 (MyoD-1), Leu
  • the pseudotyped oncolytic viruses provided herein are capable of selectively entering, replicating in, and/or lysing tumor cells. Such an embodiment is illustrated in FIG. 36 , wherein the pseudotyped oncolytic virus gains entry to the target cell due to the incorporation of viral glycoproteins derived from a different (i.e., heterologous) virus that allow for entry of the pseudotyped oncolytic virus into the target cell. In contrast, the non-pseudotyped oncolytic virus is unable to gain entry into the target cell due to the non-permissive nature of the envelope proteins.
  • the ability of a pseudotyped oncolytic virus to selectively enter, replicate in, and/or lyse a tumor cells is due to a reduced or otherwise ineffective cellular interferon (IFN) response.
  • the pseudotyped oncolytic viruses produce an engager molecule and/or a therapeutic molecule, such as an immune modulating polypeptide, that interferes or impairs the cellular IFN response, thereby enhancing the replication of the pseudotyped or engineered virus.
  • the pseudotyped oncolytic viruses described herein may be derived from a variety of viruses, non-limiting examples of which include vaccinia virus, adenovirus, herpes simplex virus 1 (HSV1), myxoma virus, reovirus, poliovirus, vesicular stomatitis virus (VSV), measles virus (MV), lassa virus (LASV) and Newcastle disease virus (NDV).
  • the pseudotyped oncolytic viruses described herein can infect substantially any cell type.
  • An exemplary lentivirus for use in oncolytic therapy is Simian immunodeficiency virus coated with the envelope proteins, G-protein (GP), from VSV. In some instances, this virus is referred to as VSV G-pseudotyped lentivirus, and is known to infect an almost universal set of cells.
  • the pseudotyped oncolytic viruses of the present invention are VSV viruses pseudotyped against healthy brain cells, i.e., neurons and exhibit considerably reduced toxicity. Since neurotropism is a dose-limiting factor in all applications of oncolytic VSV, the use of the vector according to some embodiments of the present invention is that they are used for all tumors types of solid tumors.
  • the pseudotyped VSV vectors have one or more key attributes including: (i) the VSV is not cell-toxic; (ii) the vectors are concentrated by ultracentrifugation without loss of infectivity; and (iii) the vectors show a tropism for tumor cells, whereas neurons and other non-tumor cells are infected inefficiently.
  • some embodiments of the present invention provide a vector system which ensures that replication, oncolysis and the production of VSV viruses takes place only in cells which are infected by at least two replication-deficient, mutually complementing vectors.
  • the genetic material for generating a pseudotyped oncolytic virus is obtained from a DNA virus, an RNA virus, or from both virus types.
  • a DNA virus is a single-stranded (ss) DNA virus, a double-stranded (ds) DNA virus, or a DNA virus that contains both ss and ds DNA regions.
  • an RNA virus is a single-stranded (ss) RNA virus or a double-stranded (ds) RNA virus.
  • an ssRNA virus is further classified into a positive-sense RNA virus or a negative-sense RNA virus.
  • the genetic material for generating a pseudotyped oncolytic virus is obtained from a dsDNA virus of any one of the following families: Myoviridae, Podoviridae, Siphoviridae, Alloherpesviridae, Herpesviridae, Malacoherpesviridae, Lipothrixviridae, Rudiviridae, Adenoviridae, Ampullaviridae, Ascoviridae, Asfaviridae, Baculoviridae, Bicaudaviridae, Clavaviridae, Corticoviridae, Fuselloviridae, Globuloviridae, Guttaviridae, Hytrosaviridae, Iridoviridae, Marseilleviridae, Mimiviridae, Nimaviridae, Pandoraviridae, Papillomaviridae, Phycodnaviridae, Plasmaviridae, Polydnaviruse
  • the genetic material for generating a pseudotyped oncolytic virus is obtained from a ssDNA virus of any one of the following families: Anelloviridae, Bacillariodnaviridae, Bidnaviridae, Circoviridae, Geminiviridae, Inoviridae, Microviridae, Nanoviridae, Parvoviridae, or Spiraviridae.
  • the genetic material for generating a pseudotyped oncolytic virus is obtained from a DNA virus that contains both ssDNA and dsDNA regions.
  • the DNA virus is from the group pleolipoviruses.
  • the pleolipoviruses include Haloarcula hispanica pleomorphic virus 1, Halogeometricum pleomorphic virus 1, Halorubrum pleomorphic virus 1, Halorubrum pleomorphic virus 2, Halorubrum pleomorphic virus 3, or Halorubrum pleomorphic virus 6.
  • the genetic material for generating a pseudotyped oncolytic virus is obtained from a dsRNA virus of any one of the following families: Birnaviridae, Chrysoviridae, Cystoviridae, Endornaviridae, Hypoviridae, Megavirnaviridae, Partitiviridae, Picobirnaviridae, Reoviridae, Rotavirus or Totiviridae.
  • the genetic material for generating a pseudotyped oncolytic virus is obtained from a positive-sense ssRNA virus of any one of the following families: Alphaflexiviridae, Alphatetraviridae, Alvemaviridae, Arteriviridae, Astroviridae, Bamaviridae, Betaflexiviridae, Bromoviridae, Caliciviridae, Carmotetraviridae, Closteroviridae, Coronaviridae, Dicistroviridae, Flaviviridae, Gammaflexiviridae, Iflaviridae, Leviviridae, Luteoviridae, Marnaviridae, Mesoniviridae, Namaviridae, Nodaviridae, Permutotetraviridae, Picornaviridae, Potyviridae, Roniviridae, Secoviridae, Togaviridae, Tombusviridae, Tymovirida
  • the genetic material for generating a pseudotyped oncolytic virus is obtained from a negative-sense ssRNA virus of any one of the following families: Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Nyamiviridae, Arenaviridae, Bunyaviridae, Ophioviridae, or Orthomyxoviridae.
  • the genetic material for generating a pseudotyped oncolytic virus is obtained from oncolytic DNA viruses that comprise capsid symmetry that is isocahedral or complex.
  • isosahedral oncolytic DNA viruses are naked or comprise an envelope.
  • Exemplary families of oncolytic DNA viruses include the Adenoviridae (for example, Adenovirus, having a genome size of 36-38 kb), Herpesviridae (for example, HSV1, having a genome size of 120-200 kb), and Poxviridae (for example, Vaccinia virus and myxoma virus, having a genome size of 130-280 kb).
  • the genetic material for generating a pseudotyped oncolytic virus is obtained from oncolytic RNA viruses include those having icosahedral or helical capsid symmetry.
  • icosahedral oncolytic viruses are naked without envelope and include Reoviridae (for example, Reovirus, having a genome of 22-27 kb) and Picornaviridae (for example, Poliovirus, having a genome size of 7.2-8.4 kb).
  • helical oncolytic RNA viruses are enveloped and include Rhabdoviridae (for example, VSV, having genome size of 13-16 kb) and Paramyxoviridae (for example MV and NDV, having genome sizes of 16-20 kb).
  • Rhabdoviridae for example, VSV, having genome size of 13-16 kb
  • Paramyxoviridae for example MV and NDV, having genome sizes of 16-20 kb
  • the genetic material for generating a pseudotyped oncolytic virus is obtained from a virus such as Abelson leukemia virus, Abelson murine leukemia virus, Abelson's virus, Acute laryngotracheobronchitis virus, Sydney River virus, Adeno associated virus group, Adenovirus, African horse sickness virus, African swine fever virus, AIDS virus, Aleutian mink disease parvovirus, Alpharetrovirus, Alphavirus, ALV related virus, Amapari virus, Aphthovirus, Aquareovirus, Arbovirus, Arbovirus C, arbovirus group A, arbovirus group B, Arenavirus group, Argentine hemorrhagic fever virus, Argentine hemorrhagic fever virus, Arterivirus, Astrovirus, Ateline herpesvirus group, Aujezky's disease virus, Aura virus, Ausduk disease virus, Australian bat lyssavirus, Aviadenovirus, avian erythroblastosis virus,
  • a pseudotyped oncolytic virus described herein is generated using methods well known in the art. In some instances, the methods involve one or more transfection steps and one or more infection steps. In some instances, a cell line such as a mammalian cell line, an insect cell line, or a plant cell line is infected with a pseudotyped oncolytic virus described herein to produce one or more viruses.
  • a cell line such as a mammalian cell line, an insect cell line, or a plant cell line is infected with a pseudotyped oncolytic virus described herein to produce one or more viruses.
  • Exemplary mammalian cell lines include: 293A cell line, 293FT cell line, 293F cells, 293 H cells, CHO DG44 cells, CHO-S cells, CHO-K1 cells, Expi293FTM cells, Flp-InTM T-RExTM 293 cell line, Flp-InTM-293 cell line, Flp-InTM-3T3 cell line, Flp-InTM-BHK cell line, Flp-InTM-CHO cell line, Flp-InTM-CV-1 cell line, Flp-InTM-Jurkat cell line, FreeStyleTM 293-F cells, FreeStyleTM CHO-S cells, GripTiteTM 293 MSR cell line, GS-CHO cell line, HepaRGTM cells, T-RExTM Jurkat cell line, Per.C6 cells, T-RExTM-293 cell line, T-RExTM-CHO cell line, T-RExTM-HeLa cell line, 3T6, A549, A9, AtT-20, BALB/3T3, BHK
  • any method known to one skilled in the art is used for large scale production of recombinant oncolytic vectors and vector constructs, such as pseudotyped oncolytic vectors.
  • master and working seed stocks can be prepared under GMP conditions in qualified primary CEFs or by other methods.
  • cells are plated on large surface area flasks, grown to near confluency, and infected at selected MOI.
  • the produced virus can then be purified.
  • cells are harvested and intracellular virus is released by mechanical disruption.
  • cell debris is removed by large-pore depth filtration and/or host cell DNA is digested with an endonuclease.
  • virus particles are subsequently purified and concentrated by tangential-flow filtration, followed by diafiltration.
  • the resulting concentrated virus can formulated by dilution with a buffer containing one or more stabilizers, filled into vials, and lyophilized. Compositions and formulations can be stored for later use. In some embodiments, a lyophilized virus is reconstituted by addition of one or more diluents.
  • the oncolytic viral vectors provided herein are pseudotyped oncolytic viruses that are further engineered to include a polynucleotide sequence that encodes an engager molecule, e.g., an engager polypeptide.
  • the engager molecules of the present invention comprise at least two domains each capable of binding to a different cell surface molecule.
  • engager polypeptides comprise an antigen recognition domain and an activation domain that recognize particular cell surface proteins (e.g., cell-surface receptors or ligands) expressed by target and effector cells, respectively.
  • an “antigen recognition domain” is a polypeptide that binds one or more molecules present on the cell surface of a target cell (e.g., a tumor antigen), and an “activation domain” is a polypeptide that binds to one or more molecules present on the cell surface of an effector cell (e.g., an activation molecule).
  • An activation domain may also be referred to as an “engager domain.”
  • engager polypeptides comprise a therapeutic molecule domain and an activation domain.
  • a therapeutic molecule domain is a polypeptide that binds to a particular cell surface protein expressed on an effector cell (e.g., cell-surface receptors or ligands) and that is distinct from the cell surface protein recognized by the activation domain.
  • the therapeutic molecule domain binds to a cell surface protein that is a negative regulator of effector cell function (e.g., an immune checkpoint molecule or other inhibitory molecule).
  • Exemplary cell-surface antigen for targeting by a therapeutic domain include CD47, PD1, PDL1, CTLA4, TIM2, LAG3, BTLA, KIR, TIGIT, OX40, FITR, CD27, SLAMF7, and CD200.
  • binding of an activation domain to a molecule present on the surface of the effector cell results in activation of the effector cell.
  • binding of an activation domain to a molecule on an effector cell and binding of an antigen recognition domain to a molecule present on a target cell brings the effector cell in close proximity to the target cell and thereby facilitates the destruction of the target cell by the effector cell.
  • binding of an activation domain to an activation molecule on an effector cell and binding of a therapeutic molecule domain to an inhibitory molecule present on an effector cell enhances the activation of the effector cell and thereby facilitates the destruction of one or more bystander target cells by the effector cell.
  • the engager molecule is a protein, e.g., an engineered protein. In some embodiments, the engager molecule is a bipartite polypeptide. In some embodiments, the engager molecule is a tripartite or multipartite polypeptide. In such embodiments, the engager molecule may comprise one or more activation domains and/or antigen recognition domains, or other domains, including one or more co-stimulatory domains, one or more dimerization or trimerization domains, or other domain capable of binding a molecule expressed on the cell surface. Alternatively, the one or more additional domains are optionally present on a separate polypeptide. In some embodiments, the engager molecule comprises an antibody or antibody fragment.
  • the engager molecule is a is a trifunctional antibody, an Fab 2 , a bi-specific scFv such as a bi-specific T-cell engager (BiTE), a bivalent minibody, a bispecific diabody, a DuoBody, or an Mab2.
  • the engager molecule is a bipartite T cell engager (BiTE) or a tripartite T cell engager (TiTE).
  • the activation domain, the antigen recognition domain, and/or the therapeutic molecule domain of the engager molecule comprises an antibody or an antigen-binding fragment thereof, e.g., a single chain variable fragment (scFv), a monoclonal antibody, Fv, Fab, minibody, diabody.
  • the activation domain, the antigen recognition domain, and/or the therapeutic molecule domain of the engager molecule comprises a ligand, a peptide, a peptide that recognize and interacts with a soluble TCR, or combinations thereof.
  • these antibody-derived fragments or derivatives may be modified by chemical, biochemical, or molecular biological methods.
  • polypeptides, antibodies, or antigen-binding fragments thereof used in the construction of the engager molecules described herein are humanized or deimmunized constructs. Methods for the humanization and/or deimmunization of polypeptides and, in particular, antibody constructs are known to the person skilled in the art.
  • the respective domains are in any order from N-terminus to C-terminus.
  • the engager molecule may comprise an N-terminal activation domain and a C-terminal antigen recognition domain.
  • the engager molecule may comprise an N-terminal antigen recognition domain and a C-terminal activation domain.
  • the engager molecule may comprise an N-terminal activation domain and a C-terminal therapeutic molecule domain.
  • the engager molecule may comprise an N-terminal therapeutic molecule domain and a C-terminal activation domain.
  • T-cells are modified to secrete engager molecules that have an antigen recognition domain or therapeutic molecule domain N-terminal to an activation domain.
  • linker is of any suitable length, and such a parameter is routinely optimized in the art.
  • linkers are of a length and sequence sufficient to ensure that each of the first and second domains can, independently from one another, retain their differential binding specificities.
  • peptide linker refers to an amino acid sequence by which the amino acid sequences of a first domain (e.g., an activation domain) and a second domain (e.g., an antigen recognition domain or therapeutic molecule domain) of a defined construct are linked together.
  • one technical feature of such peptide linker is that said peptide linker does not comprise any polymerization activity and/or does not promote formation of secondary structures.
  • Such peptide linkers are known in the art and described, for example, in Dall'Acqua et al. (Biochem. (1998) 37, 9266-9273); Cheadle et al. (Mol Immunol (1992) 29, 21-30); and Raag and Whitlow (FASEB (1995) 9(1), 73-80).
  • the peptide linkers of the present invention comprise less than 5 amino acids, less than 4 amino acids, less than 3 amino acids, less than 2 amino acids, or 1 amino acid.
  • the peptide linker is a single amino acid linker.
  • the single amino acid is typically a glycine (Gly).
  • peptide linkers that also do not promote any secondary structures are preferred.
  • the engager molecule is a single chain bi-specific antibody construct.
  • single chain bispecific antibody construct refers to a construct comprising two antibody-derived binding domains. One of the binding domains comprises variable regions (or parts thereof) of both heavy chain (VH) and light chain (VL) of an antibody or antigen binding fragments or derivatives thereof, capable of specifically binding to/interacting with an activation molecule expressed on an effector cell (e.g., CD3).
  • VH heavy chain
  • VL light chain
  • an activation molecule expressed on an effector cell e.g., CD3
  • the second binding domain comprises variable regions (or parts thereof) of both heavy chain (VH) and light chain (VL) of an antibody or antigen binding fragments or derivatives thereof, capable of specifically binding to/interacting with a target antigen expressed on a target cell (e.g., CD19) or an antigen expressed by and effector cell (e.g., an inhibitor molecule).
  • VH heavy chain
  • VL light chain
  • each of the two antibody or antigen binding fragments or derivatives comprise at least one complementary determining region (CDR), particularly a CDR3.
  • the single chain bi-specific antibody construct is a bispecific scFv or diabody.
  • the single chain bispecific antibody construct is a single chain bispecific scFv.
  • An scFv in general contains a VH and VL domain connected by a linker peptide.
  • a single chain bispecific scFv is comprised of a signal peptide to allow for secretion from cells, followed by two scFvs connected by one or more linker peptides (Lx, Ly, Lz).
  • Bispecific single chain molecules are known in the art and are described in International PCT Publication No. WO 99/54440; Mack, J. Immunol. (1997), 158, 3965-3970; Mack, PNAS, (1995), 92, 7021-7025; Kufer, Cancer Immunol. Immunother., (1997), 45, 193-197; Loftier, Blood, (2000), 95, 6, 2098-2103; and Bruhl, J. Immunol., (2001), 166, 2420-2426.
  • the molecular format of the polynucleotide encoding a single chain bi-specific scFv polypeptide comprises nucleic acid sequence encoding a signal peptide (such as the signal sequences of SEQ ID NO: 2 and 4) followed by two or more antibody-derived regions (e.g., a first scFv and a second scFv).
  • Each antibody-derived region e.g., scFv
  • the two or more antibody-derived regions are scFvs and are linked by a peptide linker to form a single chain bi-specific scFv construct.
  • the bi-specific scFv is a tandem bi-scFv or a diabody.
  • Bispecific scFvs can be arranged in different formats including the following: VHO-Lx-V La -Ly-V H -Lz-ViJ3, V La -Lx-V Ha -Ly-VH-Lz-ViJ3, V La -Lx-V H -Ly-VL-Lz-VH, V H -Lx-V La -Ly-VL-Lz-VH, V H -Lx-VL-Ly-VH-Lz-V La , V La -Lx-VL-Ly-VH-Lz-V H , VH-Lx-VH-Ly-VL-Lz-VLa, VLa-Lx-VH-Ly-VL-Lz-V H , VH-Lx-V La -Ly-V H -Lz-VL, V
  • the engager molecule comprises multiple (e.g., 2, 3, 4, 5 or more) antigen binding domains to allow targeting of multiple antigens. In some embodiments, the engager molecule comprises multiple (e.g., 2, 3, 4, 5 or more) activation domains to activate effector cells. In some embodiments, the engager molecule comprises multiple (e.g., 2, 3, 4, 5 or more) therapeutic molecule domains to activate effector cells.
  • the engager molecule comprises additional domains for the isolation and/or preparation of recombinantly produced constructs, such as a tag or a label.
  • the tag or label may be a short peptide sequence, such as a histidine tag (SEQ ID NO: 12), or may be a tag or label that is capable of being imaged, such as fluorescent or radioactive label.
  • the engager molecules of the present invention specifically bind to/interact with a particular conformational/structural epitope(s) of a target antigen expressed on a target cell and an activation molecule expressed on an effector cell (e.g., an activation domain that specifically binds to one of the two regions of the human CD3 complex, or parts thereof).
  • the engager molecules of the present invention specifically bind to/interact with a particular conformational/structural epitope(s) of an activation molecule expressed on an effector cell and a different cell-surface protein expressed on an effector cell. Accordingly, specificity in some instances is determined experimentally by methods known in the art and methods as disclosed and described herein.
  • Such methods comprise, but are not limited to Western blots, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunoprecipitation (RIP), electrochemiluminescence (ECL), immunoradiometric assay (IRMA), enzyme immunoassay (EIA), and peptide scans.
  • ELISA enzyme-linked immunosorbent assay
  • RIA radioimmunoassay
  • RIP radioimmunoprecipitation
  • ECL electrochemiluminescence
  • IRMA immunoradiometric assay
  • EIA enzyme immunoassay
  • peptide scans peptide scans.
  • the term “effector cell” refers to any mammalian cell type that is capable of facilitating the death of a target cell.
  • the effector cells of the present invention are immune cells, such as a T cell, a B cell, an innate lymphocyte, a natural killer (NK) cell, a natural killer T cell (NKT), a granulocyte (e.g., a neutrophil, basophil, mast cell, or eosinophil), a macrophage, a monocyte, or a dendritic cell.
  • exemplary effector cell types include T cells, NK cells, NKT cells, and macrophages.
  • activation of an effector cell may result in one or more of the following: (i) increased proliferation of the effector cell; (ii) changes in the expression or activity of one or more cell surface proteins of the effector cell; (iii) change in expression or activity of one or more intracellular proteins expressed by the effector cell; (iv) changes in the amount or nature of factors produced and/or secreted by the effector cell, such as cytokines, chemokines or reactive oxygen species; (v) changes in the morphology of the effector cell; (vi) changes in the chemotactic potential of the effector cell, such as through increased or decreased expression of one or more chemokine receptors; (vii) changes in the functional activity of the effector cell, such as increased cytolytic activity and/or increased phagocytic activity.
  • Activation of an effector cell, or population of effector cells can be determined by any means known in the art. For example, changes in proliferation, protein expression, production, or secretion can be determined by flow cytometry, Western blot, ELISA, immunohistochemistry, immunoprecipitation, or immunofluorescence and changes in cell morphology can be determined by numerous types of microscopy known in the art.
  • the nature of the activating molecule may vary according to the nature of the effector cell, although different groups of effector cells may share expression of certain types of activation molecules.
  • T cells express different surface receptors, i.e. different activating receptors, than NK cells or macrophages.
  • CD3 is an activating receptor expressed by T-cells that is not expressed by NK cells or macrophages
  • CD1, CD16, NKG2D, and/or NKp30 are activating receptors expressed by NK cells that are not expressed by T cells. Therefore, in some instances, engager molecules that activate T-cells have a different activation domain than engager molecules that activate NK cells, macrophages, NKT cells, or other types of effector cells. Exemplary activation molecules are described below and shown in Table 1.
  • the effector cell is a T cell and the activation domain of the engager molecule binds to an activation molecule expressed by the T cell.
  • the T-cell repertoire is comprised of numerous sub-types of T cell, including NKT cells, cytotoxic T cells (Tc or CTL), memory T cells, helper T cells (e.g., Th1, Th2, Th17, Th9, and/or Th22 cells), suppressor T cells (e.g., regulator T cells (Tregs)), mucosal-associated invariant T cells, and ⁇ T cells.
  • Tc or CTL cytotoxic T cells
  • memory T cells e.g., cytotoxic T cells (Tc or CTL)
  • helper T cells e.g., Th1, Th2, Th17, Th9, and/or Th22 cells
  • suppressor T cells e.g., regulator T cells (Tregs)
  • mucosal-associated invariant T cells e.g., mucosal-associated invariant T
  • one or more surface receptors expressed by one T cell subtype are expressed by at least one other T cell subtype. In some instances, one or more surface receptors expressed by one T cell subtype are generally expressed by all, or most, T cell subtypes.
  • CD3 is a signaling component of the T cell receptor (TCR) complex and is expressed in multiple T cell subtypes.
  • Exemplary activation molecules expressed by T cells include, but are not limited to one or more components of CD3, (e.g., CD3 ⁇ , CD3 ⁇ , CD3 ⁇ or CD3 ⁇ ), CD2, CD4, CD5, CD6, CD7, CD8, CD25, CD27, CD28, CD30, CD38, CD40, CD57, CD69, CD70, CD73, CD81, CD82, CD134, CD137, CD152, or CD278.
  • the effector cell is an NKT-cell.
  • the activation molecule includes, but is not limited to, CD3 or an invariant TCR.
  • the effector cell is an NK cell and the activation domain of the engager molecule binds to an activation molecule expressed by the NK cell.
  • exemplary activation molecules expressed by NK cells include, but are not limited to, CD116, CD94/NKG2 (e.g., NKG2D), NKp30, NKp44, NKp46, or killer activation receptors (KARs).
  • T cell Activation NKT cell Activation Molecules Molecules CD3 or components CD3 thereof (e.g., CD3 ⁇ , CD3 ⁇ , CD3 ⁇ or CD3 ⁇ ) CD2 invariant TCR CD4 NK Cell Activation Molecules CD5 CD16 CD6 CD94/NKG2 (e.g., NKG2D) CD7 NKp30 CD8 NKp44 CD16 NKp46 CD25 KARs CD27 CD28 CD30 CD38 CD40 CD57 CD69 CD70 CD73 CD81 CD82 CD134 CD137 CD152 CD278
  • CD3 or components CD3 thereof e.g., CD3 ⁇ , CD3 ⁇ , CD3 ⁇ or CD3 ⁇
  • CD2 invariant TCR CD4 NK Cell Activation Molecules CD5 CD16 CD6 CD94/NKG2 (e.g., NKG2D) CD7 NKp30 CD8 NKp44 CD16 NKp46 CD25 KARs CD27 CD28 CD30 CD38 CD
  • binding of an engager molecule to a target cell and an effector cell brings the effector cell in close proximity to the target cell and thereby facilitates the destruction of the target cell by the effector cell.
  • an effector cell refers to a mammalian cell that should be killed, attacked, destroyed, and/or controlled.
  • target cells are cells that are in some way altered compared to a normal cell of the same cell type, such as a cancerous cell, a bacterially-infected cell, a virally-infected cell, a fungally-infected cell, and/or an autoimmune cell.
  • the target cells of the present invention are cancerous cells (e.g., tumor cells).
  • Destruction (i.e., death) of a target cell can be determined by any means known in the art, such as flow cytometry (e.g., by AnnexinV, propidium iodide, or other means), cell counts, and/or microscopy to determine the cellular morphology of the target cells.
  • the antigen recognition domain of an engager molecule brings a target cell (e.g., tumor cell) into the vicinity of an effector cell via interaction between the antigen recognition domain and surface antigens expressed by the target cell (e.g., target cell antigens).
  • the target-cell antigen is a tumor antigen.
  • a tumor antigen is a tumor-specific antigen (TSA), and is expressed only by tumor cells.
  • TSA tumor-specific antigen
  • the target cell angien is a tumor-associated antigen (TAA), and is expressed by tumor cells and one or more types of normal cells or non-tumor cells.
  • TSA is also present in one or more types of normal cells or non-tumor cells, but is predominantly expressed by tumor cells.
  • a tumor antigen e.g., TSA or TAA
  • TSA or TAA is present in one cancer type.
  • a tumor antigen is present in multiple cancer types.
  • a tumor antigen is expressed on a blood cancer cell.
  • a tumor antigen is expressed on a cell of a solid tumor.
  • the solid tumor is a glioblastoma, a non-small cell lung cancer, a lung cancer other than a non-small cell lung cancer, breast cancer, prostate cancer, pancreatic cancer, liver cancer, colon cancer, stomach cancer, a cancer of the spleen, skin cancer, a brain cancer other than a glioblastoma, a kidney cancer, a thyroid cancer, or the like.
  • a tumor antigen is expressed by a tumor cell in an individual.
  • Exemplary tumor antigens include, but are not limited to, alphafetoprotein (AFP), carcinoembryonic antigen (CEA), CA-125, epithelial tumor antigen (ETA), tyrosinase, CD10 (also known as neprilysin, membrane metallo-endopeptidase (MME), neutral endopeptidase (NEP), or common acute lymphoblastic leukemia antigen (CALLA)), CD15, CD19, CD20, CD21, CD22, CD30, CD33, CD38, CD44, CD44v6, CD44v7/8, CD70, CD123, CD138, CD171, ras, p53, v-raf murine sarcoma viral oncogene homolog B1 (BRAF), calcium binding tyrosine-(Y)-pbosphorylation regulated (CABYR), cysteine-rich secretory protein 3 (CRISP3)
  • BRAF alphafetoprotein
  • Other exemplary tumor antigens are antigens that are present in the extracellular matrix of tumors, such as oncofetal variants of fibronectin, tenascin, or necrotic regions of tumors.
  • the antigen recognition domain of an engager molecule specifically binds a tumor-associated antigen (TAA) or a tumor-specific antigen (TSA).
  • TAA tumor-associated antigen
  • TSA tumor-specific antigen
  • the antigen recognition domain comprises an antibody or an antibody fragment or an antigen-binding fragment or portion thereof, such as for example, a monoclonal antibody, Fv, a scFv, Fab, minibody, or diabody that is specific for a TAA or TSA.
  • the antigen recognition domain of the engager is an scFv that is specific for a TAA or TSA.
  • the TAA or TSA is expressed on a cancer cell. In one embodiment, the TAA or TSA is expressed on a blood cancer cell.
  • the TAA or TSA is expressed on a cell of a solid tumor.
  • the solid tumor is a glioblastoma, a non-small cell lung cancer, a lung cancer other than a non-small cell lung cancer, breast cancer, prostate cancer, pancreatic cancer, liver cancer, colon cancer, stomach cancer, a cancer of the spleen, skin cancer, a brain cancer other than a glioblastoma, a kidney cancer, a thyroid cancer, or the like.
  • the TAA or TSA is expressed by a tumor cell in an individual.
  • the antigen-recognition domain of the engager molecule is specific for one or more target cell antigens shown in Table 2.
  • EphA2 is referred to as EPH receptor A2 (ephrin type-A receptor 2; EPHA2; ARCC2; CTPA; CTPP1; or ECK), which is a protein that in humans is encoded by the EPHA2 gene in the ephrin receptor subfamily of the protein-tyrosine kinase family.
  • Receptors in this subfamily generally comprise a single kinase domain and an extracellular region comprising a Cys-rich domain and 2 fibronectin type III repeats; embodiments of the antibodies of the disclosure target any of these domains.
  • An exemplary human EphA2 nucleic sequence is in GenBank® Accession No.
  • NM_004431 and an exemplary human EphA2 polypeptide sequence is in GenBank® Accession No. NP_004422, both of which sequences are incorporated herein in their entirety.
  • An exemplary human EphA2 nucleic sequence is in GenBank® Accession No. NM_004448.2, and an exemplary human EphA2 polypeptide sequence is in GenBank® Accession No. NP_004439, both of which sequences are incorporated herein in their entirety.
  • Eph family the largest group among tyrosine kinase receptor families, is comprised of the EphA (EphA1-10) or EphB (EphB1-6) subclasses of receptors classified as per their sequence homologies and their binding affinity for their ligands, Ephrins (Eph receptor interacting protein).
  • EphA2 gene is located on chromosome 1, encodes a receptor tyrosine kinase of 976 amino acids with an apparent molecular weight of 130 kDa and has a 90% amino acid sequence homology to the mouse EphA2.
  • Eph family contains an extracellular conserved N-terminal ligand-binding domain followed by a cysteine-rich domain with an epidermal growth factor-like motif and two fibronectin type-III repeats.
  • the extracellular motif is followed by a membrane spanning region and a cytoplasmic region that encompasses a juxtamembrane region, a tyrosine kinase domain, a sterile alpha motif (SAM), and a post synaptic domain (disc large and zona occludens protein (PDZ) domain-binding motif).
  • EphA2 shows 25-35% sequence homologies with other Eph receptors, and the tyrosine residues are conserved within the juxtamembrane and kinase domain.
  • EphA2 mRNA expression is observed in the skin, bone marrow, thymus, uterus, testis, prostate, urinary bladder, kidney, small intestine, colon, spleen, liver, lung and brain. EphA2 expression in the colon, skin, kidney and lung was over ten-fold relative to the bone marrow. EphA2 is also expressed during gastrulation in the ectodermal cells and early embryogenesis in the developing hind brain. In the skin, EphA2 is present in keratinocytes of epidermis and hair follicles but not in dermal cells (fibroblasts, vascular cells and inflammatory cells).
  • EphA2 is also expressed in proliferating mammary glands in female mice at puberty and differentially expressed during the estrous cycle. Besides its expression in embryo and in normal adult tissues, EphA2 is overexpressed in several cancers, such as breast cancer, gastric cancer, melanoma, ovarian cancer, lunch cancer, gliomas, urinary bladder cancer, prostate cancer, esophageal, renal, colon and vulvar cancers. In particular, a high level of EphA2 is detected in malignant cancer-derived cell lines and advanced forms of cancer.
  • EphA2 In light of the EphA2 overexpression in pre-clinical models and clinical specimens of many different types of cancer, the increased level of EphA2 expression is informative in both the prediction of cancer outcomes and in the clinical management of cancer.
  • the differential expression of EphA2 in normal cells compared to cancer cells also signifies its importance as a therapeutic target.
  • HER2 is referred to as human Epidermal Growth Factor Receptor 2 (Neu, ErbB-2, CD340, or pi 85), which is a protein that in humans is encoded by the ERBB2 gene in the epidermal growth factor receptor (EFR/ErbB) family.
  • HER2 contains an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain that interacts with a multitude of signaling molecules.
  • HER2 is a member of the epidermal growth factor receptor family having tyrosine kinase activity.
  • HER2 HER2 dimerization of the receptor results in the autophosphorylation of tyrosine residues within the cytoplasmic domain of the receptors and initiates a variety of signaling pathways leading to cell proliferation and tumorigenesis.
  • Amplification or overexpression of HER2 occurs in approximately 15-30% of breast cancers and 10-30% of gastric/gastroesophageal cancers and serves as a prognostic and predictive biomarker.
  • HER2 overexpression has also been seen in other cancers like ovary, endometrium, bladder, lung, colon, and head and neck.
  • HER2 is overexpressed in 15-30% of invasive breast cancers, which has both prognostic and predictive implications.
  • HER2 overexpression is directly correlated with poorer outcome in gastric cancer.
  • HER2 overexpression was an independent negative prognostic factor and HER2 staining intensity was correlated with tumor size, serosal invasion, and lymph node metastases.
  • Other studies also confirmed the negative impact of HER2 overexpression in gastric cancer.
  • HER2 overexpression is reported in 0-83% of esophageal cancers, with a tendency towards higher rates of positivity in adenocarcinoma (10-83%) compared to squamous cell carcinomas (0-56%). Overexpression of HER2 is seen in 20-30% patients with ovarian cancer. In endometrial serous carcinoma, the reported rates of HER2 overexpression range between 14% and 80% with HER2 amplification (by fluorescence in situ hybridization [FISH]) ranging from 21% to 47%.
  • FISH fluorescence in situ hybridization
  • Disialoganglioside GD2 is a sialic acid-containing glycosphingolipid expressed primarily on the cell surface. The function of this carbohydrate antigen is not completely understood; however, it is thought to play an important role in the attachment of tumor cells to extracellular matrix proteins. GD2 expression in normal fetal and adult tissues is primarily restricted to the central nervous system, peripheral nerves, and skin melanocytes, although GD2 expression has been described in the stromal component of some normal tissues and white pulp of the spleen. In malignant cells, GD2 is uniformly expressed in neuroblastomas and most melanomas and to a variable degree in a variety of other tumors, including bone and soft-tissue sarcomas, small cell lung cancer, and brain tumors.
  • GD2 is present and concentrated on cell surfaces, with the two hydrocarbon chains of the ceramide moiety embedded in the plasma membrane and the oligosaccharides located on the extracellular surface, where they present points of recognition for extracellular molecules or surfaces of neighboring cells. Because of the relatively tumor-selective expression combined with its presence on the cell surface, GD2 is an attractive target for tumor-specific antibody therapy. Embodiments of the antibodies of the disclosure target the extracellular domain.
  • the pseudotyped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule and one or more additional nucleic acid sequences that encode one or more therapeutic molecules.
  • a “therapeutic molecule” refers to a molecule that enhances the therapeutic efficacy of an oncolytic virus described herein.
  • the therapeutic molecules described herein are proteins, nucleic acids, or a combination thereof.
  • Exemplary therapeutic molecules include cytokines, chemokines, antibodies or antigen binding fragments thereof, proteases, RNA polynucleotides, and DNA polynucleotides.
  • the therapeutic molecule is capable of increasing or enhancing the therapeutic efficacy of an oncolytic virus described herein by stimulating, or activating, a cellular immune response. In some embodiments, the therapeutic molecule is capable of increasing or enhancing the therapeutic efficacy of an oncolytic virus described herein by antagonizing a suppressive or regulatory immune response. In some embodiments, reduction of a suppressive immune response occurs in a tumor microenvironment. In some instances, reduction of a suppressive immune response by the therapeutic molecule enhances the oncolytic effects of a pseudotyped oncolytic virus described herein. In some embodiments, the therapeutic molecule further reduces immunoregulatory T cell activity in a subject treated with a pseudotyped oncolytic virus described herein. In some embodiments, the therapeutic molecule modulates or impairs the production level of a protein at a nucleic acid level or at a protein level, or disrupts a protein function.
  • a nucleic acid sequence encoding an engager molecule and a nucleic acid sequence encoding one or more therapeutic molecules are comprised within the same vector. In some embodiments, a nucleic acid sequence encoding an engager molecule and a nucleic acid sequence encoding one or more therapeutic molecules are comprised in different vectors.
  • the vector is a viral vector.
  • a therapeutic molecule comprises a polypeptide or a nucleic acid polymer. In some embodiments, the additional nucleic acid sequence is inserted into a viral vector which allows higher expression levels and production of the therapeutic molecule.
  • the therapeutic molecule is a polypeptide.
  • the polypeptide is an immune modulator polypeptide.
  • the immune modulator polypeptide is a cytokine, a co-stimulatory domain, a domain that inhibits negative regulatory molecules of T-cell activation (e.g., an immune checkpoint inhibitor), or a combination thereof.
  • the immune modulator polypeptide modulates the activity of one or more cell types, such as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), dendritic cells, and/or T cells.
  • Treg modulatory polypeptides include CCR4, Helios, TIGIT, GITR, neuropilin, neuritin, CD103, CTLA-4, ICOS, and Swap70.
  • Exemplary MDSC modulatory polypeptides include TGF- ⁇ R1, GM-CSF, INF ⁇ , interleukins such as IL- ⁇ , IL-1F2, IL-6, IL-10, IL-12, IL-13, IL-6, IL-6R ⁇ , IL-6/IL-6R complex, TGF- ⁇ 1, M-CSF, Prostaglandin E2/PGE2, Prostaglandin E Synthase 2, S100A8, and VEGF.
  • Exemplary dendritic-cell directed modulatory polypeptides include GM-CSF and/or IL-13.
  • T cell-directed modulatory polypeptides include IL-12, OX-40, GITR, CD28, or IL-28, or an antibody that agonizes a pathway comprising IL-12, OX-40, GITR, CD28, or IL-28.
  • the therapeutic polypeptides modulate the fibrotic stroma.
  • exemplary fibrotic stromal polypeptides include fibroblast activation protein-alpha (FAP).
  • FAP fibroblast activation protein-alpha
  • the therapeutic polypeptide is a protease.
  • the protease is capable of altering the extracellular matrix, particularly the extracellular matrix within a tumor microenvironment.
  • Exemplary proteases include matrixmetalloproteases (MMP), such as MMP9, collagenases, and elastases.
  • the immune modulator polypeptide is a cytokine.
  • Cytokines are a category of small proteins between about 5-20 kDa that are involved in cell signaling and include chemokines, interferons (INF), interleukins (IL), and tumor necrosis factors (TNF), among others. Chemokines play a role as a chemoattractant to guide the migration of cells and are classified into four subfamilies: CXC, CC, CX3C, and XC.
  • chemokines include chemokines from the CC subfamily, such as CCL1, CCL2 (MCP-1), CCL3, CCL4, CCL5 (RANTES), CCL6, CCL7, CCL8, CCL9 (or CCL10), CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, and CCL28; the CXC subfamily, such as CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, and CXCL17; the XC subfamily, such as XCL1 and XCL2; and the CX3C subfamily, such as C
  • Interferons comprise Type I IFNs (e.g. IFN- ⁇ , IFN- ⁇ , IFN- ⁇ , IFN- ⁇ , and IFN- ⁇ ), Type II IFNs (e.g. IFN- ⁇ ), and Type III IFNs.
  • IFN- ⁇ is further classified into about 13 subtypes including IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, and IFNA21.
  • Interleukins are a broad class of cytokine that promote the development and differentiation of immune cells, including T and B cells, and other hematopoietic cells.
  • exemplary interleukins include IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-35, and IL-36.
  • Tumor necrosis factors are a group of cytokines that modulate apoptosis.
  • TNFs tumor necrosis factors
  • TNF ⁇ lymphotoxin-alpha
  • LT- ⁇ lymphotoxin-beta
  • CD40L T cell antigen gp39
  • CD27L CD30L
  • FASL 4-1BBL
  • OX40L TNF-related apoptosis inducing ligand
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager and an additional nucleic acid sequence that encodes a cytokine selected from chemokine, interferon, interleukin, or tumor necrosis factor.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule and an additional nucleic acid sequence that encodesa chemokine, an interferon, an interleukin, and/or a tumor necrosis factor.
  • the immune modulator polypeptide is a co-stimulatory domain.
  • the co-stimulatory domain enhances antigen-specific cytotoxicity. In some cases, the co-stimulatory domain further enhances cytokine production.
  • the co-stimulatory domain comprises CD27, CD28, CD70, CD80, CD83, CD86, CD134 (OX-40), CD134L (OK-40L), CD137 (41BB), CD137L (41BBL), or CD224.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager and an additional nucleic acid sequence that encodes a co-stimulatory domain. In some embodiments, a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager and an additional nucleic acid sequence that encodes a co-stimulatory domain selected from CD27, CD28, CD80, CD83, CD86, CD134, CD134L, CD137, CD137L, or CD224.
  • the immune modulator polypeptide is an immune checkpoint inhibitor polypeptide that inhibits a negative regulatory molecule of T-cell activation.
  • Immune checkpoint inhibitor bind to immune checkpoint molecules, which are a group of molecules on the cell surface of CD4 and CD8 T cells. In some instances, these molecules effectively serve as “brakes” to down-modulate or inhibit an anti-tumor immune response.
  • An immune checkpoint inhibitor refers to any molecule that modulates or inhibits the activity of an immune checkpoint molecule.
  • immune checkpoint inhibitors include antibodies, antibody-derivatives (e.g., Fab fragments, scFvs, minobodies, diabodies), antisense oligonucleotides, siRNA, aptamers, or peptides.
  • antibody-derivatives e.g., Fab fragments, scFvs, minobodies, diabodies
  • antisense oligonucleotides e.g., siRNA, aptamers, or peptides.
  • Exemplary immune checkpoint molecules include, but are not limited to, programmed death-ligand 1 (PDL1, also known as B7-H1, CD274), programmed death 1 (PD-1), PD-L2 (B7-DC, CD273), LAG3, TIM3, 2B4, A2aR, B7H1, 87H3, B7H4, BTLA, CD2, CD16, CD27, CD28, CD30, CD40, CD70, CD80, CD86, CD137, CD160, CD226, CD276, DR3, GAL9, GITR, HAVCR2, HVEM, IDO1, IDO2, inducible T cell costimulatory (ICOS), KIR, LAIR, LIGHT, macrophage receptor with collageneous structure (MARCO), OX-40, phosphatidylserine (PS), SLAM, TIGHT, VISTA, and VTCN1.
  • PDL1 programmed death-ligand 1
  • PD-1 programmed death 1
  • PD-L2 B7-DC, CD
  • an immune checkpoint inhibitor inhibits on or more of PDL1, PD-1, CTLA-4, PD-L2, LAG3, TIM3, 2B4, A2aR, B7H1, B7H3, B7H4, BTLA, CD2, CD27, CD28, CD30, CD40, CD70, CD80, CD86, CD137, CD160, CD226, CD276, DR3, GAL9, GITR, HAVCR2, HVEM, IDO1, IDO2, ICOS, KIR, LAIR1, LIGHT, MARCO, OX-40, PS, SLAM, TIGHT, VISTA, and VTCN1.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule and an additional nucleic acid sequence that encodes an immune checkpoint inhibitor.
  • the immune checkpoint inhibitor reduces the expression or activity of one or more immune checkpoint molecules.
  • the immune checkpoint inhibitor reduces the interaction between an immune checkpoint molecule and its ligand (e.g., reduced the interaction between PD-1 and PDL1).
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager and an additional nucleic acid sequence that encodes an immune checkpoint inhibitor that inhibits one or more of PDL1, PD-1, CTLA-4, PD-L2, LAG3, TIM3, 2B4, A2aR, B7H1, B7H3, B7H4, BTLA, CD2, CD27, CD28, CD30, CD40, CD70, CD80, CD86, CD137, CD160, CD226, CD276, DR3, GAL9, GITR, HAVCR2, HVEM, IDO1, IDO2, ICOS, KIR, LAIR1, LIGHT, MARCO, OX-40, PS, SLAM, TIGHT, VISTA, and VTCN1.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and a therapeutic molecule domain, wherein the therapeutic molecule domain is an immune checkpoint inhibitor.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and a therapeutic molecule domain, wherein the therapeutic molecule domain is an immune checkpoint inhibitor that inhibits one or more of PDL1, PD-1, CTLA-4, PD-L2, LAG3, TIM3, 2B4, A2aR, B7H1, B7H3, B7H4, BTLA, CD2, CD27, CD28, CD30, CD40, CD70, CD80, CD86, CD137, CD160, CD226, CD276, DR3, GAL9, GITR, HAVCR2, HVEM, IDO1, IDO2, ICOS, KIR, LAIR1, LIGHT, MARCO, OX-40, PS, SLAM, TIGHT, VISTA, and VTCN1.
  • the therapeutic molecule domain is an immune checkpoint inhibitor that inhibits one or more of PDL1, PD-1, CTLA-4, PD-L2, LAG3, TIM3, 2B
  • the immune checkpoint inhibitor is an inhibitor of PDL1.
  • the immune checkpoint inhibitor is an antibody (e.g., a monoclonal antibody or antigen-binding fragments thereof, or a humanized or chimeric antibody or antigen-binding fragments thereof) against PDL1.
  • the inhibitor of PDL1 reduces the expression or activity of PDL1.
  • the inhibitor of PDL1 reduces the interaction between PD-1 and PDL1.
  • Exemplary inhibitors of PDL1 include anti-PDL1 antibodies, RNAi molecules (e.g., anti-PDL1 RNAi), antisense molecules (e.g., an anti-PDL1 antisense RNA), or dominant negative proteins (e.g., a dominant negative PDL1 protein).
  • RNAi molecules e.g., anti-PDL1 RNAi
  • antisense molecules e.g., an anti-PDL1 antisense RNA
  • dominant negative proteins e.g., a dominant negative PDL1 protein
  • anti-PDL1 antibodies includes clone EH12; MPDL3280A (Genentech, RG7446); anti-mouse PDL1 antibody Clone 10F.9G2 (BioXcell, Cat # BE0101); anti-PDL1 monoclonal antibody MDX-1105 (BMS-936559 and BMS-935559 from Bristol-Meyers Squibb; MSB0010718C; mouse anti-PDL11 Clone 29E.2A3; and AstraZeneca's MED14736.
  • the anti-PDL1 antibody is an anti-PDL1 antibody disclosed in International PCT Publication Nos. WO 2013/079174; WO 2010/036959; WO 2013/056716; WO 2007/005874; WO 2010/089411; WO 2010/077634; WO 2004/004771; WO 2006/133396; WO 2013/09906; WO 2012/145493; WO 2013/181634; U.S. Patent Application Publication No. 20140294898; or Chinese Patent Application Publication No. CN 101104640.
  • the PDL1 inhibitor is a nucleic acid inhibitor of PDL1 expression. In some embodiments, the PDL1 inhibitor is one disclosed in international PCT Publication Nos. WO 2011/127180 or WO 2011/000841. In some embodiments, the PDL1 inhibitor is rapamycin.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain that binds to CD3 (e.g., an anti-CD3 scFv) and a therapeutic molecule domain that binds to PDL1 (e.g., an anti-PDL scFv).
  • the pseudytoped oncolytic virus may further comprise an additional nucleic acid sequence that encodes an additional therapeutic molecule.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and a therapeutic molecule domain that binds to PDL1. In some embodiments, a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and an antigen recognition domain, and an additional nucleic acid sequence that encodes a PDL1 inhibitor.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager and an additional nucleic acid sequence that encodes PDL1 inhibitor selected from EH12, Genentech's MPDL3280A (RG7446); Anti-mouse PDL1 antibody Clone 10F.9G2 (Cat # BE0101) from BioXcell; anti-PDL1 monoclonal antibody MDX-1105 (BMS-936559) and BMS-935559 from Bristol-Meyer's Squibb; MSB0010718C; mouse anti-PDL1 Clone 29E.2A3; and AstraZeneca's MED14736.
  • PDL1 inhibitor selected from EH12, Genentech's MPDL3280A (RG7446); Anti-mouse PDL1 antibody Clone 10F.9G2 (Cat # BE0101) from BioXcell; anti-PDL1 monoclonal antibody MDX-1105 (BMS-936559) and BMS-9355
  • the immune checkpoint inhibitor is an inhibitor of PD-L2.
  • the inhibitor of PD-L2 is an antibody (e.g., a monoclonal antibody or fragments, or a humanized or chimeric antibody or fragments thereof) against PD-L2.
  • the inhibitor of PD-L2 reduces the expression or activity of PD-L2.
  • the inhibitor of PD-L2 reduces the interaction between PD-1 and PD-L2.
  • Exemplary inhibitors of PD-L2 include antibodies (e.g., an anti-PD-L2 antibody), RNAi molecules (e.g., an anti-PD-L2 RNAi), antisense molecules (e.g., an anti-PD-L2 antisense RNA), or dominant negative proteins (e.g., a dominant negative PD-L2 protein).
  • antibodies e.g., an anti-PD-L2 antibody
  • RNAi molecules e.g., an anti-PD-L2 RNAi
  • antisense molecules e.g., an anti-PD-L2 antisense RNA
  • dominant negative proteins e.g., a dominant negative PD-L2 protein
  • the PD-L2 inhibitor is GlaxoSmithKline's AMP-224 (Amplimmune). In some embodiments, the PD-L2 inhibitor is rHIgM12B7.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and an antigen recognition domain, and an additional nucleic acid sequence that encodes a PD-L2 inhibitor.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager and an additional nucleic acid sequence that encodes PD-L2 inhibitor selected from AMP-224 (Amplimmune) or rHIgM12B7.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and a therapeutic molecule domain that binds to PDL2.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain that binds to CD3 (e.g., an anti-CD3 scFv) and a therapeutic molecule domain that binds to PD-L2 (e.g., an anti-PDL2 scFv).
  • the pseudytoped oncolytic virus may further comprise an additional nucleic acid sequence that encodes an additional therapeutic molecule.
  • the immune checkpoint inhibitor is an inhibitor of PD1.
  • the inhibitor of PDL1 is an antibody (e.g., a monoclonal antibody or fragments, or a humanized or chimeric antibody or fragments thereof) against PD-1.
  • Exemplary antibodies against PD-1 include: anti-mouse PD-1 antibody Clone J43 (Cat # BE0033-2) from BioXcell; anti-mouse PD-1 antibody Clone RMP1-14 (Cat # BE0146) from BioXcell; mouse anti-PD-1 antibody Clone EH12; Merck's MK-3475 anti-mouse PD-1 antibody (Keytruda, pembrolizumab, lambrolizumab); and AnaptysBio's anti-PD-1 antibody, known as ANB011; antibody MDX-1 106 (ONO-4538); Bristol-Myers Squibb's human lgG4 monoclonal antibody nivolumab (Opdivo®, BMS-936558, MDX1106); AstraZeneca's AMP-514, and AMP-224; and Pidilizumab (CT-011), CureTech Ltd.
  • CT-011 CureTech Ltd.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and an antigen recognition domain, and an additional nucleic acid sequence that encodes a PD1 inhibitor selected from ANB011; antibody MDX-1 106 (ONO-4538); Bristol-Myers Squibb's human IgG4 monoclonal antibody nivolumab (Opdivo®, BMS-936558, MDX1106); AstraZeneca's AMP-514, and AMP-224; and Pidilizumab (CT-011).
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager and an additional nucleic acid sequence that encodes PD-1 inhibitor selected from ANB011; antibody MDX-1 106 (ONO-4538); Bristol-Myers Squibb's human IgG4 monoclonal antibody nivolumab (Opdivo®, BMS-936558, MDX1106); AstraZeneca's AMP-514, and AMP-224; and Pidilizumab (CT-011).
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and an antigen recognition domain, and an additional nucleic acid sequence that encodes a PD-L2 inhibitor.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule and an additional nucleic acid sequence that encodes PD-L2 inhibitor selected from AMP-224 (Amplimmune) or rHIgM1287.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and a therapeutic molecule domain that binds to PD1.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain that binds to CD3 (e.g., an anti-CD3 scFv) and a therapeutic molecule domain that binds to PD1 (e.g., an anti-PD1 scFv).
  • the pseudytoped oncolytic virus may further comprise an additional nucleic acid sequence that encodes an additional therapeutic molecule.
  • the immune checkpoint inhibitor is an inhibitor of CTLA-4.
  • the an inhibitor of CTLA-4 is an antibody (e.g., a monoclonal antibody or fragments, or a humanized or chimeric antibody or fragments thereof) against CTLA-4.
  • the anti-CTLA-4 antibody blocks the binding of CTLA-4 to CD80 (B7-1) and/or CD86 (B7-2) expressed on antigen presenting cells.
  • Exemplary antibodies against CTLA-4 include ipilimumab (also known as Yervoy®, MDX-010, BMS-734016 and MDX-101, Bristol Meyers Squibb); anti-CTLA4 antibody clone 9H10 from Millipore; tremelimumab (CP-675,206, ticilimumab, Pfizer); and anti-CTLA4 antibody clone BNI3 from Abcam.
  • ipilimumab also known as Yervoy®, MDX-010, BMS-734016 and MDX-101, Bristol Meyers Squibb
  • anti-CTLA4 antibody clone 9H10 from Millipore
  • tremelimumab CP-675,206, ticilimumab, Pfizer
  • anti-CTLA4 antibody clone BNI3 from Abcam.
  • the anti-CTLA-4 antibody is one disclosed in any of International PCT Publication Nos. WO 2001/014424; WO 2004/035607; WO 2003/086459; WO 2012/120125; WO 2000/037504; WO 2009/100140; WO 2006/09649; WO 2005/092380; WO 2007/123737; WO 2006/029219; WO 2010/0979597; WO 2006/12168; WO 1997/020574 U.S. Patent Application Publication No. 2005/0201994; or European Patent Application Publication No. EP 1212422. Additional CTLA-4 antibodies are described in U.S. Pat. Nos.
  • the anti-CTLA-4 antibody is one disclosed in any of International PCT Publication Nos. WO 1998/42752; U.S. Pat. Nos. 6,682,736 and 6,207,156; Hurwitz et al, Proc. Natl. Acad. Sci.
  • the CTLA-4 inhibitor is a CTLA-4 ligand as disclosed in International PCT Publication No. WO 1996/040915.
  • the CTLA-4 inhibitor is a nucleic acid inhibitor of CTLA-4 expression, such as an RNAi molecule.
  • anti-CTLA4 RNAi molecules take the form of those described in any of International PCT Publication Nos. WO 1999/032619 and WO 2001/029058; U.S. Patent Application Publication Nos. 2003/0051263, 2003/0055020, 2003/0056235, 2004/265839, 2005/0100913, 2006/0024798, 2008/0050342, 2008/0081373, 2008/0248576, and 2008/055443; and/or U.S. Pat. Nos. 6,506,559; 7,282,564; 7,538,095; and 7,560,438.
  • the anti-CTLA4 RNAi molecules are double stranded RNAi molecules, such as those disclosed in European Patent No. EP 1309726. In some instances, the anti-CTLA4 RNAi molecules are double stranded RNAi molecules, such as those described in U.S. Pat. Nos. 7,056,704 and 7,078,196.
  • the CTLA4 inhibitor is an aptamer, such as those described in International PCT Publication No. WO 2004/081021, such as Del 60 or M9-14 del 55.
  • the anti-CTLA4 RNAi molecules of the present invention are RNA molecules, such as those described in U.S. Pat. Nos. 5,898,031, 6,107,094, 7,432,249, and 7,432,250, and European Application No. EP 0928290.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and an antigen recognition domain, and an additional nucleic acid sequence that encodes a CTLA-4 inhibitor.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule and an additional nucleic acid sequence that encodes a CTLA-4 inhibitor selected from ipilimumab (also known as Yervoy®, MDX-010, BMS-734016 and MDX-101); anti-CTLA4 Antibody, clone 9H10 from Millipore; Pfizer's tremelimumab (CP-675,206, ticilimumab); and anti-CTLA4 antibody clone BNI3 from Abcam.
  • ipilimumab also known as Yervoy®, MDX-010, BMS-734016 and MDX-101
  • anti-CTLA4 Antibody clone 9H10 from Millipore
  • Pfizer's tremelimumab CP-675,206, ticilimumab
  • anti-CTLA4 antibody clone BNI3 from Abcam.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and a therapeutic molecule domain that binds to CTLA-4.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain that binds to CD3 (e.g., an anti-CD3 scFv) and a therapeutic molecule domain that binds to CTLA-4 (e.g., an anti-CTLA-4 scFv).
  • the pseudytoped oncolytic virus may further comprise an additional nucleic acid sequence that encodes an additional therapeutic molecule.
  • the immune checkpoint inhibitor is an inhibitor of LAG3 (CD223).
  • the inhibitor of LAG3 is an antibody (e.g., a monoclonal antibody or fragments, or a humanized or chimeric antibody or fragments thereof) against LAG3.
  • an antibody against LAG3 blocks the interaction of LAG3 with major histocompatibility complex (MHC) class II molecules.
  • MHC major histocompatibility complex
  • Exemplary antibodies against LAG3 include: anti-Lag-3 antibody clone eBioC9B7W (C97W) from eBioscience; anti-Lag3 antibody LS-B2237 from LifeSpan Biosciences; IMP321 (ImmuFact) from Immutep; anti-Lag3 antibody BMS-986016; and the LAG-3 chimeric antibody A9H12.
  • the anti-LAG3 antibody is an anti-LAG3 antibody disclosed in International PCT Publication Nos. WO 2010/019570; WO 2008/132601; or WO 2004/078928.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and an antigen recognition domain, and an additional nucleic acid sequence that encodes LAG3 inhibitor.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule and an additional nucleic acid sequence that encodes LAG3 inhibitor selected from anti-Lag-3 antibody clone eBioC9B7W (C9B7W) from eBioscience; anti-Lag3 antibody LS-B2237 from LifeSpan Biosciences; IMP321 (ImmuFact) from Immutep; anti-Lag3 antibody BMS-986016; and the LAG-3 chimeric antibody A9H12.
  • LAG3 inhibitor selected from anti-Lag-3 antibody clone eBioC9B7W (C9B7W) from eBioscience; anti-Lag3 antibody LS-B2237 from LifeSpan Biosciences; IMP321 (ImmuFact) from Immutep; anti-Lag3 antibody BMS-986016; and the LAG-3 chimeric antibody A9H12.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and a therapeutic molecule domain that binds to LAG3.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain that binds to CD3 (e.g., an anti-CD3 scFv) and a therapeutic molecule domain that binds to LAG3 (e.g., an anti-LAG3 scFv).
  • the pseudytoped oncolytic virus may further comprise an additional nucleic acid sequence that encodes an additional therapeutic molecule.
  • the immune checkpoint inhibitor is an inhibitor of TIM3.
  • the inhibitor of TIM3 is an antibody (e.g., a monoclonal antibody or fragments, or a humanized or chimeric antibody or fragments thereof) against TIM3 (also known as HAVCR2).
  • an antibody against TIM3 blocks the interaction of TIM3 with galectin-9 (Gal9).
  • the anti-TIM3 antibody is an anti-TIM3 antibody disclosed in International PCT Publication Nos. WO 2013/006490; WO 2011/55607; WO 2011/159877; or WO 2001/17057.
  • a TIM3 inhibitor is a TIM3 inhibitor disclosed in International PCT Publication No. WO 2009/052623.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and an antigen recognition domain, and an additional nucleic acid sequence that encodes TIM3 inhibitor.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule and an additional nucleic acid sequence that encodes TIM3 inhibitor such as an antibody against TIM3 blocks the interaction of TIM3 with galectin-9 (Gal9).
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and a therapeutic molecule domain that binds to TIM3.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain that binds to CD3 (e.g., an anti-CD3 scFv) and a therapeutic molecule domain that binds to LAG3 (e.g., an anti-TIM3 scFv).
  • the pseudytoped oncolytic virus may further comprise an additional nucleic acid sequence that encodes an additional therapeutic molecule.
  • the immune checkpoint inhibitor is an inhibitor of B7-3.
  • the inhibitor of B7-H3 is an antibody (e.g., a monoclonal antibody or fragments, or a humanized or chimeric antibody or fragments thereof) against B7-H3.
  • the inhibitor of B7-H3 is MGA271 (MacroGenics).
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and an antigen recognition domain, and an additional nucleic acid sequence that encodes a B7-H3 inhibitor.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager and an additional nucleic acid sequence that encodes a B7-H3 inhibitor such as MGA271.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain and a therapeutic molecule domain that binds to B7-H3.
  • a pseudytoped oncolytic virus comprises a nucleic acid sequence that encodes an engager molecule comprising an activation domain that binds to CD3 (e.g., an anti-CD3 scFv) and a therapeutic molecule domain that binds to B7-H3 (e.g., an anti-B7-H3 scFv).
  • the pseudytoped oncolytic virus may further comprise an additional nucleic acid sequence that encodes an additional therapeutic molecule.
  • the engager molecule additionally comprises one or more other domains, e.g., one or more of a cytokine, a co-stimulatory domain, a domain that inhibits negative regulatory molecules of T-cell activation, or a combination thereof.
  • the engager is a first polypeptide provided within the pseudotyped oncolytic virus with a second polypeptide having one or more other domains, e.g., one or more of a cytokine, a co-stimulatory domain, a domain that inhibits negative regulatory molecules of T-cell activation, or a combination thereof.
  • the first polypeptide and the second polypeptide are encoded in the same vector (e.g., viral vector).
  • the first polypeptide and the second polypeptide are encoded in different vectors (e.g., viral vectors).
  • the cytokine is IL-15, IL-2, and/or IL-7.
  • the co-stimulatory domain is CD27, CD80, CD83, CD86, CD134, or CD137,
  • the domain that inhibits negative regulatory molecules of T-cell activation is PD-1, PDL1, CTLA4, or B7-H4.
  • the therapeutic molecule is a polypeptide such as an anti-angiogenic factor.
  • Angiogenesis or neovascularization is the formation of new microvessels from an established vascular network.
  • the angiogenic process involves communications from multiple cell types such as endothelial cells (EC) and circulating endothelial progenitor cells, pericytes, vascular smooth muscle cells, stromal cells, including stem cells, and parenchymal cells. These communications or interactions occur through secreted factors such as VEGF, fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), or angiopoietins.
  • VEGF vascular smooth muscle cells
  • stromal cells including stem cells, and parenchymal cells.
  • an anti-angiogenic factor is a polypeptide that disrupts one or more of the interactions of the cell types: endothelial cells (EC) and circulating endothelial progenitor cells, pericytes, vascular smooth muscle cells, stromal cells, including stem cells, and parenchymal cells.
  • an anti-angiogenic factor is a polypeptide that disrupts one or more of the interactions of secreted factors such as VEGF, fibroblast growth factor (FGF), platelet-derived growth factor (PDGF) or angiopoietins.
  • pseudotyped oncolytic viruses comprising nucleic acids that encode therapeutic polypeptides that modulate regulatory T cells.
  • regulatory T cells maintain the tolerance to self-antigens and in some instances abrogate autoimmune.
  • Treg suppresses or downregulates induction and proliferation of effector T cells.
  • Exemplary Treg modulatory polypeptides include CCR4, Helios, TIGIT, GITR, neuropilin, neuritin, CD103, CTLA-4, ICOS, and Swap70.
  • pseudotyped oncolytic viruses comprising nucleic acids that encode therapeutic polypeptides that modulate myeloid-derived suppressor cells (MDSCs).
  • MDSCs are a heterogenous population of immune cells from the myeloid lineage (a cluster of different cell types that originate from bone marrow stem cells), to which also includes dendritic cells, macrophages and neutrophils.
  • myeloid cells interact with T cells to regulate the T cell's function.
  • MDSC modulatory polypeptides include TGF- ⁇ R1, GM-CSF, IFN- ⁇ , Interleukins (e.g., IL- ⁇ , IL-1F2, IL-6, IL-10, IL-12, IL-13, IL-6, IL-6R ⁇ , IL-6/IL-6R complex, TGF- ⁇ 1, M-CSF, Prostaglandin E2/PGE2, Prostaglandin E Synthase 2, S100A8, and VEGF.
  • Interleukins e.g., IL- ⁇ , IL-1F2, IL-6, IL-10, IL-12, IL-13, IL-6, IL-6R ⁇ , IL-6/IL-6R complex
  • TGF- ⁇ 1, M-CSF Prostaglandin E2/PGE2, Prostaglandin E Synthase 2, S100A8, and VEGF.
  • pseudotyped oncolytic viruses comprising nucleic acids that encode therapeutic polypeptides that modulate the fibrotic stroma.
  • fibrosis occurs in response to inflammation, either chronic or recurrent. Over time, the repeated bouts of inflammation irritate and scar the tissue, causing buildups of fibrous tissue. In some instances, if enough fibrous material develops, it turns into stromal fibrosis.
  • Exemplary fibrotic stromal polypeptides include fibroblast activation protein-alpha (FAP).
  • the therapeutic molecule is a nucleic acid polymer.
  • the nucleic acid polymer is a RNA polymer.
  • the RNA polymer is an antisense polymer those sequence is complementary to a microRNA (miRNA or miR) target sequence.
  • the RNA polymer is a microRNA polymer.
  • the RNA polymer comprises a DNA-directed RNAi (ddRNAi) sequence, which enables in vivo production of short hairpin RNAs (shRNAs).
  • a microRNA polymer is a short non-coding RNA that is expressed in different tissue and cell types which suppresses the expression of a target gene.
  • miRNAs are transcribed by RNA polymerase 11 as part of the capped and polyadenylated primary transcripts (pri-miRNAs).
  • the primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products.
  • the mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and in some instances results in translational inhibition or destabilization of the target mRNA.
  • RISC RNA-induced silencing complex
  • dysregulated microRNA expression is correlated with one or more types of cancer.
  • the microRNA is referred to as an oncomiR.
  • the dysregulated microRNA expression is an elevated expression.
  • the elevated expression level of microRNA correlates to one or more types of cancer. For example, overexpression of microRNA-155 (miR-155) has been observed in cancers such as Burkitt lymphoma, or laryngeal squamous cell carcinoma (LSCC) and overexpression of microRNA-21 (miR-21) has been observed in breast cancer.
  • LSCC laryngeal squamous cell carcinoma
  • exemplary microRNAs with an elevated expression level include, but are not limited to, miR-10 family (e.g., miR-10b), miR-17, miR-21, miR-106 family (e.g., miR-106a), miR-125 family (e.g., miR-125b), miR-145, miR-146 family (e.g., miR-146a, miR-146b), miR-155, miR-96, miR-182, miR-183, miR-221, miR-222, and miR-1247-5p.
  • miR-10 family e.g., miR-10b
  • miR-17 miR-17
  • miR-21 miR-106 family
  • miR-125 family e.g., miR-125b
  • miR-145 miR-146 family
  • miR-155 miR-96
  • miR-182 miR-183, miR-221, miR-222, and miR-1247-5p.
  • the nucleic acid polymer is an antisense polymer those sequence complements an oncomiR. In some instances, the nucleic acid polymer is an antisense polymer those sequence complements an oncomiR that is characterized with an overexpression. In some instances, the nucleic acid polymer is an antisense polymer those sequence complements a microRNA target sequence. In some instances, the nucleic acid polymer is an antisense polymer those sequence complements a microRNA target sequence that is characterized with an overexpression. In some instances, the therapeutic molecule is an antisense polymer those sequence complements a microRNA target sequence. In some instances, the therapeutic molecule is an antisense polymer those sequence complements a microRNA target sequence that is characterized with an overexpression. In some instances, the overexpression level is relative to the endogenous expression level of the microRNA.
  • the dysregulated microRNA expression is a reduced expression.
  • the reduced expression level of microRNA correlates to one or more types of cancer. For example, a depleted level of miR-31 has been observed in both human and mouse metastatic breast cancer cell lines.
  • exemplary microRNAs with reduced expression levels include, but are not limited to, miR-31, miR-34 family (e.g., miR34a, miR-34b, and miR-34c), miR-101, miR-126, miR-145, miR-196a, and the miR-200 family.
  • miR-31 miR-34 family (e.g., miR34a, miR-34b, and miR-34c), miR-101, miR-126, miR-145, miR-196a, and the miR-200 family.
  • the nucleic acid polymer is an oncomiR. In some instances, the oncomiR is equivalent to an endogeous oncomiR wherein the endogeous oncomiR is characterized with a reduced expression level. In some instances, the nucleic acid polymer is a microRNA polymer. In some instances, the therapeutic molecule is a microRNA polymer. In some instances, the microRNA is equivalent to an endogeous microRNA polymer wherein the endogenous microRNA is characterized with a reduced expression level.
  • the RNA polymer comprises a DNA-directed RNAi (ddRNAi) sequence.
  • a ddRNAi construct encoding a shRNA is packaged into a viral vector such as a viral vector of a pseudotyped oncolytic virus described herein.
  • the viral genome is processed to produce the encoded shRNAs.
  • the shRNAs are then processed by endogenous host systems and enter the RNAi pathway to modulate or silence the desired gene target.
  • the gene target is a gene that is overexpressed in a cancer type. In some instances, the gene target is a gene that is overexpressed in a solid tumor.
  • the gene target is a gene that is overexpressed in a hematologic cancer.
  • genes that are overexpressed in cancer include, but are not limited to, TP53, human epidermal growth factor receptor 2 (HER2), mucin 1-cell surface associated (MUC1), human pituitary tumour-transforming gene 1 (hPPTG1), prostate and breast cancer overexpressed gene 1 protein (PBOV1), and the like.
  • the nucleic acid polymer comprises a ddRNAi sequence. In some instances, the nucleic acid polymer is comprises a ddRNAi sequence which targets a gene that is overexpressed in a cancer. In some instances, the therapeutic molecule comprises a ddRNAi sequence. In some instances, the therapeutic molecule comprises a ddRNAi sequence which targets a gene that is overexpressed in a cancer.
  • the engager molecules described herein comprise a bi-specific antibody construct comprising an activation domain and an antigen recognition domain, in which the activation domain interacts or binds to an effector cell surface receptor shown in Table 1; and the antigen recognition domain interacts or binds to a target-cell antigen shown in Table 2.
  • the engager molecules described herein comprise a bi-specific antibody construct comprising an activation domain and a therapeutic molecule domain, in which the activation domain interacts or binds to an effector cell surface receptor shown in Table 1; and the therapeutic molecule domain interacts or binds to a cell surface antigen shown in Table 2.
  • the engager molecules provided herein comprise an activation domain, wherein the activation domain comprises an anti-CD3 scFv.
  • the anti-CD3 scFv comprises a light chain variable fragment comprising an amino acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 20 and a heavy chain variable fragment comprising an amino acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 22.
  • the anti-CD3 scFv comprises a light chain variable fragment comprising an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 20 and a heavy chain variable fragment that is 100% identical to the amino acid sequence of SEQ ID NO: 22. In some embodiments, the anti-CD3 scFv comprises a light chain variable fragment comprising the amino acid sequence of SEQ ID NO: 20 and a heavy chain variable fragment comprising the amino acid sequence of SEQ ID NO: 22. In some embodiments, the anti-CD3 scFv comprises a light chain variable fragment consisting of the amino acid sequence of SEQ ID NO: 20 and a heavy chain variable fragment consisting of the amino acid sequence of SEQ ID NO: 22.
  • the engager molecules provided herein comprise an activation domain, wherein the activation domain comprises an anti-CD3 scFv, wherein the anti-CD3 scFv comprises a light chain variable fragment nucleic acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 19 and a heavy chain variable fragment nucleic acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 21.
  • the anti-CD3 scFv comprises a light chain variable fragment nucleic acid sequence that is 100% identical to the nucleic acid sequence of SEQ ID NO: 19 and a heavy chain variable fragment nucleic acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 21.
  • the anti-CD3 scFv comprises a light chain variable fragment nucleic acid sequence comprising SEQ ID NO: 19 and a heavy chain variable fragment nucleic acid sequence comprising SEQ ID NO: 21.
  • the anti-CD3 scFv comprises a light chain variable fragment nucleic acid sequence consisting of SEQ ID NO: 19 and a heavy chain variable fragment nucleic acid sequence consisting of SEQ ID NO: 21.
  • the engager molecules provided herein comprise an antigen recognition domain, wherein the antigen recognition domain comprises an anti-CD19 scFv.
  • the anti-CD19 scFv comprises a light chain variable fragment comprising an amino acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 16 and a heavy chain variable fragment comprising an amino acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 18.
  • the anti-CD19 scFv comprises a light chain variable fragment comprising an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 16 and a heavy chain variable fragment that is 100% identical to the amino acid sequence of SEQ ID NO: 18. In some embodiments, the anti-CD19 scFv comprises a light chain variable fragment comprising the amino acid sequence of SEQ ID NO: 16 and a heavy chain variable fragment comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, the anti-CD19 scFv comprises a light chain variable fragment consisting of the amino acid sequence of SEQ ID NO: 16 and a heavy chain variable fragment consisting of the amino acid sequence of SEQ ID NO: 18.
  • the engager molecules provided herein comprise an antigen recognition domain, wherein the antigen recognition domain comprises an anti-CD19 scFv, wherein the anti-CD19 scFv comprises a light chain variable fragment nucleic acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 15 and a heavy chain variable fragment nucleic acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 17.
  • the anti-CD19 scFv comprises a light chain variable fragment nucleic acid sequence that is 100% identical to the nucleic acid sequence of SEQ ID NO: 15 and a heavy chain variable fragment nucleic acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 17.
  • the anti-CD19 scFv comprises a light chain variable fragment nucleic acid sequence comprising SEQ ID NO: 15 and a heavy chain variable fragment nucleic acid sequence comprising SEQ ID NO: 17.
  • the anti-CD19 scFv comprises a light chain variable fragment nucleic acid sequence consisting of SEQ ID NO: 15 and a heavy chain variable fragment nucleic acid sequence consisting of SEQ ID NO: 17.
  • the engager molecules provided herein comprise a therapeutic molecule domain, wherein the therapeutic molecule domain comprises an anti-PDL1 scFv.
  • the anti-PDL1 scFv comprises a light chain variable fragment comprising an amino acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 36 and a heavy chain variable fragment comprising an amino acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 38.
  • the anti-PDL1 scFv comprises a light chain variable fragment comprising an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 36 and a heavy chain variable fragment that is 100% identical to the amino acid sequence of SEQ ID NO: 38. In some embodiments, the anti-PDL1 scFv comprises a light chain variable fragment comprising the amino acid sequence of SEQ ID NO: 36 and a heavy chain variable fragment comprising the amino acid sequence of SEQ ID NO: 38. In some embodiments, the anti-PDL1 scFv comprises a light chain variable fragment consisting of the amino acid sequence of SEQ ID NO: 36 and a heavy chain variable fragment consisting of the amino acid sequence of SEQ ID NO: 38.
  • the engager molecules provided herein comprise a therapeutic molecule domain, wherein the therapeutic molecule domain comprises an anti-PDL1 scFv, wherein the anti-PDL1 scFv comprises a light chain variable fragment nucleic acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 35 and a heavy chain variable fragment nucleic acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 37.
  • the anti-PDL1 scFv comprises a light chain variable fragment nucleic acid sequence that is 100% identical to the nucleic acid sequence of SEQ ID NO: 35 and a heavy chain variable fragment nucleic acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 37.
  • the anti-PDL1 scFv comprises a light chain variable fragment nucleic acid sequence comprising SEQ ID NO: 35 and a heavy chain variable fragment nucleic acid sequence comprising SEQ ID NO: 37.
  • the anti-PDL1 scFv comprises a light chain variable fragment nucleic acid sequence consisting of SEQ ID NO: 35 and a heavy chain variable fragment nucleic acid sequence consisting of SEQ ID NO: 37.
  • the engager molecules provided herein comprise a therapeutic molecule domain, wherein the therapeutic molecule domain comprises a SIRP1 ⁇ polypeptide fragment.
  • the SIRP1 ⁇ polypeptide fragment comprises an amino acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 32.
  • the SIRP1 ⁇ polypeptide fragment comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 32.
  • the SIRP1 ⁇ polypeptide fragment comprises the amino acid sequence of SEQ ID NO: 32.
  • the SIRP1 ⁇ polypeptide fragment consists of the amino acid sequence of SEQ ID NO: 32.
  • the engager molecules provided herein comprise a therapeutic molecule domain, wherein the therapeutic molecule domain comprises a SIRP1 ⁇ polypeptide fragment, wherein the SIRP1 ⁇ polypeptide fragment comprises a nucleic acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 31.
  • the SIRP1 ⁇ polypeptide fragment comprises a nucleic acid sequence that is 100% identical to the nucleic acid sequence of SEQ ID NO: 31.
  • the SIRP1 ⁇ polypeptide fragment comprises the nucleic acid sequence of SEQ ID NO: 31.
  • the SIRP1 ⁇ polypeptide fragment consists of the nucleic acid sequence of SEQ ID NO: 31.
  • the engager molecules comprise an activation domain comprising an scFv that binds to CD3 and an antigen recognition domain comprising an scFv that binds to CD19, referred to herein as a CD19-CD3 BiTE, or a CD19 BiTE.
  • a CD19-CD3 BiTE A schematic of an exemplary CD19-CD3 BiTE is shown in FIG. 1 (SEQ ID NO: 44).
  • the anti-CD3 scFv and the anti-CD19 scFv are linked together by a G4S linker (SEQ ID NO: 6).
  • the oncolytic viruses described herein comprise a bicistronic or multicistronic nucleic acid sequence, wherein a first nucleic acid sequence encodes a CD19-CD3 BiTE and a second nucleic acid sequence encodes a therapeutic molecule such as IL-15 ( FIG. 2 , SEQ ID NO: 53), IL-12 ( FIG. 3 , SEQ ID NO: 54), or CXCL10 ( FIG. 4 , SEQ ID NO: 55).
  • the CD19-CD3 BiTE (e.g., SEQ ID NO; 44) is linked to the therapeutic molecule, e.g., IL-15 (SEQ ID NO: 24), IL-12 p35 (SEQ ID NO: 28), IL-12 p40 (SEQ ID NO: 26), and/or CXCL10 (SEQ ID NO: 30), by a T2A self-cleaving peptide linker (SEQ ID NO: 14).
  • the engager molecules comprise an activation domain comprising an scFv that binds to CD3 and a therapeutic molecule domain comprising a SIRP1 ⁇ polypeptide fragment that binds to CD47 (SEQ ID NO: 32), referred to herein as an SIRP1 ⁇ -CD3 BiTE or a SIRP1 ⁇ BiTE.
  • SIRP1 ⁇ -CD3 BiTE A schematic of an exemplary SIRP1 ⁇ -CD3 BiTE is shown in FIG. 5 (SIRP1 ⁇ -CD3 (SL), SEQ ID NO: 46) and FIG. 6 (SIRP1 ⁇ -CD3 (LL), SEQ ID NO: 48).
  • the anti-CD3 scFv and the SIRP1 ⁇ peptide fragment are linked together by a single amino acid linker, or a “short linker” (SL) (e.g., SIRP1 ⁇ -CD3 (SL) as shown in FIG. 5 ).
  • the anti-CD3 scFv and the SIRP1a peptide fragment are linked together by G4S linker, or a “long linker” (LL) (e.g., SIRP1 ⁇ -CD3 (LL) as shown in FIG. 6 ).
  • the oncolytic viruses described herein comprise a bicistronic or multicistronic nucleic acid sequence, wherein a first nucleic acid sequence encodes a SIRP1 ⁇ -CD3 BiTE and a second nucleic acid sequence encodes a therapeutic molecule such as IL-15 ( FIG. 7 , SEQ ID NO: 56 and FIG. 8 , SEQ ID NO: 57), IL-12 ( FIG. 9 , SEQ ID NO: 58 and FIG. 10 , SEQ ID NO: 59), or CXCL10 ( FIG. 11 , SEQ ID NO: 60 and FIG. 12 , SEQ ID NO: 61).
  • IL-15 FIG. 7 , SEQ ID NO: 56 and FIG. 8 , SEQ ID NO: 57
  • IL-12 FIG. 9 , SEQ ID NO: 58 and FIG. 10 , SEQ ID NO: 59
  • CXCL10 FIG. 11 , SEQ ID NO: 60 and FIG. 12 , SEQ ID NO: 61.
  • the SIRP1 ⁇ -CD3 BiTE (e.g., SEQ ID NO: 46 or SEQ ID NO: 48) is linked to the therapeutic molecule, e.g., IL-15 (SEQ ID NO: 24), IL-12 p35 (SEQ ID NO: 28), IL-12 p40 (SEQ ID NO: 26), and/or CXCL10 (SEQ ID NO: 30), by a T2A self-cleaving peptide linker (SEQ ID NO: 14).
  • the oncolytic viruses described herein comprise a bicistronic or multicistronic nucleic acid sequence, wherein a first nucleic acid sequence encodes a SIRP1 ⁇ -CD3 BiTE and a second nucleic acid sequence encodes a therapeutic molecule such as MMP9 ( FIG. 18A , SEQ ID NO: 65 and FIG. 18B , SEQ ID NO: 66).
  • the SIRP1 ⁇ -CD3 BiTE e.g., SEQ ID NO: 65 or 66
  • the MMP9 polypeptide SEQ ID NO: 34
  • T2A self-cleaving peptide linker SEQ ID NO: 14
  • the oncolytic viruses described herein comprise a bicistronic or multicistronic nucleic acid sequence, wherein a first nucleic acid sequence encodes a SIRP1 ⁇ -CD3 BiTE and a second nucleic acid sequence encodes a therapeutic molecule comprising an anti-PDL1 scFv linked to an IgG1 Fc domain (e.g., comprises an IgG1 CH2-CH3-Hinge, SEQ ID NO: 40), such as the SIRP1 ⁇ -CD3-PDL1-Fc (SL) construct shown in FIG. 37 (SEQ ID NO: 68) or the SIRP1 ⁇ -CD3-PDL1-Fc (LL) construct show in FIG. 38 (SEQ ID NO: 70).
  • a first nucleic acid sequence encodes a SIRP1 ⁇ -CD3 BiTE
  • a second nucleic acid sequence encodes a therapeutic molecule comprising an anti-PDL1 scFv linked to an IgG1 Fc domain (e.g.,
  • the engager molecules comprise an activation domain comprising an scFv that binds to CD3 and a therapeutic molecule domain comprising an scFv that binds to PDL1, referred to herein as an PDL1-CD3 BiTE or a PDL1 BiTE.
  • PDL1-CD3 BiTEs Exemplary PDL1-CD3 BiTEs are shown in FIG. 13 (SEQ ID NO: 50).
  • the anti-CD3 scFv and the anti-PDL1 scFv are linked together by G4S linker (SEQ ID NO: 6).
  • the oncolytic viruses described herein comprise a bicistronic or multicistronic nucleic acid sequence, wherein a first nucleic acid sequence encodes a PDL1-CD3 BiTE and a second nucleic acid sequence encodes a therapeutic molecule such as IL-15 ( FIG. 14 , SEQ ID NO: 62), IL-12 ( FIG. 15 , SEQ ID NO: 63), or CXCL10 ( FIG. 16 , SEQ ID NO: 64).
  • the SIRP1 ⁇ -CD3 BiTE (e.g., SEQ ID NO: 50) is linked to the therapeutic molecule, e.g., IL-15 (SEQ ID NO: 24), IL-12 p35 (SEQ ID NO: 28), IL-12 p40 (SEQ ID NO: 26), and/or CXCL10 (SEQ ID NO: 30), by a T2A self-cleaving peptide linker (SEQ ID NO: 14).
  • the engager molecule is a tripartite engager molecule and comprises an activation domain comprising an scFv that binds to CD3, a therapeutic molecule domain comprising an scFv that binds to PDL1, and a third domain comprising an IgG1 Fc domain (e.g., comprises an IgG1 CH2-CH3-Hinge, SEQ ID NO: 40) and capable of binding to one or more Fc ⁇ Rs, referred to herein as an PDL1-CD3-Fc tripartite T cell engager, or TiTE, or a PDL1 TiTE.
  • FIG. 17 A schematic of an exemplary PDL1-CD3-Fc TiTE is shown in FIG. 17 (SEQ ID NO: 52).
  • amino acid sequences of exemplary engager molecules and therapeutic molecules are shown in Table 3.
  • the present invention provides recombinant nucleic acid sequences encoding an engager molecule and/or a therapeutic molecule. Exemplary recombinant nucleic acid sequences are shown in Table 4.
  • the nucleic acid sequences provided herein encode a therapeutic molecule, wherein the therapeutic molecule is IL-15.
  • the nucleic acid sequences provided herein encode an IL-15 therapeutic molecule comprising an amino acid sequence that is at least 80%, at least, 85%, at least 900%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 24.
  • the nucleic acid sequences provided herein encode an IL-15 therapeutic molecule that is 100% identical to the amino acid sequence of SEQ ID NO: 24.
  • the nucleic acid sequences provided herein encode an IL-15 therapeutic molecule comprising the amino acid sequence of SEQ ID NO: 24. In some embodiments, the nucleic acid sequences provided herein encode an IL-15 therapeutic molecule consisting of the amino acid sequence of SEQ ID NO: 24. In some embodiments, the nucleic acid sequences provided herein encode an IL-15 therapeutic molecule and comprise a sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 23.
  • the nucleic acid sequences provided herein encode an IL-15 therapeutic molecule and comprise the nucleic acid sequence of SEQ ID NO: 23. In some embodiments, the nucleic acid sequences provided herein encode an IL-15 therapeutic molecule and consist of the nucleic acid sequence of SEQ ID NO: 23.
  • the nucleic acid sequences provided herein encode a therapeutic molecule, wherein the therapeutic molecule is IL-12 (i.e., IL-12 p35 and/or IL-12 p40).
  • the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule comprising an amino acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 26.
  • the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule that is 100% identical to the amino acid sequence of SEQ ID NO: 26.
  • the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule comprising the amino acid sequence of SEQ ID NO: 26. In some embodiments, the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule consisting of the amino acid sequence of SEQ ID NO: 26. In some embodiments, the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule and comprise a sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 25.
  • the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule and comprise the nucleic acid sequence of SEQ ID NO: 25. In some embodiments, the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule and consist of the nucleic acid sequence of SEQ ID NO: 25.
  • the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule comprising an amino acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 28. In some embodiments, the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule that is 100% identical to the amino acid sequence of SEQ ID NO: 28. In some embodiments, the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule comprising the amino acid sequence of SEQ ID NO: 28.
  • the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule consisting of the amino acid sequence of SEQ ID NO: 28. In some embodiments, the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule and comprise a sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 27. In some embodiments, the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule and comprise the nucleic acid sequence of SEQ ID NO: 27. In some embodiments, the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule and consist of the nucleic acid sequence of SEQ ID NO: 27.
  • the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule comprising an amino acid sequence of SEQ ID NO: 26 and 28. In some embodiments, the nucleic acid sequences provided herein encode an IL-12 therapeutic molecule and comprise the nucleic acid sequences of SEQ ID NO: 25 and 27.
  • the nucleic acid sequences provided herein encode a therapeutic molecule, wherein the therapeutic molecule is CXCL10.
  • the nucleic acid sequences provided herein encode a CXCL10 therapeutic molecule comprising an amino acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 30.
  • the nucleic acid sequences provided herein encode a CXCL10 therapeutic molecule that is 100% identical to the amino acid sequence of SEQ ID NO: 30.
  • the nucleic acid sequences provided herein encode a CXCL10 therapeutic molecule comprising the amino acid sequence of SEQ ID NO: 30. In some embodiments, the nucleic acid sequences provided herein encode a CXCL10 therapeutic molecule consisting of the amino acid sequence of SEQ ID NO: 30. In some embodiments, the nucleic acid sequences provided herein encode a CXCL10 therapeutic molecule and comprise a sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 29.
  • the nucleic acid sequences provided herein encode a CXCL10 therapeutic molecule and comprise the nucleic acid sequence of SEQ ID NO: 29. In some embodiments, the nucleic acid sequences provided herein encode a CXCL10 therapeutic molecule and consist of the nucleic acid sequence of SEQ ID NO: 29.
  • the nucleic acid sequences provided herein encode a therapeutic molecule, wherein the therapeutic molecule is MMP9.
  • the nucleic acid sequences provided herein encode an MMP9 therapeutic molecule comprising an amino acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 34.
  • the nucleic acid sequences provided herein encode an MMP9 therapeutic molecule that is 100% identical to the amino acid sequence of SEQ ID NO: 34.
  • the nucleic acid sequences provided herein encode an MMP9 therapeutic molecule comprising the amino acid sequence of SEQ ID NO: 34. In some embodiments, the nucleic acid sequences provided herein encode an MMP9 therapeutic molecule consisting of the amino acid sequence of SEQ ID NO: 34. In some embodiments, the nucleic acid sequences provided herein encode an MMP9 therapeutic molecule and comprise a sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 33.
  • the nucleic acid sequences provided herein encode an MMP9 therapeutic molecule and comprise the nucleic acid sequence of SEQ ID NO: 33. In some embodiments, the nucleic acid sequences provided herein encode an MMP9 therapeutic molecule and consist of the nucleic acid sequence of SEQ ID NO: 33.
  • the nucleic acid sequences provided herein encode a therapeutic molecule, wherein the therapeutic molecule comprises an anti-PDL1 scFv. In some embodiments, the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv, wherein the anti-PDL1 scFv comprises a light chain variable fragment comprising an amino acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 36 and a heavy chain variable fragment comprising an amino acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 38.
  • the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv, wherein the anti-PDL1 scFv comprises a light chain variable fragment comprising an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 36 and a heavy chain variable fragment that is 100% identical to the amino acid sequence of SEQ ID NO: 38.
  • the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv, wherein the anti-PDL1 scFv comprises a light chain variable fragment comprising the amino acid sequence of SEQ ID NO: 36 and a heavy chain variable fragment comprising the amino acid sequence of SEQ ID NO: 38.
  • the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv, wherein the anti-PDL1 scFv comprises a light chain variable fragment consisting of the amino acid sequence of SEQ ID NO: 36 and a heavy chain variable fragment consisting of the amino acid sequence of SEQ ID NO: 38.
  • the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv, wherein the anti-PDL1 scFv comprises a light chain variable fragment nucleic acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 35 and a heavy chain variable fragment nucleic acid sequence that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 37.
  • the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv, wherein the anti-PDL1 scFv comprises a light chain variable fragment nucleic acid sequence that is 100% identical to the nucleic acid sequence of SEQ ID NO: 35 and a heavy chain variable fragment nucleic acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 37.
  • the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv, wherein the anti-PDL1 scFv comprises a light chain variable fragment nucleic acid sequence comprising SEQ ID NO: 35 and a heavy chain variable fragment nucleic acid sequence comprising SEQ ID NO: 37.
  • the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv, wherein the anti-PDL1 scFv comprises a light chain variable fragment nucleic acid sequence consisting of SEQ ID NO: 35 and a heavy chain variable fragment nucleic acid sequence consisting of SEQ ID NO: 37.
  • the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv and an IgG1 Fc domain. In some embodiments, the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv and an IgG1 Fc domain, wherein the IgG1 Fc domain comprises an amino acid sequence that is that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 40.
  • the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv and an IgG1 Fc domain, wherein the IgG1 Fc domain is 100% identical to the amino acid sequence of SEQ ID NO: 40. In some embodiments, the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv and an IgG1 Fc domain, wherein the IgG1 Fc domain comprises the amino acid sequence of SEQ ID NO: 40.
  • the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv and an IgG1 Fc domain, wherein the IgG1 Fc domain consists of the amino acid sequence of SEQ ID NO: 40.
  • the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv and an IgG1 Fc domain, wherein the IgG1 Fc domain nucleic acid sequence is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 39.
  • the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv and an IgG1 Fc domain, wherein the IgG1 Fc domain nucleic acid sequence comprises SEQ ID NO: 39. In some embodiments, the nucleic acid sequences provided herein encode a therapeutic molecule comprising an anti-PDL1 scFv and an IgG1 Fc domain, wherein the IgG1 Fc domain nucleic acid sequence comprises SEQ ID NO: 39.
  • the nucleic acid sequences provided herein comprise a nucleic acid sequence selected from SEQ ID NOs: 43, 45, 47, 49, 51, 67, and 69. In some embodiments, the nucleic acid sequences provided herein are at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from SEQ ID NOs: 43, 45, 47, 49, 51, 67, and 69. In some embodiments, the nucleic acid sequences provided herein are 100% identical to a nucleic acid sequence selected from SEQ ID NOs: 43, 45, 47, 49, 51, 67, and 69. In some embodiments, the nucleic acid sequences provided herein consist of a nucleic acid sequence selected from SEQ ID NOs: 43, 45, 47, 49, 51, 67, and 69.
  • the nucleic acid sequences provided herein encode an engager molecule and/or therapeutic molecule that is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to an amino acid sequence selected from SEQ ID NOs: 44, 46, 48, 50, and 52.
  • the nucleic acid sequences provided herein encode an engager molecule protein that is 100% identical to an amino acid sequence selected from SEQ ID NOs: 44, 46, 48, 50, and 52.
  • the nucleic acid sequences provided herein encode an engager molecule protein comprising an amino acid sequence selected from SEQ ID NOs: 44, 46, 48, 50, and 52.
  • the nucleic acid sequences provided herein encode an engager molecule protein consisting of an amino acid sequence selected from SEQ ID NOs: 44, 46, 48, 50, and 52.
  • the recombinant nucleic acid sequences provided herein encode an engager molecule and a therapeutic molecule. In some embodiments, the recombinant nucleic acid sequences encode an amino acid sequence comprising an engager molecule and a therapeutic molecule, wherein the amino acid sequence is at least 80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to an amino acid sequence selected from SEQ ID NOs: 53-66, 68 and 70.
  • the nucleic acid sequences encode an amino acid sequence comprising an engager molecule and a therapeutic molecule, wherein the amino acid sequence is 100% identical to an amino acid sequences selected from SEQ ID NOs: 53-66, 68 and 70. In some embodiments, the nucleic acid sequences encode an amino acid sequence comprising an engager molecule and a therapeutic molecule, wherein the amino acid sequence consists of an amino acid sequence selected from SEQ ID NOs: 53-66, 68 and 70.
  • engager molecules include engager molecules comprising an activation domain comprising an anti-CD3 scFv (e.g., comprised of SEQ ID NOs: 20 and 22) and a therapeutic domain comprising an scFv that binds to a cell surface protein such as CTLA4, TIM3, LAG3, BTLA, KIR, TIGIT, OX40, or GITR.
  • an activation domain comprising an anti-CD3 scFv (e.g., comprised of SEQ ID NOs: 20 and 22) and a therapeutic domain comprising an scFv that binds to a cell surface protein such as CTLA4, TIM3, LAG3, BTLA, KIR, TIGIT, OX40, or GITR.
  • a cell surface protein such as CTLA4, TIM3, LAG3, BTLA, KIR, TIGIT, OX40, or GITR.
  • the oncolytic viruses described herein comprise a bicistronic or multicistronic nucleic acid sequence, wherein a first nucleic acid sequence encodes an engager molecules comprising an activation domain comprising an anti-CD3 scFv (e.g., comprised of SEQ ID NOs: 20 and 22) and a therapeutic domain comprising an scFv that binds to a cell surface protein such as CTLA4, TIM3, LAG3, BTLA, KIR, TIGIT, OX40, CD47, or GITR, and a second nucleic acid sequence encoding a therapeutic molecule such as IL-15 (SEQ ID NO: 24), IL-12 (SEQ ID NOs: 26 and 28), CXCL10 (SEQ ID NO: 30), or MMP9 (SEQ ID NO: 34).
  • the engager molecule is linked to the therapeutic molecule polypeptide by a T2A self-cleaving peptide linker (SEQ ID NO: 14).
  • engager molecules include engager molecules comprising an activation domain comprising an anti-CD3 scFv (e.g., comprised of SEQ ID NOs: 20 and 22) and an antigen recognition domain comprising an scFv that binds to SLAMF7 (also known as CD319) or CD27 (either the membrane bound form of CD27 or the soluble form of CD27).
  • an activation domain comprising an anti-CD3 scFv (e.g., comprised of SEQ ID NOs: 20 and 22) and an antigen recognition domain comprising an scFv that binds to SLAMF7 (also known as CD319) or CD27 (either the membrane bound form of CD27 or the soluble form of CD27).
  • the oncolytic viruses described herein comprise a bicistronic or multicistronic nucleic acid sequence, wherein a first nucleic acid sequence encodes an engager molecules comprising an activation domain comprising an anti-CD3 scFv (e.g., comprised of SEQ ID NOs: 20 and 22) and an antigen-recognition domain comprising an scFv that binds to a target cell antigen such as SLAMF7 or CD27, and a second nucleic acid sequence encoding a therapeutic molecule such as IL-15 (SEQ ID NO: 24), IL-12 (SEQ ID NOs: 26 and 28), CXCL10 (SEQ ID NO: 30), or MMP9 (SEQ ID NO: 34).
  • the engager molecule is linked to the therapeutic molecule polypeptide by a T2A self-cleaving peptide linker (SEQ ID NO: 14).
  • the present invention provides compositions and methods of use for the prevention, treatment, and/or amelioration of a cancerous disease.
  • the methods described herein comprise administering an effective amount (e.g., a therapeutically effective amount) of an oncolytic virus described herein to a subject in need thereof, wherein the virus expresses an engager molecule or an engager molecule and a therapeutic molecule.
  • compositions and methods of the present invention are useful for all stages and types of cancer, including for minimal residual disease, early solid tumor, advanced solid tumor and/or metastatic solid tumor.
  • compositions and methods of the present invention are used to treat a variety of solid tumors associated with a number of different cancers.
  • solid tumors refers to relapsed or refractory tumors as well as metastases (wherever located), other than metastatses observed in lymphatic cancer.
  • Exemplarly solid tumors include, but are not limited to, brain and other central nervous system tumors (e.g. tumors of the meninges, brain, spinal cord, cranial nerves and other parts of central nervous system, e.g. glioblastomas or medulla blastomas); head and/or neck cancer; breast tumors; circulatory system tumors (e.g. heart, mediastinum and pleura, and other intrathoracic organs, vascular tumors and tumor-associated vascular tissue); excretory system tumors (e.g. kidney, renal pelvis, ureter, bladder, other and unspecified urinary organs); gastrointestinal tract tumors (e.g.
  • oesophagus oesophagus, stomach, small intestine, colon, colorectal, rectosigmoid junction, rectum, anus and anal canal
  • vulva vagina, Cervix uteri, Corpus uteri, uterus, ovary, and other sites associated with female genital organs, placenta, penis, prostate, testis, and other sites associated with male genital organs); respiratory tract tumors (e.g. nasal cavity and middle ear, accessory sinuses, larynx, trachea, bronchus and lung, e.g. small cell lung cancer or non-small cell lung cancer); skeletal system tumors (e.g. bone and articular cartilage of limbs, bone articular cartilage and other sites); skin tumors (e.g.
  • malignant melanoma of the skin non-melanoma skin cancer, basal cell carcinoma of skin, squamous cell carcinoma of skin, mesothelioma, Kaposi's sarcoma); and tumors involving other tissues including peripheral nerves and autonomic nervous system, connective and soft tissue, retroperitoneum and peritoneum, eye and adnexa, thyroid, adrenal gland and other endocrine glands and related structures, secondary and unspecified malignant neoplasm of lymph nodes, secondary malignant neoplasm of respiratory and digestive systems and secondary malignant neoplasm of other sites, oligodendroglioma, oligoastrocytoma, astrocytoma, glioblastoma or medulloblastoma or other solid tumor.
  • the solid tumor is a brain tumor.
  • the brain tumor includes, but is not limited to, a glioma, in particular ependymoma, oligodendroglioma, oligoastrocytoma, astrocytoma, glioblastoma, or a medulloblastoma.
  • compositions and methods of the present invention are used to treat a hematologic cancer.
  • hematologic cancer refers herein to a cancer of the blood system and includes relapsed or refractory hematologic cancer as well as a metastasized hematologic cancer (wherever located).
  • the hematologic cancer is a T-cell malignancy or a B-cell malignancy.
  • T-cell malignancies include, but are not limited to, peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), anaplastic large cell lymphoma, angioimmunoblastic lymphoma, cutaneous T-cell lymphoma, adult T-cell leukemia/lymphoma (ATLL), blastic NK-cell lymphoma, enteropathy-type T-cell lymphoma, hematosplenic gamma-delta T-cell lymphoma, lymphoblastic lymphoma, nasal NK/T-cell lymphomas, or treatment-related T-cell lymphomas.
  • PTCL-NOS peripheral T-cell lymphoma not otherwise specified
  • anaplastic large cell lymphoma angioimmunoblastic lymphoma
  • ATLL adult T-cell leukemia/lymphoma
  • blastic NK-cell lymphoma enteropathy-type T-cell lymphoma
  • Exemplary B-cell malignancies include, but are not limited to, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high risk CLL, a non-CLL/SLL lymphoma, prolymphocytic leukemia (PLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt's lymphoma, non-Burkitt high grade B cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma,
  • the oncolytic virus is engineered to produce a high level of expression of the engager molecule and/or the therapeutic polypeptide prior to the death of the virally-infected cell, e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours of infection, or within 2, 3, 4, 5, or 6 days of infection.
  • Expression of the engager molecule and/or the therapeutic polypeptide can be determined by methods known in the art, including Western blot, ELISA, immunoprecipitation, or electrophoresis, among others.
  • a “high level of expression” in reference to a therapeutic molecule refers to a level of expression that is greater than the basal level of expression of a corresponding polypeptide in a cell that is not infected with the oncolytic virus
  • compositions described herein relates to a composition for administration to an individual.
  • Administration of the compositions described herein can be local or systemic and can be effected by different ways, e.g., by intravenous, subcutaneous, intraperitoneal, intramuscular, topical or intradermal administration.
  • compositions disclosed herein are administered by any means known in the art.
  • compositions described herein may be administered to a subject intravenously, intratumorally, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostaticaly, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intrathecally, subcutaneously, subconjunctival, intravesicularily, mucosally, intrapericardially, intraumbilically, intraocularly, orally, locally, by inhalation, by injection, by infusion, by continuous infusion, by localized perfusion, via a catheter, via a lavage, in a cream, or in a lipid composition.
  • the composition is administered to the individual via infusion or injection.
  • administration is parenteral, e.g., intravenous.
  • the oncolytic virus or composition thereof is administered directly to the target site, e.g., by biolistic delivery to an internal or external target site or by catheter to a site in an artery.
  • the compositions described herein are administered subcutaneously or intravenously.
  • the oncolytic viruses or compositions thereof described herein are administered intravenously or intraarterially.
  • compositions described herein are formulated for a particular route of administration, for parenteral, transdermal, intraluminal, intra-arterial, intrathecal, intravenous administration, or for direct injection into a cancer.
  • the compositions further comprise a pharmaceutically acceptable carrier.
  • “Pharmaceutically or pharmacologically acceptable” refer herein to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.
  • the pharmaceutical compositions of the present disclosure further comprise a pharmaceutically acceptable carrier.
  • a “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, buffer, stabilizing formulation, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • suitable pharmaceutical carriers include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions, etc.
  • Compositions comprising such carriers are formulated by well-known conventional methods.
  • supplementary active ingredients are also incorporated into the compositions.
  • the compositions described herein are met with sterility, pyrogenicity, and general safety and purity standards as required by FDA Office of Biologics standards.
  • the compositions described herein comprise a carrier such as a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • a carrier such as a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • a coating such as lecithin
  • surfactants by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms is brought about by various antibacterial and antifungal agents known in the art. In many cases, it is preferable to include isotonic agents, for example, sugars or sodium chloride.
  • prolonged absorption of the injectable compositions is brought about by the use in the compositions of agents
  • the oncolytic viruses described herein are formulated into a composition in a neutral or salt form.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups are derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • compositions suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form is sterile and is fluid. In some cases, it is stable under the conditions of manufacture and certain storage parameters (e.g. refrigeration and freezing) and is preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • Aqueous compositions of some embodiments herein include an effective amount of a virus, nucleic acid, therapeutic protein, peptide, construct, stimulator, inhibitor, and the like, dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium.
  • Aqueous compositions of vectors expressing any of the foregoing are also contemplated.
  • biological material is extensively dialyzed to remove undesired small molecular weight molecules and/or lyophilized for more ready formulation into a desired vehicle, where appropriate.
  • the active compounds or constructs are formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, intralesional, intranasal or intraperitoneal routes. Any route used for vaccination or boost of a subject is used.
  • the preparation of an aqueous composition that contains an active component or ingredient is known to those of skill in the art in light of the present disclosure. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for use in preparing solutions or suspensions upon the addition of a liquid prior to injection is also prepared; and the preparations are also emulsified.
  • the oncolytic virus is dispersed in a pharmaceutically acceptable formulation for injection.
  • sterile injectable solutions are prepared by incorporating the active compounds or constructs in the required amount in the appropriate solvent with any of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • compositions described herein are administered in a manner compatible with disease to be treated and the dosage formulation and in such amount as is therapeutically effective.
  • the formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but also as slow release capsules or microparticles and microspheres and the like.
  • aqueous solutions for parenteral administration in an aqueous solution, for example, the solution is suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intratumorally, intramuscular, subcutaneous and intraperitoneal administration.
  • sterile aqueous media that is employed is known to those of skill in the art in light of the present disclosure.
  • one dosage is dissolved in 1 mL of isotonic NaCl solution and either added to 1000 mL of hypodermolysis fluid or injected at the proposed site of infusion.
  • parenteral administration such as intravenous, intratumorally, intradermal or intramuscular injection
  • other pharmaceutically acceptable forms include, e.g., tablets or other solids for oral administration; liposomal formulations; time release capsules; biodegradable and any other form currently used.
  • the viruses are encapsulated to inhibit immune recognition and placed at the site of a tumor.
  • preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishes, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives are also present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
  • the pharmaceutical composition of the present disclosure might comprise proteinaceous carriers, like, e.g., serum albumin or immunoglobulin, preferably of human origin. It is envisaged that the pharmaceutical composition of the disclosure might comprise, in addition to the proteinaceous bispecific single chain antibody constructs or nucleic acid molecules or vectors encoding the same (as described in this disclosure), further biologically active agents, depending on the intended use of the pharmaceutical composition.
  • tumor-infiltrating virus-producing cells which continuously release vectors are formulated for direct implantation into a tumor in order to increase the viral oncolysis and the transfer efficiency of the therapeutic genes.
  • Intranasal formulations are known in the art and are described in, for example, U.S. Pat. Nos. 4,476,116; 5,116,817; and 6,391,452.
  • Formulations which are prepared according to these and other techniques well-known in the art are prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, fluorocarbons, and/or other solubilizing or dispersing agents known in the art. See, for example, Ansel, H. C. et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, Sixth Ed. (1995).
  • these compositions and formulations are prepared with suitable nontoxic pharmaceutically acceptable ingredients.
  • Nasal dosage forms generally contain large amounts of water in addition to the active ingredient. Minor amounts of other ingredients such as pH adjusters, emulsifiers or dispersing agents, preservatives, surfactants, gelling agents, or buffering and other stabilizing and solubilizing agents are also present.
  • the nasal dosage form is isotonic with nasal secretions.
  • compositions described herein are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit is determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of, such as, by way of example only, gelatin for use in an inhaler or insufflator is formulated containing a powder mix of the compound described herein and a suitable powder base such as lactose or starch.
  • the oncolytic viruses and compositions thereof described herein are administered to a subject at therapeutically effective amount.
  • the therapeutically effective amount will depend on the subject to be treated, the state (e.g., general health) of the subject, the protection desired, the disease to be treated, the route of administration, and/or the nature of the virus.
  • the person responsible for administration e.g., an attending physician
  • dosages for any one patient depend upon many factors, including the patient's size, weight, body surface area, age, sex, and general health, the particular compound to be administered, the particular disease to be treated, timing and route of administration, and other drugs being administered concurrently. Therefore, it is expected that for each individual patient, even if the viruses that are administered to the population at large, each patient is monitored for the proper dosage for the individual, and such practices of monitoring a patient are routine in the art.
  • the therapeutically effective amount of an oncolytic virus described herein is administered in a single dose.
  • the pseudotyped oncolytic viruses or compositions thereof are administered to a subject at a dose ranging from about 1 ⁇ 10 +5 pfu to about 1 ⁇ 10 +15 pfu (plaque forming units), about 1 ⁇ 10 +8 pfu to about 1 ⁇ 10 +15 pfu, about 1 ⁇ 10 +10 pfu to about 1 ⁇ 10 +15 pfu, or about 1 ⁇ 10 +8 pfu to about 1 ⁇ 10 +12 pfu.
  • the pseudotyped oncolytic viruses or compositions thereof are administered to a subject at a dose of about 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , or 10 15 pfu of virus.
  • the dose depends, on the age of the subject to which a composition is being administered. For example, a lower dose may be required if the subject is juvenile, and a higher dose may be required if the subject is an adult human subject.
  • a juvenile subject receives about 1 ⁇ 10 +8 pfu and about 1 ⁇ 10 +10 pfu, while an adult human subject receives a dose between about 1 ⁇ 10 +10 pfu and about 1 ⁇ 10 +12 pfu.
  • the therapeutically effective amount of an oncolytic virus described herein is administered over the course of two or more doses.
  • the two or more doses are administered simultaneously (e.g., on the same day or over a short period of time) or at appropriate intervals, for example as two, three, four or more sub-doses per day.
  • the oncolytic viruses or compositions thereof described herein are administered to a subject once. In some embodiments, the oncolytic viruses or compositions thereof described herein are administered to a subject more than once. For example, a composition disclosed herein may be administered multiple times, including 1, 2, 3, 4, 5, 6, or more times. In some embodiments, a composition disclosed herein may be administered to a subject on a daily or weekly basis for a time period or on a monthly, bi-yearly, or yearly basis depending on need or exposure to a pathogenic organism or to a condition in the subject (e.g. cancer). In particular embodiments, the oncolytic viruses and compositions thereof are formulated in such a way, and administered in such and amount and/or frequency, that they are retained by the subject for extended periods of time.
  • the pseudotyped oncolytic viruses or compositions thereof are administered for therapeutic applications or is administered as a maintenance therapy, such as for example, for a patient in remission.
  • the pseudotyped oncolytic viruses or compositions thereof are administered once every month, once every 2 months, once every 6 months, once a year, twice a year, three times a year, once every two years, once every three years, or once every five years.
  • the pseudotyped oncolytic viruses or compositions thereof may be administered continuously upon the doctor's discretion.
  • the dose composition is temporarily reduced and/or administration of the composition is temporarily suspended for a certain length of time (i.e., a “drug holiday”).
  • the length of the drug holiday varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days.
  • the dose reduction during a drug holiday is from 10%100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
  • a maintenance dose may be administered if necessary.
  • the dosage and/or the frequency of administration of the composition is reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained.
  • patients may require intermittent treatment on a long-term basis upon any recurrence of symptoms.
  • toxicity and therapeutic efficacy of such therapeutic regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between the toxic and therapeutic effects is the therapeutic index and it is expressed as the ratio between LD 50 and ED 50 .
  • Compounds exhibiting high therapeutic indices are preferred.
  • the data obtained from cell culture assays and animal studies are used in formulating a range of dosage for use in human.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50 with minimal toxicity. The dosage varies within this range depending upon the dosage form employed and the route of administration utilized.
  • tumor antigen expression levels are evaluated to assess the progress of treatment in a patient, to stratify a patient, and/or to modulate a therapeutic regimen.
  • assessment of antigen expression levels include the use of immunohistochemistry (IHC) (including semi-quantitative or quantitative IHC) or other antibody-based assays (Western blot, fluorescent immunoassay (FIA), fluorescence in situ hybridization (FISH), radioimmunoassay (RIA), radioinununoprecipitation (RIP), enzyme-linked immunosorbent assay (ELISA), immunoassay, immunoradiometric assay, fluoroimmunoassay, chemiluminescent assay, bioluminescent assay, gel electrophoresis), or indirectly by quantitating the transcripts for these genes (e.g.
  • cells for example, lymphocytes, are analyzed using FACs technology or paraffin embedded tumor sections using antibodies.
  • antibodies are used to characterize the protein content of target cells through techniques such as immunohistochemistry, ELISAs and Western blotting. In some cases, this provides a screen e.g. for the presence or absence of a subject likely to respond favorably to oncolytic virus therapy and/or a need for co-administering an immune stimulating agent with an oncolytic virus.
  • immunohistochemistry is performed on a sample of tissue from a biopsy.
  • the sample is examined fresh or frozen.
  • antibodies against antigens presented in the cell are added to the sample on a slide and the antibodies bind wherever the antigens are present.
  • excess antibody is then washed away.
  • the antibodies that remain bound to the cell are further labeled by a secondary antibody for visualization under a microscope.
  • test samples are obtained from a subject such as for example, from tissue (e.g. tumor biopsy), cerebrospinal fluid (CSF), lymph, blood, plasma, serum, peripheral blood mononuclear cells (PBMCs), lymph fluid, lymphocytes, synovial fluid and urine.
  • tissue e.g. tumor biopsy
  • CSF cerebrospinal fluid
  • PBMCs peripheral blood mononuclear cells
  • lymph fluid lymphocytes
  • synovial fluid and urine e.g. tumor biopsy
  • CSF cerebrospinal fluid
  • PBMCs peripheral blood mononuclear cells
  • lymph fluid lymphocytes
  • synovial fluid and urine e.g., synovial fluid and urine.
  • the test sample is obtained from CSF or tumor tissue.
  • the test sample is obtained from tumor tissue and e.g. the relative number of CD4 + and/or CD8 + cells in the sample is determined and/or the level of one or more Th1 and/or Th2 cytokines in the sample is measured e.g
  • test sample is obtained from blood and e.g. the level of one or more Th1 and/or Th2 cytokines in the sample is measured by ELISA.
  • the viruses, expression constructs, nucleic acid molecules and/or vectors described herein are administered in combination with another therapeutic agent.
  • the oncolytic viruses and an additional therapeutic agent are formulated in the same compositions.
  • the composition may further comprise a pharmaceutically acceptable carrier or excipient.
  • the oncolytic viruses and an additional therapeutic agent are formulated in separate compositions (e.g., two or more compositions suitable for administration to patient or subject).
  • the disclosure further encompasses co-administration protocols with other cancer therapies, e.g. bispecific antibody constructs, targeted toxins or other compounds, including those which act via immune cells, including T-cell therapy.
  • the clinical regimen for co-administration of the inventive composition(s) encompass(es) co-administration at the same time, before and/or after the administration of the other component.
  • Particular combination therapies include chemotherapy, radiation, surgery, hormone therapy, and/or other types of immunotherapy.
  • a therapeutically effective amount of a pseudotyped oncolytic virus is administered to a subject in need thereof in combination with an additional therapeutic agent.
  • the additional therapeutic agent is a chemotherapeutic agent, a steroid, an immunotherapeutic agent, a targeted therapy, or a combination thereof.
  • compositions are administered in conjunction with an adjuvant therapy.
  • activating adjuvant treatments are administered prior to, contemporaneous with, or after one or more administrations (e.g., intratumoral injection of the pseudotyped virus).
  • adjuvant therapy includes modulation of Toll-like receptor (TLR) ligands, such as TLR9 activation by DNA molecules comprising CpG sequences, or TLR9 activation (e.g., by RNA ligands).
  • TLR Toll-like receptor
  • Other adjuvant treatments include agonizing antibodies or other polypeptides (e.g., activation of CD40 or GITR by CD40 Ligand (CD40L) or GITR Ligand (GITRL), respectively).
  • cyclic dinucleotides e.g., c-di-GMP
  • Another activating adjuvant includes interleukins such as IL-33.
  • the additional therapeutic agent comprises an agent selected from: bendamustine, bortezomib, lenalidomide, idelalisib (GS-1101), vorinostat, everolimus, panobinostat, temsirolimus, romidepsin, vorinostat, fludarabine, cyclophosphamide, mitoxantrone, pentostatine, prednisone, etopside, procarbazine, and thalidomide.
  • the additional therapeutic agent is a multi-agent therapeutic regimen.
  • the additional therapeutic agent comprises the HyperCVAD regimen (cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with methotrexate and cytarabine).
  • the HyperCVAD regimen is administered in combination with rituximab.
  • the additional therapeutic agent comprises the R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
  • the additional therapeutic agent comprises the FCR regimen (FCR (fludarabine, cyclophosphamide, rituximab).
  • FCR fludarabine, cyclophosphamide, rituximab
  • the additional therapeutic agent comprises the FCMR regimen (fludarabine, cyclophosphamide, mitoxantrone, rituximab).
  • the additional therapeutic agent comprises the FMR regimen (fludarabine, mitoxantrone, rituximab).
  • the additional therapeutic agent comprises the PCR regimen (pentostatin, cyclophosphamide, rituximab).
  • the additional therapeutic agent comprises the PEPC regimen (prednisone, etoposide, procarbazine, cyclophosphamide).
  • the additional therapeutic agent comprises radioimmunotherapy with 90 Y-ibritumomab tiuxetan or 131 I-tositumomab.
  • the additional therapeutic agent is an autologous stem cell transplant.
  • the additional therapeutic agent is selected from: nitrogen mustards such as for example, bendamustine, chlorambucil, chlormethine, cyclophosphamide, ifosfamide, meiphalan, prednimustine, trofosfamide; alkyl sulfonates like busulfan, mannosulfan, treosulfan; ethylene imines like carboquone, thiotepa, triaziquone; nitrosoureas like carmustine, fotemustine, lomustine, nimustine, ranimustine, semustine, streptozocin; epoxides such as for example, etoglucid; other alkylating agents such as for example dacarbazine, mitobronitol, pipobroman, temozolomide; folic acid analogues such as for example methotrexate, permetrexed, pralatrexate, raltitrexed;
  • the additional therapeutic agent is selected from: interferons, interleukins, tumor necrosis factors, growth factors, or the like.
  • the additional therapeutic agent is selected from: ancestim, filgrastim, lenograstim, molgramostim, pegfilgrastim, sargramostim; Interferons such as for example IFN ⁇ natural, IFN ⁇ -2a, IFN ⁇ -2b, IFN alfacon-1, IFN ⁇ -n1, IFN ⁇ natural, IFN ⁇ -1 ⁇ , IFN ⁇ -1b, IFN ⁇ , peginterferon ⁇ -2a, peginterferon ⁇ -2b; interleukins such as for example aldesleukin, oprelvekin; other immunostimulants such as for example BCG vaccine, glatiramer acetate, histamine dihydrochloride, immunocyanin, lentinan, melanoma vaccine, mifamurtide, pegademase, pidotimod, plerixafor, poly I:C, poly ICLC, roquinimex, tason
  • the additional therapeutic agent is selected from: Adalimumab, Alemtuzumab, Basiliximab, Bevacizumab, Cetuximab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Gemtuzumab, Ibritumomab tiuxetan, Infliximab, Muromonab-CD3, Natalizumab, Panitumumab, Ranibizumab, Rituximab, Tositumomab, Trastuzumab, or the like, or a combination thereof.
  • the additional therapeutic agent is selected from: monoclonal antibodies such as for example alemtuzumab, bevacizumab, catumaxomab, cetuximab, edrecolomab, gemtuzumab, panitumumab, rituximab, trastuzumab; Immunosuppressants, eculizumab, efalizumab, muromab-CD3, natalizumab; TNF alpha Inhibitors such as for example adalimumab, afelimomab, certolizumab pegol, golimumab, infliximab; Interleukin Inhibitors, basiliximab, canakinumab, daclizumab, mepolizumab, tocilizumab, ustekinumab; Radiopharmaceuticals, ibritumomab tiuxetan, tositumomab; additional monoclonal antibodies
  • the additional therapeutic agent is selected from: agents that affect the tumor micro-enviroment such as cellular signaling network (e.g. phosphatidylinositol 3-kinase (PI3K) signaling pathway, signaling from the B-cell receptor and the IgE receptor).
  • cellular signaling network e.g. phosphatidylinositol 3-kinase (PI3K) signaling pathway, signaling from the B-cell receptor and the IgE receptor.
  • the additional therapeutic agent is a PI3K signaling inhibitor or a syc kinase inhibitor.
  • the syk inhibitor is R788.
  • is a PKC ⁇ inhibitor such as by way of example only, enzastaurin.
  • agents that affect the tumor micro-environment include PI3K signaling inhibitor, syc kinase inhibitor, protein kinase inhibitors such as for example dasatinib, erlotinib, everolimus, gefitinib, imatinib, lapatinib, nilotinib, pazonanib, sorafenib, sunitinib, temsirolimus; other angiogenesis inhibitors such as for example GT-111, 11-101, R1530; other kinase inhibitors such as for example AC220, AC480, ACE-041, AMG 900, AP24534, Arry-614, AT7519, AT9283, AV-951, axitinib, AZD1152, AZD7762, AZD8055, AZD8931, bafetinib, BAY 73-4506, BGJ398, BGT226, BI 811283, BI6727, BIBF 11
  • the additional therapeutic agent is selected from: inhibitors of mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002; Syk inhibitors; mTOR inhibitors; and antibodies (e.g., rituxan).
  • mitogen-activated protein kinase signaling e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002
  • Syk inhibitors e.g., mTOR inhibitors
  • mTOR inhibitors e.g., rituxan
  • the additional therapeutic agent is selected from: 20-epi-1, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA;
  • the additional therapeutic agent is selected from: alkylating agents, antimetabolites, natural products, or hormones, e.g., nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, ete.), or triazenes (decarbazine, etc.).
  • nitrogen mustards e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.
  • alkyl sulfonates e.g., busulfan
  • nitrosoureas e.g., carmustine, lomusitne, ete.
  • triazenes decarbazine, etc.
  • antimetabolites include but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
  • folic acid analog e.g., methotrexate
  • pyrimidine analogs e.g., Cytarabine
  • purine analogs e.g., mercaptopurine, thioguanine, pentostatin.
  • compositions are administered in conjunction with an adjuvant therapy.
  • activating adjuvant treatments are administered prior to, contemporaneous with, or after one or more administrations (e.g., intratumoral injection of the pseudotyped virus).
  • adjuvant therapy includes modulation of Toll-like receptor (TLR) ligands, such as TLR9 activation by DNA molecules comprising CpG sequences, or TLR9 activation (e.g., by RNA ligands).
  • TLR Toll-like receptor
  • Other adjuvant treatments include agonizing antibodies or other polypeptides (e.g., activation of CD40 or GITR by CD40 Ligand (CD40L) or GITR Ligand (GITRL), respectively).
  • cyclic dinucleotides e.g., c-di-GMP
  • Another activating adjuvant includes interleukins such as IL-33.
  • the pharmaceutical compositions described herein are administered in conjunction with an adjuvant therapy.
  • kits comprising one or more oncolytic viruses as described herein, a nucleic acid sequence as described herein, a vector as described herein, and/or a host cell as described herein.
  • the kits comprise a pharmaceutical composition as described herein above, either alone or in combination with further therapeutic agents to be administered to an individual in need thereof.
  • the present invention provides kits for the use of vectors and virus-producing cells according to the invention as drugs in therapeutic methods.
  • the vectors and virus producing cells according to some embodiments of the invention are used for the therapy or treatment of solid tumors in a subject.
  • the therapeutic effect is caused by the oncolytic properties of the recombinant vectors and viruses as well as by the use of therapeutic genes.
  • kits for use with methods and compositions concern kits having vaccine compositions of use to reduce onset of or treat subjects having one or more solid tumors.
  • kits concern kits for making and using molecular constructs described herein.
  • kits also include a suitable container, for example, vials, tubes, mini- or microfuge tubes, test tube, flask, bottle, syringe or other container. Where an additional component or agent is provided, the kit contains one or more additional containers into which this agent or component is placed.
  • Kits herein also include a means for containing the constructs, vaccine compositions and any other reagent containers in close confinement for commercial sale. Such containers include injection or blow-molded plastic containers into which the desired vials are retained.
  • one or more additional agents such as other anti-viral agents, anti-fungal or anti-bacterial agents are needed for compositions described, for example, for compositions of use as a vaccine.
  • VSV-GP VSV-Glycoprotein
  • DNA of the following packaging plasmids was mixed and prepared for transfection into 293T cells: pMDLg/pRRE expressing HIV-1 GAG/POL; pRSVIREV expressing HIV-1 REV; and pMD2.G 5 60 5.8 VSV glycoprotein.
  • the DNA mix was added to 500 ⁇ L of pre-warmed Optimem II medium.
  • a working stock of polyethyleneimine transfection reagent (PEI) was prepared at 1 ⁇ g/ ⁇ L in 1 ⁇ PBS, pH 4.5, and 88 ⁇ L of the working stock was added to the mixture, maintaining a 4:1 v/w ratio of PEI:DNA. The mixture was vortexed briefly and left for 5-10 min at room temperature to form a PEI:DNA transfection complex.
  • a total of 2.5 ⁇ 10 6 low passage (less than P20) 293T cells were seeded per 15 cm dish in 15 mL DMEM supplemented with 10% serum and 1% Pen/Strep. 2 hours prior to transfection, the cell culture medium was aspirated and replaced with 15 mL of fresh pre-warmed growth medium (GM). The transfection complex was then added drop-wise to each 15 cm plate, swirled briefly to mix and incubated for 8 hrs in 10% CO 2 , 35° C. After 8 hours, the medium was replaced with 10 mL of fresh growth medium containing 25 mM HEPES and 10% serum. The mixture was then incubated for 48 hrs post-transfection.
  • GM pre-warmed growth medium
  • the medium from each dish was removed, pooled, and filtered through a 0.22 ⁇ m low protein binding/fast flow filter unit and stored at 4° C. A 5 mL volume of fresh growth medium was added to each dish and incubated overnight at 4° C. (60-72 hours post transfection). The second lot of medium from each dish was collected, as in the previous step, and pooled with previous media harvest.
  • the plasmid carry-over is removed by digestion with DNASE-I (1 mg/mL stock).
  • a 1 ⁇ g/mL solution the viral supernatant, supplemented with 1 ⁇ L of 1M MgCl 2 , was incubated at room temperature for 30 min followed by 2-4 hrs at 4° C.
  • the filtered supernatants can be used directly on cultured cells, or aliquoted and stored at ⁇ 80° C.
  • the pseduotyped VSV-G viral supernatant can be optionally concentrated and purified.
  • Pseudotyped VSV-G is prepared as described in Example 1 and further processed to express a nucleic acid encoding an engager polypeptide comprising an activation domain comprising an anti-CD28 molecule and an antigen recognition domain comprising an anti-CA125 molecule, and a nucleic acid encoding an anti-PD immune modulatory peptide.
  • the resulting oncolytic virus is a pseudotyped oncolytic VSV-G virus encoding a CD28-CA125 engager molecule and an anti-PD1 therapeutic molecule (CD28-CA125-PD1 VSV-G).
  • Example 3 CD28-CA125-PD1 VSV-G Activates Human T Cells and Exhibits Anti-Tumor Activity
  • Human T cells are infected with the pseudotyped CD28-CA125-PD1 VSV-G virus. 24 hrs to 48 hrs post viral infection, the T cell culture medium is collected and checked for the presence of proinflammatory cytokines. These results will show that T cells are activated by CD28-CA125-PD1 VSV-G, as evidenced by presence of proinflammatory cytokines such as IFN- ⁇ and IL-2 in the cell culture supernatant of CD28-CA125-PD1 VSV-G infected human T cells.
  • proinflammatory cytokines such as IFN- ⁇ and IL-2
  • EphA2-overexpressing gastric cancer cells from KATO3 cell line, are infected with pseudotyped CD28-CA125-PD1 VSV-G or non-pseudotyped CD28-CA125-PD1 VSV virus and the cell proliferation is assessed. These results will show that cell proliferation is significantly reduced in cells KATO3 cells infected with pseudotyped CD28-CA125-PD1 VSV-G compared to KATO3 cells infected with non-pseudotyped CD28-CA125-PD VSV virus.
  • Example 4 CD19-CD3, SIRP1 ⁇ -CD3, and PDL1-CD3-Fc Engager Molecules Specifically Bind to T-Cells Via CD3
  • T cells were stimulated with 200 U/mL IL-2 for 12 days. After 12 days, T cell were incubated with varying concentrations of engager molecules (500, 1000, or 2000 ng/mL for CD19-CD3 and SIRP1 ⁇ -CD3; neat supernatant for PDL1-CD3-Fc) for 20 minutes at room temperature in triplicate. Cells were then washed twice, followed by staining with an anti-6 ⁇ His APC antibody at 500 ng/mL for an additional 20 minutes.
  • engager molecules 500, 1000, or 2000 ng/mL for CD19-CD3 and SIRP1 ⁇ -CD3; neat supernatant for PDL1-CD3-Fc
  • results for CD19-CD3 show that the CD3 binding moiety of each of these molecules functional binds to CD3-expressing 293F T cells, as indicated by an increase in the percentage of cells that are positive for the engager molecules compared to the secondary antibody alone.
  • a dose dependent increase in the % positive cells is observed for CD19-CD3 ( FIG. 19A ), while the SIRP1 ⁇ -CD3 construct demonstrated maximal binding at all concentrations.
  • the amount of the neat PDL1-CD3-Fc supernatant used resulted in binding of the construct to the majority of T cells ( FIG. 19C ).
  • FIG. 23 The results of SIRP1 ⁇ -CD3 and CD19-CD3 binding to CD19 + CD47 + Raji cells are shown in FIG. 23 .
  • Quantitation of the binding data showing percentage of BiTE positive cells is show in FIG. 23B .
  • FIG. 24 The results of SIRP1 ⁇ -CD3 and CD19-CD3 binding to CD19 ⁇ CD47 + U2OS cells are shown in FIG. 24 .
  • CD19-CD3 BiTEs were unable to bind to U2OS cells, which was expected based on the lack of CD19 expression by U2OS cells. Quantitation of these binding data showing percentage of BiTE positive cells is show in FIG. 24B .
  • FIG. 25 The results of SIRP1 ⁇ -CD3 and CD19-CD3 binding to CD19 ⁇ CD47 + GBM30-luc cells are shown in FIG. 25 .
  • SIRP1 ⁇ -CD3 BiTE were able to bind to GBM30-luc cells at all concentrations used, as indicated by a shift towards the right of the engager histograms compared to the IgG control histogram ( FIG. 25A ).
  • CD19-CD3 BiTEs were unable to bind to GBM30-luc cells, which was expected based on the lack of CD19 expression by GBM30-luc cells. Quantitation of these binding data showing percentage of BiTE positive cells is show in FIG. 25B .
  • FIG. 26 The results of SIRP1 ⁇ -CD3 and CD19-CD3 binding to CD19 ⁇ CD47 + U251 cells are shown in FIG. 26 .
  • SIRP1 ⁇ -CD3 BiTE were able to bind to U251 cells at all concentrations used, as indicated by a shift towards the right of the engager histograms compared to the IgG control histogram ( FIG. 26A ).
  • CD19-CD3 BiTEs were unable to bind to U251 cells, which was expected based on the lack of CD19 expression by U251 cells. Quantitation of these binding data showing percentage of BiTE positive cells is show in FIG. 26B .
  • the PDL1-CD3-Fc TiTE construct comprises 2 domains that are capable of binding to target cells (the anti-PDL1 and the Fc domain) experiments were performed to assess the binding specificity of these constructs.
  • CD19 ⁇ CD47 + U251 cells were treated with 2 g/mL of a fluorescently labeled anti-PDL1 antibody, an isotype control, or PDL1-CD3-Fc transfection supernant.
  • Relative to negative control Ig the PDL1-CD3-Fc TiTE bound to U251 cells ( FIG. 27B ). To assess whether this observed binding was due to interactions with CD47 or Fc ⁇ Rs expressed by U251 cells, the Fc ⁇ R expression on U251 cells was determined.
  • Example 8 CD19-CD3, SIRP1 ⁇ -CD3, and PDL1-CD3-Fc Constructs Stimulate CD8 + T Cell-Mediated Killing of Target Cells
  • CD19-CD3, SIRP1 ⁇ -CD3, and PDL1-CD3-Fc constructs were stimulated for 8-12 days in the presence of 200 U/mL IL-2 and Dynabeads. Prior to co-culture with target cells, all Dynabeads were removed by magnet and cells were washed to remove IL-2. Raji ( FIG. 28 ), THP1 ( FIG. 29 ), U251 ( FIG. 30 ), and 293F ( FIG. 31 ) target cells were labeled with the fluorescent membrane dye PKH67 green before plating.
  • CD8 + effector T cells were then co-cultured with target cells at an effector to target ratio of 1:1 along with 1000 ng/mL CD19-CD3 BiTE, SIRP1 ⁇ -CD3 BiTEs, or a 1:3 dilution of PDL1-CD3-Fc transfection supernatant.
  • Co-cultures of target and effector cells were incubated for 18 hours, after which they were stained with 7-AAD and live/dead analysis was performed by flow cytometry on a BD LSR Fortesa cytometer.
  • the PDL1-CD3-Fc engager constructs were capable of inducing effector cell-mediated death of U251 target cells ( FIG. 30 ), while the CD19-CD3 constructs did not induce effector cell-mediated death of U251 cells due to a lack of CD19 expression by U251 cells.
  • the EC 50 for each of the CD19-CD3 and PDL1-CD3-Fe constructs on U251 cells are shown below in Table 8.
  • SIRP1 ⁇ -CD3 engager constructs were capable of inducing effector cell-mediated death of 293F target cells ( FIG. 31 ), indicated by the increase in cell death in SIRP1 ⁇ -CD3 containing cultures compared to a control osteopontin-fusion protein (OPN 1).
  • OPN 1 osteopontin-fusion protein
  • Vero cells were infected with oHSV expressing SIRP1 ⁇ -CD3 BiTEs ( FIG. 32 ) with either a short linker (SL) (ONCR-085; 2A5B SIRP1 ⁇ -CD3 (SL) BiTE) or long linker (LL) (ONCR-087; 2A5B SIRP1 ⁇ -CD3 (LL) BiTE), or with oHSV expressing PD1-CD3-Fc TiTEs (ONCR-089, FIG. 33 ). Cells were infected for 3 days, after which supernatants from infected cells were passed through a 100K MWCO ultrafiltration membrane to remove any viral particles.
  • the flowthrough was concentrated with a 10K MWCO ultrafiltration membrane. Concentrated viral supernatants and 100 ng, 50 ng, 25 ng, or 12.5 ng of purified SIRP1 ⁇ -CD3 or PDL1-CD3-Fc protein were then analyzed by PAGE followed by Western blotting with an anti-6 ⁇ His detection antibody in order to determine the amount of engager protein present in the viral supernatants.
  • the workflow for clarifying viral supernatants comprises low-speed centrifugation of the supernatants followed by filtration through a 0.8 ⁇ m filter membrane.
  • SIRP1 ⁇ -CD3 and PDL1-CD3-Fc constructs were prepared from Vero cells as described in Example 10. 50 ⁇ L of the resulting SIRP1 ⁇ -CD3 (SL), SIRP1 ⁇ -CD3 (LL), and PDL1-CD3-Fc engager proteins protein samples were diluted 1:1 in tissue culture media containing 20% FBS.
  • the diluted engager proteins were then incubated with activated CD8 + effector T cells co-cultured with fluorescently labelled U251 target cells at a target to effector ratio of 1:1 for 18 hours. Cell death of U251 cells was assessed by flow cytometry on a BD LSR Fortesa cytometer.
  • Two expression plasmids encoding a SIRP1 ⁇ -CD3 engager molecule and a PDL1-Fc therapeutic molecule were generated.
  • One construct comprised a first gene encoding an HA-tagged PDL1-Fc linked to a second gene encoding a His-tagged SIRP1 ⁇ -CD3 BiTE.
  • the SIRP1 ⁇ amino acid sequence was linked to the anti-CD3 scFv by a single amino acid linker (i.e., a short linker) (SIRP1 ⁇ -CD3/PDL1-Fc (SL), FIG. 37 ).
  • the other construct comprised a first gene encoding a PDL1-Fc linked to a second gene encoding a SIRP1 ⁇ -CD3 BiTE.
  • SIRP1 ⁇ amino acid sequence was linked to the anti-CD3 scFv by a G4S linker (i.e., a long linker) (SIRP1 ⁇ -CD3/PDL1-Fc (LL), FIG. 38 ).
  • the constructs were inserted into a plasmid ( FIG. 39 ) and the resultant SIRP1 ⁇ -CD3/PDL1-Fc expression plasmids were transfected into 293 Free Style T cells. Four days after plasmid transfection, culture supernatants were collected.
  • Anti-PDL1-Fc compounds were purified from the culture supernatants using a HiTrap MabSelect SuRe Protein A column HiTrap column (GE Healthcare). Briefly, supernatants from 293 T cells transfected with either the SIRP1 ⁇ -CD3/PDL1-Fc (LL) or the SIRP1 ⁇ -CD3/PDL1-Fc (LL) expression plasmids were loaded onto the column to purify the anti-PDL1-Fc compounds by binding of the HA-tag to the column. Flow through was collected for SIRP1 ⁇ -CD3 BiTE detection by Western Blot using an anti-His antibody ( FIG. 40B ).
  • the anti-PDL1-Fc protein content of different elution fractions then were visualized by Coomassie staining. Briefly, elution fractions were run on a 4%-12% Bis-Tris NuPAGE gel in MOPS buffer at 180 volts for 1 hour. Gels were stained for 1 hour in Simply Blue SafeStain followed by destaining with water. Anti-PDL1-Fc protein content for each elution fraction is show in FIG. 40A . After Coomassie analysis, elution fractions were combined and dialyzed against PBS at 4° C. Total anti-PDL1-Fc protein concentration was then determined by a BCA assay.
  • Example 13 Isolated PDL1-Fe Proteins Stimulate T Cell-Mediated Death of Target Cells
  • the ability of the anti-PDL1-Fc proteins to induce effector cell-mediated death of target cells was assessed by a PD1/PDL1 blockade assay.
  • a general schematic of the assay is show in FIG. 41A-41B . Briefly, CD8 + T cells were co-cultured with PDL1-expressing target cells (CHO-K1 cells). Varying concentrations of the anti-PDL1-Fc protein isolated as described in Example 12 were then added to the culture. The highest concentration of anti-PDL1-Fc used was 50 ⁇ g/mL. 8, 2.5 fold serial dilutions were then performed to generate the remainder of the anti-PDL1-Fc concentrations.
  • Example 13 oHSV-Infected Vero Cells Express MMP9 and Anti-PDL1-Fc Therapeutic Molecules
  • Vero cells are infected with oHSV expressing SIRP1 ⁇ -CD3/PDL1-Fc constructs BiTEs ( FIG. 37 and FIG. 38 ) or with oHSV expressing SIRP1 ⁇ -CD3/MMP9 constructs ( FIG. 18A and FIG. 18B ).
  • Cells are infected for 3 days, after which supernatants from infected cells are passed through a 100K MWCO ultrafiltration membrane to remove any viral particles. The flowthrough is concentrated with a 10K MWCO ultrafiltration membrane.
  • MMP9 and anti-PDL1-Fc are purified from filtered, concentrated supernatants according to the protocol outlined in Example 11. Protein A-isolated MMP9 and anti-PDL1 fractions are analyzed by PAGE followed by Coomassie staining. SIRP1 ⁇ -CD3 BiTEs present in the Protein A flowthrough are analyzed by Western blotting with an anti-6 ⁇ His detection antibody.
  • SIRP1 ⁇ -CD3 HIV-induced engager molecules
  • MMP9 and anti-PDL1-Fc virally-produced engager molecules
  • SL SIRP1 ⁇ -CD3
  • LL therapeutic molecules
  • anti-PDL1-Fc proteins are prepared from Vero cells as described in Example 13. 50 ⁇ L of the resulting protein samples are diluted in tissue culture media containing 20% FBS. The diluted proteins are then incubated with activated CD8 + effector T cells or NK effector cells and are co-cultured with fluorescently labelled target cells at a target to effector ratio of 1:1 for 18 hours. Cell death of target cells is assessed by flow cytometry on a BD LSR Fortesa cytometer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US15/720,696 2016-06-30 2017-09-29 Pseudotyped oncolytic viral delivery of therapeutic polypeptides Abandoned US20180057594A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/720,696 US20180057594A1 (en) 2016-06-30 2017-09-29 Pseudotyped oncolytic viral delivery of therapeutic polypeptides
US16/170,764 US10604574B2 (en) 2016-06-30 2018-10-25 Oncolytic viral delivery of therapeutic polypeptides
US16/775,164 US11078280B2 (en) 2016-06-30 2020-01-28 Oncolytic viral delivery of therapeutic polypeptides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357195P 2016-06-30 2016-06-30
PCT/US2017/040354 WO2018006005A1 (en) 2016-06-30 2017-06-30 Pseudotyped oncolytic viral delivery of therapeutic polypeptides
US15/720,696 US20180057594A1 (en) 2016-06-30 2017-09-29 Pseudotyped oncolytic viral delivery of therapeutic polypeptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/040354 Continuation WO2018006005A1 (en) 2016-06-30 2017-06-30 Pseudotyped oncolytic viral delivery of therapeutic polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/170,764 Continuation US10604574B2 (en) 2016-06-30 2018-10-25 Oncolytic viral delivery of therapeutic polypeptides

Publications (1)

Publication Number Publication Date
US20180057594A1 true US20180057594A1 (en) 2018-03-01

Family

ID=60787595

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/720,696 Abandoned US20180057594A1 (en) 2016-06-30 2017-09-29 Pseudotyped oncolytic viral delivery of therapeutic polypeptides
US16/170,764 Active US10604574B2 (en) 2016-06-30 2018-10-25 Oncolytic viral delivery of therapeutic polypeptides
US16/775,164 Active US11078280B2 (en) 2016-06-30 2020-01-28 Oncolytic viral delivery of therapeutic polypeptides

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/170,764 Active US10604574B2 (en) 2016-06-30 2018-10-25 Oncolytic viral delivery of therapeutic polypeptides
US16/775,164 Active US11078280B2 (en) 2016-06-30 2020-01-28 Oncolytic viral delivery of therapeutic polypeptides

Country Status (13)

Country Link
US (3) US20180057594A1 (ja)
EP (1) EP3478321A4 (ja)
JP (3) JP2019519245A (ja)
KR (1) KR20190035714A (ja)
CN (1) CN109983121A (ja)
AU (1) AU2017290828A1 (ja)
BR (1) BR112019000015A2 (ja)
CA (1) CA3029426A1 (ja)
IL (2) IL263879B (ja)
MX (1) MX2019000252A (ja)
RU (2) RU2758007C2 (ja)
SG (1) SG11201811600PA (ja)
WO (1) WO2018006005A1 (ja)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018218137A1 (en) 2017-05-25 2018-11-29 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
WO2020142725A1 (en) * 2019-01-04 2020-07-09 Oncorus, Inc. Encapsulated rna polynucleotides and methods of use
WO2020160047A3 (en) * 2019-01-28 2020-09-10 Rhode Island Council On Postsecondary Education Phlip® peptide-mediated epitope tethering at cell surfaces
WO2020237050A1 (en) 2019-05-22 2020-11-26 Leidos, Inc. Lag3 binding peptides
US10888549B2 (en) 2016-03-07 2021-01-12 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
US20210147548A1 (en) * 2018-04-16 2021-05-20 Institute Of Biophysics Chinese Academy Of Sciences Fusion protein of interferon (ifn) and anti-pd-l1 antibody and use thereof
US20210386804A1 (en) * 2020-06-11 2021-12-16 Tibor Bakács Combination of viral superinfection therapy with subthreshold doses of nivolumab plus ipilimumab in chronic HBV patients
WO2022026496A2 (en) 2020-07-31 2022-02-03 Leidos, Inc. Lag3 binding peptides
WO2022081426A1 (en) 2020-10-12 2022-04-21 Leidos, Inc. Immunomodulatory peptides

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
JP7249323B2 (ja) * 2017-07-26 2023-03-30 オンコラス， インコーポレイテッド 腫瘍溶解性ウイルスベクター及びその使用
MA56289B1 (fr) 2017-08-03 2022-04-29 Amgen Inc Mutéines d'interleukine-21 et méthodes de traitement
TWI731264B (zh) 2017-09-08 2021-06-21 美商安進公司 Kras g12c抑制劑以及其使用方法
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
CA3087273A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Anti-pd-1 antibodies and methods of treatment
CN112074297B (zh) * 2018-04-15 2023-11-14 深圳市亦诺微医药科技有限公司 结合pd-1的抗体及其用途
WO2019201169A1 (en) * 2018-04-15 2019-10-24 Salubris (Chengdu) Biotech Co., Ltd Antibodies binding pd-1 and uses thereof
BR112021000315A2 (pt) 2018-07-11 2021-08-03 Actym Therapeutics, Inc. cepas bacterianas imunoestimulantes modificadas geneticamente e seus usos
CN110819657B (zh) * 2018-08-10 2021-11-19 睿丰康生物医药科技(浙江)有限公司 一种减毒棒状病毒的制备方法及应用
WO2020102285A1 (en) * 2018-11-13 2020-05-22 Oncorus, Inc. Encapsulated polynucleotides and methods of use
WO2020106924A1 (en) 2018-11-21 2020-05-28 Mayo Foundation For Medical Education And Research Adenoviruses and methods for using adenoviruses
AU2019414450A1 (en) 2018-12-27 2021-06-17 Amgen Inc. Lyophilized virus formulations
BR112021014255A2 (pt) * 2019-01-30 2022-01-18 Wistar Inst Molécula de ácido nucleico, composição, e, método de prevenção ou tratamento de uma doença ou distúrbio
BR112021016728A2 (pt) 2019-02-27 2022-01-11 Actym Therapeutics Inc Bactérias imunostimulatórias projetadas para colonizar tumores, residentes em tumores células imunológicas e o microambiente tumoral
JP2022522817A (ja) 2019-03-05 2022-04-20 アムジエン・インコーポレーテツド がんを治療するための腫瘍溶解性ウイルスの使用
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
JP7381604B2 (ja) * 2019-04-29 2023-11-15 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 癌を治療するための多価ｐｄ－ｌ１結合化合物
AU2020285291A1 (en) * 2019-05-31 2022-01-27 Guangzhou Virotech Pharmaceutical Co., Ltd. M1 virus mutant and use thereof
EP3999092A4 (en) * 2019-07-17 2023-08-09 The Regents of the University of California AGENTS AND METHODS OF POLYTHERAPY AGAINST CANCER
MX2022004323A (es) * 2019-10-10 2022-08-02 Univ Arizona State Virus oncoliticos que expresan captadores multiespecificos de celulas inmunitarias.
EP4058578A2 (en) 2019-11-12 2022-09-21 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
CN115916226A (zh) * 2020-02-07 2023-04-04 希望之城 用于治疗癌症的溶瘤病毒组合物和方法
CN111759841A (zh) * 2020-06-03 2020-10-13 山西第三医学研究发展有限公司 一种用匹多莫德在抗新型冠状病毒感染中的应用
CN113832114A (zh) * 2020-06-23 2021-12-24 南京大学 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用
EP4196139A2 (en) 2020-08-12 2023-06-21 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
CN112143711B (zh) * 2020-09-29 2021-07-23 杭州荣谷生物科技有限公司 重组痘瘤病毒、药物组合物及其构建方法和应用
WO2022148736A1 (en) * 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2022151078A1 (zh) * 2021-01-13 2022-07-21 嘉兴允英医学检验有限公司 溶瘤病毒及其应用
EP4319782A1 (en) * 2021-04-05 2024-02-14 Implicyte, Inc. Armed chimeric oncolytic viruses
CN113969266B (zh) * 2021-10-26 2023-10-13 山东大学齐鲁医院 一种重组溶瘤腺病毒及其应用
CN113980915B (zh) * 2021-11-04 2023-07-07 江苏省人民医院（南京医科大学第一附属医院） 一种新型的表达cxcl10的复制型溶瘤腺病毒和应用
WO2023086796A2 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
CN114249836A (zh) * 2021-12-27 2022-03-29 上海鑫湾生物科技有限公司 双特异性t细胞衔接器、其重组溶瘤病毒及其用途
WO2023235596A1 (en) * 2022-06-03 2023-12-07 10X Genomics, Inc. Systems and methods for determining antigen binding specificity of antigen binding molecules
WO2024055022A2 (en) * 2022-09-08 2024-03-14 Virogin Biotech Canada Ltd Oncolytic virus expressing an immune cell engager for tumor targeting
WO2024067540A1 (en) * 2022-09-30 2024-04-04 Immvira Biopharmaceuticals Co., Limited Genetically engineered herpes simplex virus type 1 for treatment of hematologic cancers

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
JPH0668B2 (ja) 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6071742A (en) 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
WO1998040475A1 (en) 1997-03-11 1998-09-17 Abbott Laboratories Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
JP4255211B2 (ja) 1997-12-17 2009-04-15 イミュネックス・コーポレーション ヒトｂ細胞リンパ腫に関連した細胞表面糖タンパク質−ｕｌｂｐ、ｄｎａ及びポリペプチド
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
PT1071752E (pt) 1998-04-21 2003-11-28 Micromet Ag Polipeptidos especificos para cd19xcd3 e suas utilizacoes
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
JP2003530092A (ja) 2000-03-17 2003-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ヒトＦＡＰ−α−特異抗体
DK2796553T3 (da) 2000-03-30 2019-09-30 Whitehead Inst Biomedical Res Rna-sekvensspecifikke formidlere af rna-interferens
DK1407044T4 (en) 2000-12-01 2017-12-04 Max-Planck-Gesellschaft Zur Förderung Der Wss E V RNA interference mediating small RNA molecules
ATE508635T1 (de) 2001-03-27 2011-05-15 Catherex Inc Virusvektoren und ihre verwendung bei therapeutischen methoden
PL373594A1 (en) 2001-10-04 2005-09-05 Immunex Corporation Ul16 binding protein 4
KR100900249B1 (ko) 2001-12-07 2009-05-29 포항공과대학교 산학협력단 ＳＩＶｍａｃ239의 면역원성 플라스미드 및 이들을 함유한ＡＩＤＳ ＤＮＡ 백신
PT1503794E (pt) 2002-04-12 2012-06-21 Medarex Inc Métodos de tratamento usando anticorpos contra ctla-4
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
US8927251B2 (en) 2002-10-07 2015-01-06 The University Of Chicago Targeting of herpes simplex virus to specific receptors
KR100932340B1 (ko) 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US7563869B2 (en) * 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
JP2006523226A (ja) 2003-02-28 2006-10-12 ザ ジョンズ ホプキンス ユニバーシティ Ｔ細胞調節方法
JP2006522101A (ja) 2003-03-12 2006-09-28 デューク・ユニバーシティー オリゴヌクレオチド類似体
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
RU2346702C2 (ru) 2004-03-26 2009-02-20 Пфайзер Продактс Инк. Применение антител к ctla-4
WO2006017914A1 (en) 2004-08-20 2006-02-23 Viralytics Limited Methods and compositions for treatment of hematologic cancers
WO2006029219A2 (en) 2004-09-08 2006-03-16 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
JP2008518599A (ja) 2004-10-28 2008-06-05 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 脊髄損傷疼痛のための末梢送達グルタミン酸脱炭酸酵素遺伝子治療
WO2006074526A1 (en) 2005-01-17 2006-07-20 Viralytics Limited Method and composition for treatment of neoplasms
SI2002003T1 (sl) 2005-05-27 2016-05-31 Ospedale San Raffaele S.R.L. Genski vektor, ki vsebuje mi-RNA
NZ564243A (en) 2005-06-08 2011-03-31 Dana Farber Cancer Inst Inc Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1) pathway
CN101248089A (zh) 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
RU2008129080A (ru) 2005-12-16 2010-01-27 Микромет Аг (De) Средства и способы лечения опухолевых заболеваний
CA2633713A1 (en) 2005-12-21 2007-06-28 Micromet Ag Epha2 bite molecules and uses thereof
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
AU2007266306A1 (en) 2006-05-26 2007-12-06 Apollo Life Sciences Limited An isolated IL-12 molecule or chimeric molecules thereof
CN101104640A (zh) 2006-07-10 2008-01-16 苏州大学 抗人pd-l1单克隆抗体制备及应用
JP2008066402A (ja) 2006-09-05 2008-03-21 Fujifilm Corp 撮像素子および撮像装置
EP2839837B1 (en) * 2006-09-15 2019-05-08 Children's Hospital of Eastern Ontario Research Institute Inc. Oncolytic farmington rhabdovirus
EP2125032A4 (en) 2007-02-20 2011-02-23 Mayo Foundation TREATMENT OF CANCER USING VIRAL NUCLEIC ACID
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2008134878A1 (en) * 2007-05-04 2008-11-13 University Health Network Compositions and methods for cancer treatment
WO2008141151A2 (en) 2007-05-09 2008-11-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
US9416165B2 (en) 2007-10-26 2016-08-16 The Regents Of The University Of California Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
WO2009100140A1 (en) 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
WO2009111892A1 (en) 2008-03-14 2009-09-17 Ottawa Health Research Institute Microrna mediated oncolytic targeting
EP2307033A4 (en) 2008-05-29 2012-06-13 Gen Hospital Corp USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
ES2667622T3 (es) 2008-05-29 2018-05-11 Alma Mater Studiorum - Università di Bologna Virus del herpes simple (VHS) con tropismo modificado, utilizaciones y procedimiento de preparación del mismo
GB0810912D0 (en) 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP3133086B1 (en) 2008-09-26 2018-08-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
CN104479018B (zh) 2008-12-09 2018-09-21 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
WO2010105277A1 (en) 2009-03-13 2010-09-16 Egen, Inc. Compositions and methods for the delivery of biologically active rnas
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
WO2011127180A1 (en) 2010-04-06 2011-10-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd274/pd-l1 gene
WO2011125469A1 (ja) 2010-04-09 2011-10-13 国立大学法人東京大学 マイクロrna制御組換えワクシニアウイルス及びその使用
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
LT2603530T (lt) 2010-08-13 2018-01-25 Roche Glycart Ag Anti-fap antikūnai ir jų naudojimo metodai
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
CA2846372C (en) * 2011-09-08 2021-01-12 New York University Oncolytic herpes simplex virus and therapeutic uses thereof
JP6489353B2 (ja) 2011-10-11 2019-03-27 ウニヴェルズィテート チューリッヒ 腫瘍療法のためのｉｌ−１２とｔ細胞阻害分子遮断薬とを含む医薬組成物
EP2591796A1 (en) 2011-11-10 2013-05-15 Universität Zürich Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
EP4079319A1 (en) 2011-10-17 2022-10-26 IO Biotech ApS Pd-l1 based immunotherapy
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
EA036814B9 (ru) 2011-11-28 2021-12-27 Мерк Патент Гмбх Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение
JP2015508156A (ja) 2012-01-25 2015-03-16 ディーエヌエートリックス インコーポレイテッド バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法
EP3553086A1 (en) 2012-05-31 2019-10-16 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
WO2014047350A1 (en) * 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
JP6420776B2 (ja) * 2013-03-05 2018-11-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 免疫療法のためのエンゲージャー細胞
JP2016512199A (ja) * 2013-03-05 2016-04-25 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 腫瘍溶解性ウイルス
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
AU2014255733B2 (en) 2013-04-18 2019-05-16 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
US20160163211A1 (en) 2013-05-16 2016-06-09 Pearson Education, Inc. Accessible content publishing engine
WO2015066042A1 (en) 2013-10-28 2015-05-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic hsv vector
EP3441084A1 (en) 2014-02-27 2019-02-13 Viralytics Limited Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer
DK3169341T3 (da) * 2014-07-16 2019-08-05 Transgene Sa Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
MX2017004526A (es) 2014-10-08 2017-06-07 Hoffmann La Roche Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
US20180318365A1 (en) 2015-10-19 2018-11-08 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
MX2018007249A (es) * 2015-12-17 2019-05-16 Psioxus Therapeutics Ltd Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este.
EP3805376A1 (en) 2016-01-08 2021-04-14 Replimune Limited Engineered virus
CN116904404A (zh) 2016-01-27 2023-10-20 昂克诺斯公司 溶瘤病毒载体及其用途
EP3426271A4 (en) 2016-03-10 2019-10-16 Cold Genesys, Inc. METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY POLYTHERAPY
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
CA3032669A1 (en) 2016-08-01 2018-02-08 William Jia Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
JP2019527737A (ja) 2016-08-09 2019-10-03 アルケヤール， アルモハナッドＡＬＫＡＹＹＡＬ， Ａｌｍｏｈａｎａｄ Ｉｌ１２を発現する腫瘍溶解性ラブドウイルス
WO2018049248A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus equipped with bispecific engager molecules
EP3534923A4 (en) 2016-11-01 2020-05-27 DNAtrix, Inc. POLYTHERAPY FOR THE TREATMENT OF BRAIN CANCERS
CA3048185A1 (en) 2016-12-21 2018-06-28 Memgen, Llc Armed replication-competent oncolytic adenoviruses
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10888549B2 (en) 2016-03-07 2021-01-12 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
WO2018218137A1 (en) 2017-05-25 2018-11-29 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
US20210147548A1 (en) * 2018-04-16 2021-05-20 Institute Of Biophysics Chinese Academy Of Sciences Fusion protein of interferon (ifn) and anti-pd-l1 antibody and use thereof
WO2020142725A1 (en) * 2019-01-04 2020-07-09 Oncorus, Inc. Encapsulated rna polynucleotides and methods of use
WO2020160047A3 (en) * 2019-01-28 2020-09-10 Rhode Island Council On Postsecondary Education Phlip® peptide-mediated epitope tethering at cell surfaces
WO2020237050A1 (en) 2019-05-22 2020-11-26 Leidos, Inc. Lag3 binding peptides
US20210386804A1 (en) * 2020-06-11 2021-12-16 Tibor Bakács Combination of viral superinfection therapy with subthreshold doses of nivolumab plus ipilimumab in chronic HBV patients
WO2022026496A2 (en) 2020-07-31 2022-02-03 Leidos, Inc. Lag3 binding peptides
WO2022081426A1 (en) 2020-10-12 2022-04-21 Leidos, Inc. Immunomodulatory peptides

Also Published As

Publication number Publication date
AU2017290828A1 (en) 2019-01-24
IL282216A (en) 2021-05-31
MX2019000252A (es) 2019-10-09
CN109983121A (zh) 2019-07-05
CA3029426A1 (en) 2018-01-04
JP2022048304A (ja) 2022-03-25
US20190048082A1 (en) 2019-02-14
JP2023174945A (ja) 2023-12-08
EP3478321A1 (en) 2019-05-08
RU2019102391A (ru) 2020-07-30
US20200157221A1 (en) 2020-05-21
RU2758007C2 (ru) 2021-10-25
RU2019102391A3 (ja) 2021-01-26
SG11201811600PA (en) 2019-01-30
US10604574B2 (en) 2020-03-31
IL263879B (en) 2021-04-29
EP3478321A4 (en) 2020-04-22
BR112019000015A2 (pt) 2019-04-24
US11078280B2 (en) 2021-08-03
IL263879A (en) 2019-01-31
WO2018006005A1 (en) 2018-01-04
JP2019519245A (ja) 2019-07-11
RU2021127872A (ru) 2021-11-09
KR20190035714A (ko) 2019-04-03

Similar Documents

Publication Publication Date Title
US11078280B2 (en) Oncolytic viral delivery of therapeutic polypeptides
US11865081B2 (en) Oncolytic viral delivery of therapeutic polypeptides
TWI761868B (zh) FLT3L-Fc融合蛋白及其使用方法
CN105392888B (zh) 使用人源化抗cd19嵌合抗原受体治疗癌症
JP6409009B2 (ja) がんにおけるｃｄ１３８の標的化
KR20210020932A (ko) Bcma 키메라 항원 수용체 및 이의 용도
JP2017536812A (ja) バイパータイト型およびトリパータイト型のシグナル伝達免疫細胞
BR112015021414B1 (pt) vírus da doença newcastle e seus usos
CA2984624A1 (en) Her2/erbb2 chimeric antigen receptor
JP7467414B2 (ja) 改良したｔ細胞治療方法
JP2023525720A (ja) Ｉｎ ｖｉｖｏ形質導入のためのベクター及び方法
US20220389394A1 (en) METHODS OF USING FLT3L-Fc FUSION PROTEINS
CN115777017A (zh) 用于t细胞工程改造的组合物及方法
CN111971071A (zh) 用于治疗和预防癌症的靶向ctla-4的dna单克隆抗体
US20230147832A1 (en) Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer
JP2022527081A (ja) 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ）
NZ749647A (en) Pseudotyped oncolytic viral delivery of therapeutic polypeptides
CN116635062A (zh) 使用表达嵌合抗原受体（car）的细胞的组合疗法
WO2024059834A2 (en) Downregulating inos to increase car-t killing
CN110678192A (zh) 溶瘤痘苗病毒与免疫检查点抑制剂联合疗法

Legal Events

Date Code Title Description
AS Assignment

Owner name: ONCORUS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MPM CAPITAL;REEL/FRAME:043743/0602

Effective date: 20170630

Owner name: MPM CAPITAL, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EVNIN, LUKE;REEL/FRAME:043743/0588

Effective date: 20170630

AS Assignment

Owner name: ONCORUS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MPM CAPITAL;REEL/FRAME:044162/0810

Effective date: 20170630

Owner name: MPM CAPITAL, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EVNIN, LUKE;REEL/FRAME:044162/0790

Effective date: 20170630

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: ONCORUS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MPM CAPITAL;REEL/FRAME:048312/0228

Effective date: 20180925

Owner name: MPM CAPITAL, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EVNIN, LUKE;REEL/FRAME:048312/0188

Effective date: 20180925

AS Assignment

Owner name: ONCORUS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FINER, MITCHELL H.;REEL/FRAME:055993/0301

Effective date: 20210408